Please wait...
| ID | PMID | YEAR | Sequence | MAP | Name | C-ter MOD | N-ter MOD | Linear/Cyclic | Stereo-Chemistry | Modified | Length | Nature | Activity | RBCs Source | Origin | Experimental structure | Non-Hemolytic |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18081258 | 2008 | GLPVCGETCVGGTCNTPGCTCSWPVCTRN{cyc:N-C} | Katala B1 | Free | Free | Cyclic | L | None | 29 | Anti-HIV | HD50 =11.7μM | Human | Cyclotides (Chinese herb from the Violaceae family Viola yedoensis) | NA | NA | ||
| 18081258 | 2008 | GGTIFDCGETCFLGTCYTPGCSCGNYGFCYGTN{cyc:N-C} | Cycloviolacin Y1 | Free | Free | Cyclic | L | None | 33 | Anti-HIV | Poor hemolytic | Human | Cyclotides (Chinese herb from the Violaceae family Viola yedoensis) | NA | NA | ||
| 18081258 | 2008 | GVPCGESCVFIPCITGVIGCSCSSNVCYLN{cyc:N-C} | Cycloviolacin Y4 | Free | Free | Cyclic | L | None | 30 | Anti-HIV | HD50 =9.3μM | Human | Cyclotides (Chinese herb from the Violaceae family Viola yedoensis) | NA | NA | ||
| 18081258 | 2008 | GIPCAESCVWIPCTVTALVGCSCSDKVCYN{cyc:N-C} | Cycloviolacin Y5 | Free | Free | Cyclic | L | None | 30 | Anti-HIV | HD50 = 8.7μM | Human | Cyclotides (Chinese herb from the Violaceae family Viola yedoensis) | NA | NA | ||
| 18243710 | 2008 | DAACAAHCLWR{cyc:N-C}{ct:Amid} | DHWRox | Amidation | Free | Cyclic | L | None | 11 | Antimicrobial | HC50 >200μg/ml | Human | α-helical domain of Tenecin 1,an insect defensin | α-helix | NA | ||
| 18243710 | 2008 | DAACAAKCLWR{cyc:N-C}{ct:Amid} | DKWRox | Amidation | Free | Cyclic | L | None | 11 | Antimicrobial | HC50 >200μg/ml | Human | α-helical domain of Tenecin 1,an insect defensin | α-helix | NA | ||
| 18243710 | 2008 | KAACAAHCLWR{cyc:N-C}{ct:Amid} | KHWRox | Amidation | Free | Cyclic | L | None | 11 | Antimicrobial | HC50 >200μg/ml | Human | α-helical domain of Tenecin 1,an insect defensin | α-helix | NA | ||
| 18243710 | 2008 | KAACAAKCLWR{cyc:N-C}{ct:Amid} | KKWRox | Amidation | Free | Cyclic | L | None | 11 | Antimicrobial | HC50 >200μg/ml | Human | α-helical domain of Tenecin 1,an insect defensin | α-helix | NA | ||
| 17212422 | 2007 | {nnr:APC}-L-{nnr:ACPC}-K-{nnr:ACPC}-L-{nnr:APC}-L-{nnr:ACPC}-K-{nnr:ACPC}-L-{nnr:APC}-L-{nnr:ACPC}{cyc:N-C}{ct:Amid} | Peptide 1 | Amidation | Free | Cyclic | L | APC = APC, ACPC = ACPC | 15 | Antibacterial | >10% hemolysis at 3.1 μg/ml | Human | Synthetic peptide | NA | NA | ||
| 17212422 | 2007 | {nnr:APC}-L-{nnr:ACPC}-L-{nnr:APC}-L-{nnr:ACPC}-K-{nnr:ACPC}-L-{nnr:ACPC}-K-{nnr:ACPC}-L-{nnr:APC}{cyc:N-C}{ct:Amid} | Peptide 2 | Amidation | Free | Cyclic | L | APC = APC, ACPC = ACPC | 15 | Antibacterial | >10% hemolysis at 1.6 μg/ml | Human | Synthetic peptide | NA | NA | ||
| 17212422 | 2007 | {nnr:ACPC}-L-{nnr:APC}-K-{nnr:APC}-L-{nnr:ACPC}-K-{nnr:APC}-L-{nnr:ACPC}-L-{nnr:ACPC}-L-{nnr:ACPC}{cyc:N-C}{ct:Amid} | Peptide 3 | Amidation | Free | Cyclic | L | APC = APC, ACPC = ACPC | 15 | Antibacterial | >10% hemolysis at 100 μg/ml | Human | Synthetic peptide | NA | NA | ||
| 17212422 | 2007 | {nnr:APC}-L-{nnr:APC}-L-{nnr:ACPC}-K-{nnr:ACPC}-L-{nnr:ACPC}-L-{nnr:APC}-L-{nnr:ACPC}-K-{nnr:ACPC}{cyc:N-C}{ct:Amid} | Peptide 4 | Amidation | Free | Cyclic | L | APC = APC, ACPC = ACPC | 15 | Antibacterial | >10% hemolysis at 100 μg/ml | Human | Synthetic peptide | NA | NA | ||
| 17212422 | 2007 | {nnr:APC}-L-{nnr:ACPC}-L-{nnr:APC}-L-{nnr:ACPC}-L-{nnr:APC}-L-{nnr:ACPC}-K-{nnr:ACPC}-L-{nnr:APC}{cyc:N-C}{ct:Amid} | Peptide 5 | Amidation | Free | Cyclic | L | APC = APC, ACPC = ACPC | 15 | Antibacterial | >10% hemolysis at 1.6 μg/ml | Human | Synthetic peptide | NA | NA | ||
| 17212422 | 2007 | {nnr:APC}-F-{nnr:ACPC}-L-{nnr:APC}-L-{nnr:ACPC}-F-{nnr:APC}-F-{nnr:ACPC}-K-{nnr:ACPC}-L-{nnr:APC}{cyc:N-C}{ct:Amid} | Peptide 6 | Amidation | Free | Cyclic | L | APC = APC, ACPC = ACPC | 15 | Antibacterial | >10% hemolysis at 1.6 μg/ml | Human | Synthetic peptide | NA | NA | ||
| 17212422 | 2007 | {nnr:APC}-L-{nnr:ACPC}-K-{nnr:ACPC}-A-{nnr:APC}-A-{nnr:ACPC}-K-{nnr:ACPC}-A-{nnr:APC}-L-{nnr:ACPC}{cyc:N-C}{ct:Amid} | Peptide 7 | Amidation | Free | Cyclic | L | APC = APC, ACPC = ACPC | 15 | Antibacterial | >10% hemolysis at >400 μg/ml | Human | Synthetic peptide | NA | NA | ||
| 17212422 | 2007 | {nnr:APC}-L-{nnr:ACPC}-A-{nnr:APC}-A-{nnr:ACPC}-K-{nnr:ACPC}-L-{nnr:ACPC}-K-{nnr:ACPC}-A-{nnr:APC}{cyc:N-C}{ct:Amid} | Peptide 8 | Amidation | Free | Cyclic | L | APC = APC, ACPC = ACPC | 15 | Antibacterial | >10% hemolysis at 100 μg/ml | Human | Synthetic peptide | NA | NA | ||
| 17212422 | 2007 | {nnr:ACPC}-A-{nnr:APC}-K-{nnr:APC}-L-{nnr:ACPC}-K-{nnr:APC}-A-{nnr:ACPC}-A-{nnr:ACPC}-L-{nnr:ACPC}{cyc:N-C}{ct:Amid} | Peptide 9 | Amidation | Free | Cyclic | L | APC = APC, ACPC = ACPC | 15 | Antibacterial | >10% hemolysis at >400 μg/ml | Human | Synthetic peptide | NA | NA | ||
| 18186149 | 2008 | KKKKKKAAFAAWAAFDA{cyc:N-C}{ct:Amid} | 7K-F18-1D17 | Amidation | Free | Cyclic | L | None | 17 | Antimicrobial | MHC =650μM | Human | Synthetic peptide | random coil | NA | ||
| 18186149 | 2008 | K{d}K{d}K{d}K{d}K{d}K{d}A{d}A{d}F{d}A{d}A{d}W{d}A{d}A{d}F{d}A{d}A{d}{cyc:N-C}{ct:Amid} | 6k-f17 | Amidation | Free | Cyclic | D | None | 17 | Antimicrobial | MHC =325μM | Human | Synthetic peptide | random coil | NA | ||
| 18186149 | 2008 | KKKKKKAAFALWAAFAA{cyc:N-C}{ct:Amid} | 6K-F17-1L11 | Amidation | Free | Cyclic | L | None | 17 | Antimicrobial | MHC =81μM | Human | Synthetic peptide | random coil | NA | ||
| 18186149 | 2008 | KKKKKKAAFALWLAFAA{cyc:N-C}{ct:Amid} | 6K-F17-2L11,13 | Amidation | Free | Cyclic | L | None | 17 | Antimicrobial | MHC <81μM | Human | Synthetic peptide | random coil | NA | ||
| 18186149 | 2008 | KKKKKKAAFLAWALFAA{cyc:N-C}{ct:Amid} | 6K-F17-2L10,14 | Amidation | Free | Cyclic | L | None | 17 | Antimicrobial | MHC <81μM | Human | Synthetic peptide | random coil | NA | ||
| 18186149 | 2008 | K{d}K{d}K{d}K{d}K{d}K{d}A{d}A{d}F{d}A{d}A{d}W{d}A{d}A{d}F{d}L{d}L{d}{cyc:N-C}{ct:Amid} | 6k-f17-2l16,17 | Amidation | Free | Cyclic | D | None | 17 | Antimicrobial | MHC <81μM | Human | Synthetic peptide | random coil | NA | ||
| 18186149 | 2008 | KKKKKKALFAAWAAFLA{cyc:N-C}{ct:Amid} | 6K-F17-2L8,16 | Amidation | Free | Cyclic | L | None | 17 | Antimicrobial | MHC <81μM | Human | Synthetic peptide | random coil | NA | ||
| 18186149 | 2008 | KKKKKKLLFAAWAAFAA{cyc:N-C}{ct:Amid} | 6K-F17-2L7,8 | Amidation | Free | Cyclic | L | None | 17 | Antimicrobial | MHC <81μM | Human | Synthetic peptide | random coil | NA | ||
| 18186149 | 2008 | KKKKKKALFALWLAFAA{cyc:N-C}{ct:Amid} | 6K-F17-3L8,11,13 | Amidation | Free | Cyclic | L | None | 17 | Antimicrobial | MHC <<81μM | Human | Synthetic peptide | random coil | NA | ||
| 18186149 | 2008 | KKKKKKAAFALWLAFLA{cyc:N-C}{ct:Amid} | 6K-F17-3L11,13,16 | Amidation | Free | Cyclic | L | None | 17 | Antimicrobial | MHC <<81μM | Human | Synthetic peptide | random coil | NA | ||
| 18186149 | 2008 | KKKKKKALFALWLAFLA{cyc:N-C}{ct:Amid} | 6K-F17-4L8,11,13,16 | Amidation | Free | Cyclic | L | None | 17 | Antimicrobial | MHC <<81μM | Human | Synthetic peptide | random coil | NA | ||
| 18972522 | 2008 | PICTRNGLPVCGETCFGGTCNTPGCTCTW{cyc:N-C} | K1 (B2) | Free | Free | Cyclic | L | None | 29 | Uteroactive and antimicrobial | 100% hemolysis at >0.5 mg/ml | Human | Kalata (Oldenlandia affinis DC) | β-strands | NA | ||
| 18972522 | 2008 | PVCTRNGLPVCGETCVGGTCNTPGCTCSW{cyc:N-C} | K2 (B1) | Free | Free | Cyclic | L | None | 29 | Uteroactive and antimicrobial | 100% hemolysis at >0.5 mg/ml | Human | Kalata (Oldenlandia affinis DC) | β-strands | NA | ||
| 18972522 | 2008 | PICKRNGLPVCGETCTLGTCYTQGCTCSW{cyc:N-C} | K3 (B7) | Free | Free | Cyclic | L | None | 29 | Uteroactive and antimicrobial | 100% hemolysis at >0.5 mg/ml | Human | Kalata (Oldenlandia affinis DC) | β-strands | NA | ||
| 19132829 | 2009 | V{nnr:O}LF{d}PV{nnr:O}LF{d}P{cyc:N-C} | GS | Free | Free | Cyclic | Mix | O = L-Ornithine | 10 | Antimicrobial | HC50=21.1(±2.6)μM | Sheep | Gramicidin S (Bacillus brevis) | β-sheet structure | NA | ||
| 19132829 | 2009 | V{nnr:O}L-{nnr:hpa}-PV{nnr:O}L-{nnr:hpa}-P{cyc:N-C} | GS1 | Free | Free | Cyclic | Mix | O = L-Ornithine, Hpa = homophenylalanine | 10 | Antimicrobial | HC50=7.0(±0.3)μM | Sheep | Gramicidin S analogue (Bacillus brevis) | β-sheet structure | NA | ||
| 19132829 | 2009 | V{nnr:O}L-{nnr:1-nal}-PV{nnr:O}L-{nnr:1-nal}-P{cyc:N-C} | GS2 | Free | Free | Cyclic | Mix | O = L-Ornithine, 1-Nal = 1-naphthylalanine | 10 | Antimicrobial | HC50=5.0(±0.1)μM | Sheep | Gramicidin S analogue (Bacillus brevis) | β-sheet structure | NA | ||
| 19132829 | 2009 | V{nnr:O}L-{nnr:2-nal}-PV{nnr:O}L-{nnr:2-nal}-P{cyc:N-C} | GS3 | Free | Free | Cyclic | Mix | O = L-Ornithine, 2-Nal = 2-naphthylalanine | 10 | Antimicrobial | HC50=7.1(±3.5)μM | Sheep | Gramicidin S analogue (Bacillus brevis) | β-sheet structure | NA | ||
| 19132829 | 2009 | V{nnr:O}L-{nnr:dip}-PV{nnr:O}L-{nnr:dip}-P{cyc:N-C} | GS4 | Free | Free | Cyclic | Mix | O = L-Ornithine, Dip = β,β-diphenylalanine | 10 | Antimicrobial | HC50=8.6(±1.1)μM | Sheep | Gramicidin S analogue (Bacillus brevis) | β-sheet structure | NA | ||
| 19132829 | 2009 | V{nnr:O}L-{nnr:flg}-PV{nnr:O}L-{nnr:flg}-P{cyc:N-C} | GS5 | Free | Free | Cyclic | Mix | O = L-Ornithine, Flg = fluorenylglycine | 10 | Antimicrobial | HC50=6.2(±0.3)μM | Sheep | Gramicidin S analogue (Bacillus brevis) | β-sheet structure | NA | ||
| 19132829 | 2009 | V{nnr:O}L-{nnr:tic}-PV{nnr:O}L-{nnr:tic}-P{cyc:N-C} | GS6 | Free | Free | Cyclic | Mix | O = L-Ornithine, Tic = 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid | 10 | Antimicrobial | HC50 >50 μM | Sheep | Gramicidin S analogue (Bacillus brevis) | β-sheet structure | NA | ||
| 20449481 | 2010 | V{nnr:O}LLF{d}PV{nnr:O}LF{d}P{cyc:N-C} | 2HBr (1) | Free | Free | Cyclic | Mix | O = L-Ornithine | 11 | Antimicrobial | 100% hemolysis at 100μM | Sheep | Gramacidin S (Bacillus brevis ) | antiparallel β-sheet | NA | ||
| 20449481 | 2010 | V{nnr:O}LAF{d}PV{nnr:O}LF{d}P{cyc:N-C} | 2HBr (2) | Free | Free | Cyclic | Mix | O = L-Ornithine | 11 | Antimicrobial | 50% hemolysis at 100μM | Sheep | Gramacidin S (Bacillus brevis ) | antiparallel β-sheet | NA | ||
| 20449481 | 2010 | V{nnr:O}L{nnr:O}F{d}PV{nnr:O}LF{d}P{cyc:N-C} | 3HBr (3) | Free | Free | Cyclic | Mix | O = L-Ornithine | 11 | Antimicrobial | 10% hemolysis at 100μM | Sheep | Gramacidin S (Bacillus brevis ) | antiparallel β-sheet | NA | ||
| 20449481 | 2010 | V{nnr:O}LKF{d}PV{nnr:O}LF{d}P{cyc:N-C} | 3HBr (4) | Free | Free | Cyclic | Mix | O = L-Ornithine | 11 | Antimicrobial | 10% hemolysis at 100μM | Sheep | Gramacidin S (Bacillus brevis ) | antiparallel β-sheet | NA | ||
| 20449481 | 2010 | V{nnr:O}LRF{d}PV{nnr:O}LF{d}P{cyc:N-C} | 3HCl (5) | Free | Free | Cyclic | Mix | O = L-Ornithine | 11 | Antimicrobial | 15% hemolysis at 100μM | Sheep | Gramacidin S (Bacillus brevis ) | antiparallel β-sheet | NA | ||
| 20564013 | 2010 | GTPCGESCVYIPCISGVIGCSCTDKVCYLN{cyc:N-C} | Kalata B5 | Free | Free | Cyclic | L | None | 30 | Pesticidal | HD50 =27.4±1.2μM | Human | Cyclotides (Oldenlandia affinis) | typical bracelet cyclotide fold | NA | ||
| 15009528 | 2004 | VKLK{d}VY{d}PLKVKLY{d}P{cyc:N-C} | GS14KD4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | MHC =125 µg/ml | Human | Gramicidin S analog | NA | NA | ||
| 15009528 | 2004 | VKLL{d}VY{d}PLKVKLY{d}P{cyc:N-C} | GS14LD4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | MHC =5 µg/ml | Human | Gramicidin S analog | NA | NA | ||
| 15009528 | 2004 | VKLF{d}VY{d}PLKVKLY{d}P{cyc:N-C} | GS14FD4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | MHC =2 µg/ml | Human | Gramicidin S analog | NA | NA | ||
| 15009528 | 2004 | VKLY{d}VY{d}PLKVKLY{d}P{cyc:N-C} | GS14YD4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | MHC =5 µg/ml | Human | Gramicidin S analog | NA | NA | ||
| 15009528 | 2004 | VKLN{d}VY{d}PLKVKLY{d}P{cyc:N-C} | GS14ND4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | MHC =62 µg/ml | Human | Gramicidin S analog | NA | NA | ||
| 16235231 | 2006 | {nnr:Z}DRRLSYKQRSVTYORGR{cyc:N-C}{ct:Amid} | cyclo(2-15)[Asp2 Ser6,11, Orn15]-Gm | Amidation | Free | Cyclic | L | Z = pyroglutamic acid | 18 | Antimicrobial | ~10% hemolysis at 100µM | Human | Analog of Gomesin (Acanthoscurria gomesiana) | α-helical and β-sheet | NA | ||
| 16235231 | 2006 | {nnr:Z}SRRLDYKQROVTYSRGR{cyc:N-C}{ct:Amid} | cyclo(6-11)[Ser2,15, Asp6, Orn11]-Gm | Amidation | Free | Cyclic | L | Z = pyroglutamic acid | 18 | Antimicrobial | ~10% hemolysis at 100µM | Human | Analog of Gomesin (Acanthoscurria gomesiana) | α-helical and β-sheet | NA | ||
| 16235231 | 2006 | {nnr:Z}CRRLDYKQROVTYCRGR{cyc:N-C}{ct:Amid} | Bicyclo(2-15, 6-11)[Cys2, 15, Asp6, Orn11]-Gm | Amidation | Free | Cyclic | L | Z = pyroglutamic acid | 18 | Antimicrobial | >30% hemolysis at 100µM | Human | Analog of Gomesin (Acanthoscurria gomesiana) | α-helical and β-sheet | NA | ||
| 16235231 | 2006 | {nnr:Z}CRRLDYKQRBVTYCRGR{cyc:N-C}{ct:Amid} | Bicyclo(2-15, 6-11)[Cys2, 15, Asp6, Dap11]-Gm | Amidation | Free | Cyclic | L | Z = pyroglutamic acid | 18 | Antimicrobial | >30% hemolysis at 100µM | Human | Analog of Gomesin (Acanthoscurria gomesiana) | α-helical and β-sheet | NA | ||
| 16235231 | 2006 | {nnr:Z}DRRLCYKQRCVTYORGR{cyc:N-C}{ct:Amid} | Bicyclo(2-15, 6-11)[Asp2, Cys6, 11, Orn15]-Gm | Amidation | Free | Cyclic | L | Z = pyroglutamic acid | 18 | Antimicrobial | ~15% hemolysis at 100µM | Human | Analog of Gomesin (Acanthoscurria gomesiana) | α-helical and β-sheet | NA | ||
| 16235231 | 2006 | {nnr:Z}DRRLCYKQRCVTYBRGR{cyc:N-C}{ct:Amid} | Bicyclo(2-15, 6-11)[Asp2, Cys6, Dap15]-Gm | Amidation | Free | Cyclic | L | Z = pyroglutamic acid | 18 | Antimicrobial | ~15% hemolysis at 100µM | Human | Analog of Gomesin (Acanthoscurria gomesiana) | α-helical and β-sheet | NA | ||
| 16730857 | 2006 | KFKLKQ{cyc:N-C} | BPC6L | Free | Free | Cyclic | L | None | 6 | Hemolytic | 11±4.6% hemolysis at 360µM | Human | Synthetic peptide | NA | NA | ||
| 16730857 | 2006 | KLKFKLKQ{cyc:N-C} | BPC8L | Free | Free | Cyclic | L | None | 8 | Antibacterial | 68±7.5% hemolysis at 360µM | Human | Synthetic peptide | NA | NA | ||
| 16730857 | 2006 | KLKLKFKLKQ{cyc:N-C} | BPC10L | Free | Free | Cyclic | L | None | 10 | Antibacterial | 81 ± 5.3% hemolysis at 360µM | Human | Synthetic peptide | NA | NA | ||
| 16730857 | 2006 | KLKF{d}KLKQ{cyc:N-C} | BPC8D | Free | Free | Cyclic | Mix | None | 8 | Hemolytic | 37±5.2% hemolysis at 360µM | Human | Synthetic peptide | NA | NA | ||
| 16730857 | 2006 | KLKLKF{d}KLKQ{cyc:N-C} | BPC10D | Free | Free | Cyclic | Mix | None | 10 | Hemolytic | 42± 6.8% hemolysis at 360µM | Human | Synthetic peptide | NA | NA | ||
| 16730857 | 2006 | KLKLKLKQ{cyc:N-C} | BPC8S1 | Free | Free | Cyclic | L | None | 8 | Hemolytic | 1±0.1% hemolysis at 360µM | Human | Synthetic peptide | NA | NA | ||
| 16730857 | 2006 | LKLKLKLQ{cyc:N-C} | BPC8S3 | Free | Free | Cyclic | L | None | 8 | Hemolytic | 5±0.1% hemolysis at 360µM | Human | Synthetic peptide | NA | NA | ||
| 15003352 | 2004 | RLRLRIGRR{cyc:N-C}{ct:Amid} | 9-Fluorenylmethoxycarbonyl (F-moc) | Amidation | Free | Cyclic | L | None | 9 | Antimicrobial | 0% hemolysis at 100µg/ml (non-hemolytic) | Rabbit | Synthetic peptide | NA | Non-hemolytic | ||
| 15003352 | 2004 | RLRLRIGRR{cyc:N-C}{ct:Amid} | 9-Fluorenylmethoxycarbonyl (F-moc) | Amidation | Free | Cyclic | L | None | 9 | Antimicrobial | 0% hemolysis at 100µg/ml (non-hemolytic) | Rabbit | Synthetic peptide | NA | Non-hemolytic | ||
| 15003352 | 2004 | RLRLRIGRR{cyc:N-C}{ct:Amid} | 9-Fluorenylmethoxycarbonyl (F-moc) | Amidation | Free | Cyclic | L | None | 9 | Antimicrobial | 0% hemolysis at 100µg/ml (non-hemolytic) | Rabbit | Synthetic peptide | NA | Non-hemolytic | ||
| 15949628 | 2005 | EWGRRCCGWGPGRRYCVRWC{cyc:N-C} | Ib-AMP1 | Free | Free | Cyclic | L | None | 20 | Antimicrobial | no hemolysis upto 100μM (non-hemolytic) | Rabbit | Synthetic peptide (Impatiens balsamina) | NA | Non-hemolytic | ||
| 15949628 | 2005 | EWGRRCCGWGPGRRYCRRWC{cyc:N-C} | Ib-AMP4 | Free | Free | Cyclic | L | None | 20 | Antimicrobial | no hemolysis upto 100μM (non-hemolytic) | Rabbit | Synthetic peptide (Impatiens balsamina) | NA | Non-hemolytic | ||
| 16730857 | 2006 | KFKQ{cyc:N-C} | BPC4L | Free | Free | Cyclic | L | None | 4 | Antibacterial | 0% hemolysis at 360µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 16730857 | 2006 | KF{d}KQ{cyc:N-C} | BPC4D | Free | Free | Cyclic | Mix | None | 4 | Antibacterial | 0% hemolysis at 360µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 16730857 | 2006 | KF{d}KLKQ{cyc:N-C} | BPC6D | Free | Free | Cyclic | Mix | None | 6 | Antibacterial | 0% hemolysis at 360µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 16730857 | 2006 | KLKLKLKE{cyc:N-C} | BPC8S2 | Free | Free | Cyclic | L | None | 8 | Antibacterial | 0% hemolysis at 360µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 21928440 | 2011 | CGETCVGGTCNTPGCTCSWPVCTRNGLPV{cyc:N-C} | Kalata B1 | Free | Free | Cyclic | L | None | 29 | Anticancer and Anti-HIV | IC50 = 26 µM | Human | Kalata (Oldenlandia affinis) | NA | NA | ||
| 21928440 | 2011 | C{d}G{d}E{d}T{d}C{d}V{d}G{d}G{d}T{d}C{d}N{d}T{d}P{d}G{d}C{d}T{d}C{d}S{d}W{d}P{d}V{d}C{d}T{d}R{d}N{d}G{d}L{d}N{d}P{d}V{d}{cyc:N-C} | D-Kalata B1 | Free | Free | Cyclic | D | None | 29 | Anticancer and Anti-HIV | IC50 = 77 µM | Human | Kalata analog (Oldenlandia affinis) | NA | NA | ||
| 11892852 | 2001 | FLPLLAGLAANFLPKIFCKITRKC{cyc:N-C} | Brevinin 1E (B) | Free | Free | Cyclic | L | None | 24 | Antibacterial | 100% hemolysis at 0.7μM | Rat | Brevinin 1E from the skin secretions of Rana esculenta | NA | NA | ||
| 11892852 | 2001 | FLPLLAGLCKITRKCAANFLPKIF{cyc:N-C} | Analog of brevinin 1E (BA) | Free | Free | Cyclic | L | None | 24 | Antibacterial | 100% hemolysis at 7μM | Rat | Synthetic brevinin 1E variants (Rana esculenta) | NA | NA | ||
| 12404639 | 2002 | LRLKYRRFKYRV{cyc:N-C} | Mimetic 1 | Free | Free | Cyclic | L | None | 12 | Antibacterial | 27% hemolysis at 100µg ml-1 | Human | Synthetic peptide | NA | NA | ||
| 12404639 | 2002 | LRLQYRRFQYRV{cyc:N-C} | Mimetic 2 | Free | Free | Cyclic | L | None | 12 | Antibacterial | 27% hemolysis at 100µg ml-1 | Human | Synthetic peptide | NA | NA | ||
| 12404639 | 2002 | LRLEYRRFEYRV{cyc:N-C} | Mimetic 3 | Free | Free | Cyclic | L | None | 12 | Antibacterial | 14% hemolysis at 100µg ml-1 | Human | Synthetic peptide | NA | NA | ||
| 12404639 | 2002 | LRLKKRRWKYRV{cyc:N-C} | Mimetic 4 | Free | Free | Cyclic | L | None | 12 | Antibacterial | 1% hemolysis at 100µg ml-1 | Human | Synthetic peptide | NA | NA | ||
| 12404639 | 2002 | LRLKKRRWKYRV{cyc:N-C} | Mimetic 5 | Free | Free | Cyclic | L | None | 12 | Antibacterial | 13% hemolysis at 100µg ml-1 | Human | Synthetic peptide | NA | NA | ||
| 12404639 | 2002 | LCLKKRRWKYCV{cyc:N-C} | Mimetic 6 | Free | Free | Cyclic | L | None | 12 | Antibacterial | 3% hemolysis at 100µg ml-1 | Human | Synthetic peptide | NA | NA | ||
| 12404639 | 2002 | LRCKKRRWKCRV{cyc:N-C} | Mimetic 7 | Free | Free | Cyclic | L | None | 12 | Antibacterial | 1% hemolysis at 100µg ml-1 | Human | Synthetic peptide | NA | NA | ||
| 12569105 | 2003 | FFHLHFH-{nnr:dcΔDOPA}{cyc:N-C} | Plicatamide | Free | Free | Cyclic | L | dcΔDOPA = decarboxy-(E)α,β-dehydro3,4-dihydroxyphenylalanine | 8 | Antibacterial | 100% hemolysis at ~40 μM | Human | Plicatamide (Styela plicata) | NA | NA | ||
| 12569105 | 2003 | FFHLHFH-{nnr:dcΔDOPA}{cyc:N-C} | Plicatamide | Free | Free | Cyclic | L | dcΔDOPA = decarboxy-(E)α,β-dehydro3,4-dihydroxyphenylalanine | 8 | Antibacterial | ~10% hemolysis at 80μM | Sheep | Plicatamide (Styela plicata) | NA | NA | ||
| 12712499 | 2003 | V{nnr:O}LF{d}PV{nnr:O}LF{d}P{cyc:N-C} | GS | Free | Free | Cyclic | Mix | O = L-Ornithine | 10 | Antibacterial and Antifungal | 100% hemolysis at 15-50µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | Y{d}PY{d}P{cyc:N-C} | GS4 | Free | Free | Cyclic | Mix | None | 4 | Antibacterial and Antifungal | 100% hemolysis at >150µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | KY{d}PKY{d}P{cyc:N-C} | GS6 | Free | Free | Cyclic | Mix | None | 6 | Antibacterial and Antifungal | 100% hemolysis at >150µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKY{d}PKLY{d}P{cyc:N-C} | GS8 | Free | Free | Cyclic | Mix | None | 8 | Antibacterial and Antifungal | 100% hemolysis at >150µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKLY{d}PVKLY{d}P{cyc:N-C} | GS10 | Free | Free | Cyclic | Mix | None | 10 | Antibacterial and Antifungal | 100% hemolysis at 51–100 µg/mL | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKLKY{d}PKVKLY{d}P{cyc:N-C} | GS12 | Free | Free | Cyclic | Mix | None | 12 | Antibacterial and Antifungal | 100% hemolysis at >150µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKLKVY{d}PLKVKLY{d}P{cyc:N-C} | GS14 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at <15µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | V{d}KLKVY{d}PLKVKLY{d}P{cyc:N-C} | GS14V1 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at 15-50µg/m | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VK{d}LKVY{d}PLKVKLY{d}P{cyc:N-C} | GS14K2 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at 15-50µg/m | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKL{d}KVY{d}PLKVKLY{d}P{cyc:N-C} | GS14L3 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at <15µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKLK{d}VY{d}PLKVKLY{d}P{cyc:N-C} | GS14K4 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at >150µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKLKV{d}Y{d}PLKVKLY{d}P{cyc:N-C} | GS14V5 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at 100–150µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKLKVYPLKVKLY{d}P{cyc:N-C} | GS14Y6 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at 15-50µg/m | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKLKVY{d}P{d}L{d}KVKLY{d}P{cyc:N-C} | GS14P7 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at <15µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKLKVY{d}PL{d}KVKLY{d}P{cyc:N-C} | GS14L8 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at 15-50µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKLKVY{d}PLK{d}VKLY{d}P{cyc:N-C} | GS14K9 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at 51–100 µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKLKVY{d}PLKV{d}KLY{d}P{cyc:N-C} | GS14V10 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at <15µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKLKVY{d}PLKVK{d}LY{d}P{cyc:N-C} | GS14K11 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at 100–150µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKLKVY{d}PLKVKL{d}Y{d}P{cyc:N-C} | GS14L12 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at 15-50µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKLKVY{d}PLKVKLYP{cyc:N-C} | GS14Y13 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at < 15µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKLKVY{d}PLKVKLY{d}P{d}{cyc:N-C} | GS14P14 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at < 15µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKKLVY{d}PLKVKLY{d}P{cyc:N-C} | GS14 K3L4 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at 100–150µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | LKLK{d}LF{d}PLKLKLF{d}P{cyc:N-C} | GS14K4 Y2/F2, V3/L3 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at < 15µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | LKLK{d}LY{d}PLKLKLY{d}P{cyc:N-C} | GS14K4 V3/L3 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at 15-50µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKLK{d}VF{d}PLKVKLF{d}P{cyc:N-C} | GS14K4 Y2/F2 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at 15-50µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKLK{d}VY{d}PLKVKLY{d}P{cyc:N-C} | GS14K4 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at > 150µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | AKLK{d}AY{d}PLKAKLY{d}P{cyc:N-C} | GS14K4 V3/A3 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at > 150µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKAK{d}VY{d}PAKVKAY{d}P{cyc:N-C} | GS14K4 L3/A3 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at > 150µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | AKAK{d}AY{d}PAKAKAY{d}P{cyc:N-C} | GS14K4 V3L3/A6 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at > 150µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 15328096 | 2004 | CVKVKVKVGSGVKVKVKVC{cyc:N-C}{nt:Acet}{ct:Amid} | V1 | Amidation | Acetylation | Cyclic | L | None | 19 | Antibacterial | EC50 = 880000 nM | Human | Synthetic peptide | NA | NA | ||
| 15328096 | 2004 | CVKVSVKVGSGVKVSVKVC{cyc:N-C}{nt:Acet}{ct:Amid} | V2 | Amidation | Acetylation | Cyclic | L | None | 19 | Antibacterial | EC50 = 5,89,000 nM | Human | Synthetic peptide | NA | NA | ||
| 15328096 | 2004 | CVKVRVKVGSGVKVRVKVC{cyc:N-C}{nt:Acet}{ct:Amid} | V3 | Amidation | Acetylation | Cyclic | L | None | 19 | Antibacterial | EC50 = 590000 nM | Human | Synthetic peptide | NA | NA | ||
| 15328096 | 2004 | CVKVQVKVGSGVKVQVKVC{cyc:N-C}{nt:Acet}{ct:Amid} | V4 | Amidation | Acetylation | Cyclic | L | None | 19 | Antibacterial | EC50 = 3226000 nM | Human | Synthetic peptide | NA | NA | ||
| 15328096 | 2004 | CAKAKAKAGSGAKAKAKAC{cyc:N-C}{nt:Acet}{ct:Amid} | V5 | Amidation | Acetylation | Cyclic | L | None | 19 | Antibacterial | EC50 = 1055000 nM | Human | Synthetic peptide | NA | NA | ||
| 15328096 | 2004 | CFKFKFKFGSGFKFKFKFC{cyc:N-C}{nt:Acet}{ct:Amid} | V6 | Amidation | Acetylation | Cyclic | L | None | 19 | Antibacterial | EC50 = 35000 nM | Human | Synthetic peptide | NA | NA | ||
| 15328096 | 2004 | CWKWKWKWGSGWKWKWKWC{cyc:N-C}{nt:Acet}{ct:Amid} | V7 | Amidation | Acetylation | Cyclic | L | None | 19 | Antibacterial | EC50 = 45000 nM | Human | Synthetic peptide | NA | NA | ||
| 15345319 | 2004 | TFRRLKWK{cyc:N-C} | LALF-10 | Free | Free | Cyclic | L | None | 8 | Antimicrobial | ~5% hemolysis at 100µg/ml | Human | Limulus analogs (Limulus polyphemus) | NA | NA | ||
| 15345319 | 2004 | TFRRLKWK{cyc:N-C} | LALF-11 | Free | Free | Cyclic | L | None | 8 | Antimicrobial | ~5% hemolysis at 100µg/ml | Human | Limulus analogs (Limulus polyphemus) | NA | NA | ||
| 15345319 | 2004 | KPTFRRLKWKYK{cyc:N-C} | LALF-14 | Free | Free | Cyclic | L | None | 12 | Antimicrobial | ~5% hemolysis at 100µg/ml | Human | Limulus analogs (Limulus polyphemus) | NA | NA | ||
| 15345319 | 2004 | HYRIKPTFRRLKWKYKGKFW{cyc:N-C} | LALf-22 | Free | Free | Cyclic | L | None | 20 | Antimicrobial | ~20% hemolysis at 100µg/ml | Human | Limulus analogs (Limulus polyphemus) | NA | NA | ||
| 11846794 | 2002 | RLYRKVYG{cyc:N-C} | RLYRKVYG | Free | Free | Cyclic | L | None | 17 | Antibacterial and Antifungal | EC50 = 3950µM | Human | Synthetic peptide | NA | NA | ||
| 11846794 | 2002 | RLYRKVYGRLYRKVYGK{cyc:N-C} | (RLYRKVYG)2-[K] | Free | Free | Cyclic | L | None | 17 | Antibacterial and Antifungal | EC50 = 1420µM | Human | Synthetic peptide | NA | NA | ||
| 11846794 | 2002 | RLYRKVYGRLYRKVYGRLYRKVYGRLYRKVYGKKK{cyc:N-C} | (RLYRKVYG)4-[K2K] | Free | Free | Cyclic | L | None | 35 | Antibacterial and Antifungal | EC50 = 610µM | Human | Synthetic peptide | NA | NA | ||
| 11846794 | 2002 | RLYRKVYGRLYRKVYGRLYRKVYGRLYRKVYGRLYRKVYGRLYRKVYGRLYRKVYGKKKKK{cyc:N-C} | (RLYRKVYG)8 (K2K)2K | Free | Free | Cyclic | L | None | 63 | Antibacterial and Antifungal | EC50 = 112µM | Human | Synthetic peptide | NA | NA | ||
| 10819172 | 2000 | KLLLKLLLKLLK{cyc:N-C}{ct:Amid} | S1 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial | 100% hemolysis at 200µg/ml | Mouse | Synthetic peptide | NA | NA | ||
| 10819172 | 2000 | KLLLKLLLKLLK{cyc:N-C}{ct:Amid} | SC1 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial | 100% hemolysis at 200µg/ml | Mouse | Synthetic peptide | NA | NA | ||
| 10819172 | 2000 | KLLLKLLLKLLK{cyc:N-C}{ct:Amid} | SC2 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial | ~90% hemolysis at 200µg/ml | Mouse | Synthetic peptide | NA | NA | ||
| 11606214 | 2001 | V{nnr:O}LF{d}PV{nnr:O}LF{d}P{cyc:N-C} | GS | Free | Free | Cyclic | Mix | O = L-Ornithine | 10 | Antimicrobial | Strong hemolysis | Human | Gramicidin S | NA | NA | ||
| 11606214 | 2001 | VKLY{d}PVKLY{d}P{cyc:N-C} | GS10 | Free | Free | Cyclic | Mix | None | 10 | Antimicrobial | Strong hemolysis | Human | Gramicidin S analogs | NA | NA | ||
| 11606214 | 2001 | VKLKY{d}PKVKLY{d}P{cyc:N-C} | GS12 | Free | Free | Cyclic | Mix | None | 12 | Antimicrobial | Weak hemolysis | Human | Gramicidin S analogs | NA | NA | ||
| 11606214 | 2001 | VKLKVY{d}PLKVKLY{d}P{cyc:N-C} | GS14 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | Very strong hemolysis | Human | Gramicidin S analogs | NA | NA | ||
| 11606214 | 2001 | VKLK{d}VY{d}PLKVKLY{d}P{cyc:N-C} | [D-Lys]4GS14 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | Weak hemolysis | Human | Gramicidin S analogs | NA | NA | ||
| 11682479 | 2002 | VKLKVY{d}PLKVKLY{d}P{cyc:N-C} | GS14 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at 1.5µg/ml | Human | Synthetic peptide | NA | NA | ||
| 11682479 | 2002 | LKLK{d}LF{d}PLKLKLF{d}P{cyc:N-C} | Y2/F2, V3/L3 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at 12.5µg/ml | Human | Synthetic peptide | NA | NA | ||
| 11682479 | 2002 | LKLK{d}LY{d}PLKLKLY{d}P{cyc:N-C} | V3/L3 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at 25µg/ml | Human | Synthetic peptide | NA | NA | ||
| 11682479 | 2002 | VKLK{d}VF{d}PLKVKLF{d}P{cyc:N-C} | Y2/F2 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at 40µg/ml | Human | Synthetic peptide | NA | NA | ||
| 11682479 | 2002 | VKLK{d}VY{d}PLKVKLY{d}P{cyc:N-C} | GS14K4 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at 200µg/ml | Human | Synthetic peptide | NA | NA | ||
| 11682479 | 2002 | AKLK{d}AY{d}PLKAKLY{d}P{cyc:N-C} | V3/A3 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at >800µg/ml | Human | Synthetic peptide | NA | NA | ||
| 11682479 | 2002 | VKAK{d}VY{d}PAKVKAY{d}P{cyc:N-C} | L3/A3 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at >800µg/ml | Human | Synthetic peptide | NA | NA | ||
| 11682479 | 2002 | AKAK{d}AY{d}PAKAKAY{d}P{cyc:N-C} | V3L3/A6 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at >800µg/ml | Human | Synthetic peptide | NA | NA | ||
| 10799508 | 2000 | VKLKVY{d}PLKVKLY{d}P{cyc:N-C} | GS14 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 100% hemolysis at 10µg/ml | Human | Synthetic peptide | NA | NA | ||
| 10799508 | 2000 | VKLK{d}VY{d}PLKVKLY{d}P{cyc:N-C} | GS14 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 100% hemolysis at 100µg/ml | Human | Synthetic peptide | NA | NA | ||
| 10799508 | 2000 | VKLK{d}VY{d}PLKVKLY{d}P{cyc:N-C} | GS14K4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 1% hemolysis at 10µg/ml | Human | Synthetic peptide | NA | NA | ||
| 10799508 | 2000 | VKLK{d}VY{d}PLKVKLY{d}P{cyc:N-C} | GS14K4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 8% hemolysis at 100µg/ml | Human | Synthetic peptide | NA | NA | ||
| 10799508 | 2000 | VKKLVY{d}PLKVKLY{d}P{cyc:N-C} | GS14K3L4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 3% hemolysis at 10µg/ml | Human | Synthetic peptide | NA | NA | ||
| 10799508 | 2000 | VKKLVY{d}PLKVKLY{d}P{cyc:N-C} | GS14K3L4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 37% hemolysis at 100µg/ml | Human | Synthetic peptide | NA | NA | ||
| 10747913 | 2000 | CGETCVGGTCNTPGCTCSWPVCTRNGLPV{cyc:N-C} | Kalata B1 | Free | Free | Cyclic | L | None | 29 | Anti-HIV | 50% hemolytic at 50μM | Human | Macrocyclic peptides | NA | NA | ||
| 10799508 | 2000 | VKLKVY{d}PLKVKLY{d}P{cyc:N-C} | GS14 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 100% hemolytic at 10μg/ml | Human | Synthetic peptide | NA | NA | ||
| 10799508 | 2000 | VKLKVY{d}PLKVKLY{d}P{cyc:N-C} | GS14 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 100% hemolytic at 100μg/ml | Human | Synthetic peptide | NA | NA | ||
| 10799508 | 2000 | VKLK{d}VY{d}PLKVKLY{d}P{cyc:N-C} | GS14K4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 1% hemolytic at 10μg/ml | Human | Synthetic peptide | NA | NA | ||
| 10799508 | 2000 | VKLK{d}VY{d}PLKVKLY{d}P{cyc:N-C} | GS14K4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 8% hemolytic at 100μg/ml | Human | Synthetic peptide | NA | NA | ||
| 10799508 | 2000 | VKKLVY{d}PLKVKLY{d}P{cyc:N-C} | GS14K3L4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 3% hemolytic at 10μg/ml | Human | Synthetic peptide | NA | NA | ||
| 10799508 | 2000 | VKKLVY{d}PLKVKLY{d}P{cyc:N-C} | GS14K3L4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 37% hemolytic at 100μg/ml | Human | Synthetic peptide | NA | NA | ||
| 12931994 | 2003 | RGGRLCYCRRRFCVCVGR{cyc:N-C}{ct:Amid} | Protegrin-I (2) | Amidation | Free | Cyclic | L | None | 18 | Antimicrobial | 37% hemolytic at 100μg/ml | Human | Protegrin | NA | NA | ||
| 12931994 | 2003 | LRLKKRRWKYRVP{d}{cyc:N-C} | 5 | Free | Free | Cyclic | Mix | None | 13 | Antimicrobial | 1.4% hemolytic at 100μg/ml | Human | Protegrin | NA | NA | ||
| 10821683 | 2000 | CKLLLKWLLKLLKC{cyc:N-C} | Cyclic-K4L7W | Free | Free | Cyclic | L | None | 14 | Cytolytic | 50% hemolytic at 50μM | Human | Synthetic peptide | NA | NA | ||
| 10821683 | 2000 | C{d}K{d}L{d}L{d}L{d}K{d}W{d}L{d}L{d}K{d}L{d}L{d}K{d}C{d}{cyc:N-C} | cyclic-[D]-L3,4,8,10-K4L7W | Free | Free | Cyclic | D | None | 14 | Cytolytic | 90% hemolytic at 50μM | Human | Synthetic peptide | NA | NA | ||
| 10224074 | 1999 | V{nnr:O}LF{d}PV{nnr:O}LF{d}P{cyc:N-C} | GS | Free | Free | Cyclic | Mix | O = L-Ornithine | 10 | Antimicrobial and Hemolytic | 100% hemolytic at 12.5 μg/ml | Human | Derivative of Gramicidin S | NA | NA | ||
| 10224074 | 1999 | VKLKVY{d}PLKVKLY{d}P{cyc:N-C} | GS14 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 100% hemolytic at 1.5 μg/ml | Human | Derivative of Gramicidin S | NA | NA | ||
| 10224074 | 1999 | VKLKVY{d}PLKV{d}KLY{d}P{cyc:N-C} | GS14V10 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 100% hemolytic at 6.2 μg/ml | Human | Derivative of Gramicidin S | NA | NA | ||
| 10224074 | 1999 | VKL{d}KVY{d}PLKVKLY{d}P{cyc:N-C} | GS14L3 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 100% hemolytic at 12.5 μg/ml | Human | Derivative of Gramicidin S | NA | NA | ||
| 10224074 | 1999 | VKLKVY{d}PLKVKLY{d}P{d}{cyc:N-C} | GS14P14 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 100% hemolytic at 6.2 μg/ml | Human | Derivative of Gramicidin S | NA | NA | ||
| 10224074 | 1999 | VKLKVY{d}P{d}LKVKLY{d}P{cyc:N-C} | GS14P7 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 100% hemolytic at 12.5 μg/ml | Human | Derivative of Gramicidin S | NA | NA | ||
| 10224074 | 1999 | VKLKVY{d}PLKVKLY{d}P{cyc:N-C} | GS14V1 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 100% hemolytic at 40 μg/ml | Human | Derivative of Gramicidin S | NA | NA | ||
| 10224074 | 1999 | VKLKVY{d}PLKVKL{d}Y{d}P{cyc:N-C} | GS14L12 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 100% hemolytic at 25 μg/ml | Human | Derivative of Gramicidin S | NA | NA | ||
| 10224074 | 1999 | VKLKV{d}Y{d}PLKVKLY{d}P{cyc:N-C} | GS14V5 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 100% hemolytic at 150 μg/ml | Human | Derivative of Gramicidin S | NA | NA | ||
| 10224074 | 1999 | VKLKVY{d}PLKVKLYP{cyc:N-C} | GS14Y13 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 100% hemolytic at 12.5 μg/ml | Human | Derivative of Gramicidin S | NA | NA | ||
| 10224074 | 1999 | VKLKVY{d}PL{d}KVKLY{d}P{cyc:N-C} | GS14L8 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 100% hemolytic at 50 μg/ml | Human | Derivative of Gramicidin S | NA | NA | ||
| 10224074 | 1999 | VKLKVYPLKVKLY{d}P{cyc:N-C} | GS14Y6 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 100% hemolytic at 25 μg/ml | Human | Derivative of Gramicidin S | NA | NA | ||
| 10224074 | 1999 | VK{d}LKVY{d}PLKVKLY{d}P{cyc:N-C} | GS14K2 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 100% hemolytic at 50 μg/ml | Human | Derivative of Gramicidin S | NA | NA | ||
| 10224074 | 1999 | VKLKVY{d}PLK{d}VKLY{d}P{cyc:N-C} | GS14K9 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 100% hemolytic at 100 μg/ml | Human | Derivative of Gramicidin S | NA | NA | ||
| 10224074 | 1999 | VKLK{d}VY{d}PLKVKLY{d}P{cyc:N-C} | GS14K4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 100% hemolytic at 200 μg/ml | Human | Derivative of Gramicidin S | NA | NA | ||
| 10224074 | 1999 | VKLKVY{d}PLKVK{d}LY{d}P{cyc:N-C} | GS14K11 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 100% hemolytic at 150 μg/ml | Human | Derivative of Gramicidin S | NA | NA | ||
| 10224074 | 1999 | VK{d}LK{d}VY{d}PLKVKLY{d}P{cyc:N-C} | GS14K2K4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 100% hemolytic at >200 μg/ml | Human | Derivative of Gramicidin S | NA | NA | ||
| 10224074 | 1999 | VK{d}LK{d}VY{d}PLK{d}VK{d}LY{d}P{cyc:N-C} | GS14K2K4K9K11 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 100% hemolytic at >200 μg/ml | Human | Derivative of Gramicidin S | NA | NA | ||
| 22249992 | 2012 | NWCKRGRKQCKTHPH{cyc:N-C} | NWC15c | Free | Free | Cyclic | L | None | 15 | Antimicrobial | ~2% hemolytic at 6μM | Human | ß-amyloid precursor protein derivative (Homo sapien) | NA | NA | ||
| 22249992 | 2012 | NWCKRGRKQCKTHPH{cyc:N-C} | NWC15c | Free | Free | Cyclic | L | None | 15 | Antimicrobial | ~3% hemolytic at 60μM | Human | ß-amyloid precursor protein derivative (Homo sapien) | NA | NA | ||
| 22249992 | 2012 | NWCKRGRKQCKTHPHFVIPY{cyc:N-C} | NWC20c | Free | Free | Cyclic | L | None | 20 | Antimicrobial | ~4% hemolytic at 6μM | Human | ß-amyloid precursor protein derivative (Homo sapien) | NA | NA | ||
| 22249992 | 2012 | NWCKRGRKQCKTHPHFVIPY{cyc:N-C} | NWC20c | Free | Free | Cyclic | L | None | 20 | Antimicrobial | ~3% hemolytic at 60μM | Human | ß-amyloid precursor protein derivative (Homo sapien) | NA | NA | ||
| 22038181 | 2012 | GLPRKILCAIAKKKGKCKGPLKLVCKC{cyc:N-C} | Lasiocepsin | Free | Free | Cyclic | L | None | 27 | Antimicrobial | <1% hemolytic at 200μM | Human | Lasiocepsin (From venom of eusocial bee, Lasioglossum laticeps) | NA | NA | ||
| 22038181 | 2012 | GLPRKILCAIAKKKGKCKGPLKLVCKC{cyc:N-C}{ct:Amid} | Lasiocepsin-NH2 | Amidation | Free | Cyclic | L | None | 27 | Antimicrobial | <1% hemolytic at 200μM | Human | Lasiocepsin analogs (From venom of eusocial bee, Lasioglossum laticeps) | NA | NA | ||
| 22038181 | 2012 | GLPRKILCAIAKKKGKCKGPLKLVCKC{cyc:N-C} | Las[C8-C27, C17-C25] | Free | Free | Cyclic | L | None | 27 | Antimicrobial | <1% hemolytic at 200μM | Human | Lasiocepsin analogs (From venom of eusocial bee, Lasioglossum laticeps) | NA | NA | ||
| 22038181 | 2012 | GLPRKILCAIAKKKGKCKGPLKLVCKC{cyc:N-C} | Las[C8-C17, C25-C27] | Free | Free | Cyclic | L | None | 27 | Antimicrobial | <1% hemolytic at 200μM | Human | Lasiocepsin analogs (From venom of eusocial bee, Lasioglossum laticeps) | NA | NA | ||
| 22038181 | 2012 | GLPRKILCAIAKKKGKAKGPLKLVCKA{cyc:N-C} | Las[C8-C25, Ala17,27] | Free | Free | Cyclic | L | None | 27 | Antimicrobial | <1% hemolytic at 200μM | Human | Lasiocepsin analogs (From venom of eusocial bee, Lasioglossum laticeps) | NA | NA | ||
| 22038181 | 2012 | GLPRKILAAIAKKKGKCKGPLKLVAKC{cyc:N-C} | Las[C17-C27, Ala8,25] | Free | Free | Cyclic | L | None | 27 | Antimicrobial | <1% hemolytic at 200μM | Human | Lasiocepsin analogs (From venom of eusocial bee, Lasioglossum laticeps) | NA | NA | ||
| 22038181 | 2012 | LCAIAKKKGKCKGPLKLVCKC{cyc:N-C}{ct:Amid} | Las[des1-6]-NH2 | Amidation | Free | Cyclic | L | None | 21 | Antimicrobial | <1% hemolytic at 200μM | Human | Lasiocepsin analogs (From venom of eusocial bee, Lasioglossum laticeps) | NA | NA | ||
| 22038181 | 2012 | AKKKGKCKGPLKLVAKC{cyc:N-C}{ct:Amid} | Las[des1-10, Ala25]-NH2 | Amidation | Free | Cyclic | L | None | 17 | Antimicrobial | <1% hemolytic at 200μM | Human | Lasiocepsin analogs (From venom of eusocial bee, Lasioglossum laticeps) | NA | NA | ||
| 20848624 | 2010 | F{d}PV{nnr:O}LF{d}PV{nnr:O}L{cyc:N-C} | GS | Free | Free | Cyclic | Mix | O = L-Ornithine | 10 | Antimicrobial | HC50=17.5±1.07μM | Human | Gramicidin S | NA | NA | ||
| 20848624 | 2010 | F{d}PV{nnr:O}LF{d}P-{nnr:Ada}-G{nnr:O}L{cyc:N-C} | GS2 | Free | Free | Cyclic | Mix | O = L-Ornithine, Ada = Adamantylglycine | 10 | Antimicrobial | HC50=10.1±1.11μM | Human | Gramicidin S analogue | NA | NA | ||
| 20848624 | 2010 | F{d}PV{nnr:O}LF{d}PV{nnr:O}-{nnr:Ada}-A{cyc:N-C} | GS4 | Free | Free | Cyclic | Mix | O = L-Ornithine, Ada = Adamantylglycine | 10 | Antimicrobial | HC50 =5.20±1.13μM | Human | Gramicidin S analogue | NA | NA | ||
| 20848624 | 2010 | F{d}PV{nnr:O}-{nnr:Ada}-AF{d}PV{nnr:O}-{nnr:Ada}-A{cyc:N-C} | GS5 | Free | Free | Cyclic | Mix | O = L-Ornithine, Ada = Adamantylglycine | 10 | Antimicrobial | HC50 =10.3±1.07μM | Human | Gramicidin S analogue | NA | NA | ||
| 20848624 | 2010 | F{d}P-{nnr:Ada}-G{nnr:O}-{nnr:Ada}-AF{d}P-{nnr:Ada}-G{nnr:O}-{nnr:Ada}-A{cyc:N-C} | GS6 | Free | Free | Cyclic | Mix | O = L-Ornithine, Ada = Adamantylglycine | 10 | Antimicrobial | HC50 =7.55±1.10μM | Human | Gramicidin S analogue | NA | NA | ||
| 20848624 | 2010 | FP-{nnr:tBuGly}-{nnr:O}-{nnr:tBuAla}-F{d}P-{nnr:tBuGly}-{nnr:O}-{nnr:tBuAla}{cyc:N-C} | GS7 | Free | Free | Cyclic | Mix | O = L-Ornithine, tBuGly = tert-butylglycine, tBuAla = tert-butylalanine | 10 | Antimicrobial | HC50 =9.30±1.07μM | Human | Gramicidin S analogue | NA | NA | ||
| 20848624 | 2010 | F{d}P-{nnr:Chg}-{nnr:O}-{nnr:Cha}-F{d}P-{nnr:Chg}-{nnr:O}-{nnr:Cha}{cyc:N-C} | GS8 | Free | Free | Cyclic | Mix | O = L-Ornithine, Chg = Cyclohexylglycine, Cha = Cyclohexylalanine | 10 | Antimicrobial | HC50 =9.12±1.13μM | Human | Gramicidin S analogue | NA | NA | ||
| 20848624 | 2010 | F{d}P{nnr:O}V{nnr:O}{cyc:N-C} | GS9 | Free | Free | Cyclic | Mix | O = L-Ornithine | 10 | Antimicrobial | Non-hemolytic | Human | Gramicidin S analogue | NA | NA | ||
| 20848624 | 2010 | F{d}P{nnr:O}-{nnr:Ada}Gly-{nnr:O}F{d}P{nnr:O}-{nnr:Ada}-Gly-{nnr:O}{cyc:N-C} | GS10 | Free | Free | Cyclic | Mix | O = L-Ornithine, Ada = Adamantylglycine | 10 | Antimicrobial | HC50=107±1.07μM | Human | Gramicidin S analogue | NA | NA | ||
| 21820306 | 2011 | {nnr:tle}-K-{nnr:tle}-A-{nnr:tle}-A-{nnr:tle}-A{cyc:N-C} | A | Free | Free | Cyclic | Mix | tle = D-Tert-leucine | 8 | Antimicrobial | HC50 =17μM | Human | Synthetic peptides | NA | NA | ||
| 21820306 | 2011 | {nnr:Tle}-K{d}-{nnr:Tle}-A{d}-{nnr:Tle}-A{d}-{nnr:Tle}-A{d}{cyc:N-C} | B | Free | Free | Cyclic | Mix | Tle = Tert-leucine | 8 | Antimicrobial | HC50 =17μM | Human | Synthetic peptides | NA | NA | ||
| 21820306 | 2011 | {nnr:tle}-K{d}-{nnr:tle}-A-{nnr:tle}-A-{nnr:tle}-A{cyc:N-C} | C | Free | Free | Cyclic | Mix | tle = D-Tert-leucine | 8 | Antimicrobial | HC50 =316μM | Human | Synthetic peptides | NA | NA | ||
| 21820306 | 2011 | {nnr:Tle}-K-{nnr:Tle}-A{d}-{nnr:Tle}-A{d}-{nnr:Tle}-A{d}{cyc:N-C} | D | Free | Free | Cyclic | Mix | Tle = Tert-leucine | 8 | Antimicrobial | HC50 =316μM | Human | Synthetic peptides | NA | NA | ||
| 22040603 | 2011 | CYCRKGHCKRGERVRGTCGIRFLYCCPRRGLL{cyc:N-C} | Crp4-1 | Free | Free | Cyclic | L | None | 32 | Antimicrobial | 4.2% hemolytic at 0μg/ml | Human | Synthetic peptide of Crp4 | NA | NA | ||
| 22040603 | 2011 | CYCRKGHCKRGERVRGTCGIRFLYCCPRRGLL{cyc:N-C} | Crp4-1 | Free | Free | Cyclic | L | None | 32 | Antimicrobial | 5.4% hemolytic at 12.5μg/ml | Human | Synthetic peptide of Crp4 | NA | NA | ||
| 22040603 | 2011 | CYCRKGHCKRGERVRGTCGIRFLYCCPRRGLL{cyc:N-C} | Crp4-1 | Free | Free | Cyclic | L | None | 32 | Antimicrobial | 5.8% hemolytic at 25μg/ml | Human | Synthetic peptide of Crp4 | NA | NA | ||
| 22040603 | 2011 | CYCRKGHCKRGERVRGTCGIRFLYCCPRRGLL{cyc:N-C} | Crp4-1 | Free | Free | Cyclic | L | None | 32 | Antimicrobial | 5.9% hemolytic at 50μg/ml | Human | Synthetic peptide of Crp4 | NA | NA | ||
| 22040603 | 2011 | CYCRKGHCKRGERVRGTCGIRFLYCCPRRGLL{cyc:N-C} | Crp4-1 | Free | Free | Cyclic | L | None | 32 | Antimicrobial | 4.9% hemolytic at 100 μ g/mL | Human | Synthetic peptide of Crp4 | NA | NA | ||
| 21576247 | 2011 | GLPVCGETCVGGTCNTPGCTCSWPVCTRN{cyc:N-C} | kB1 | Free | Free | Cyclic | L | None | 29 | Hemolytic and Anti-HIV | 41.2 ±1.5% hemolytic at 25μM | Human | Kalata B1 (Oldenlandia affinis) | NA | NA | ||
| 21576247 | 2011 | GLPKCGETCVGGTCNTPGCTCSWPVCTRN{cyc:N-C} | V4K | Free | Free | Cyclic | L | None | 29 | Hemolytic and Anti-HIV | 2.9±0.5% hemolytic at 25μM | Human | kalata B1 analog (Oldenlandia affinis) | NA | NA | ||
| 21576247 | 2011 | GLPVCGDTCVGGTCNTPGCTCSWPVCTRN{cyc:N-C} | E7D | Free | Free | Cyclic | L | None | 29 | Hemolytic and Anti-HIV | 3.8±0.4% hemolytic at 25μM | Human | kalata B1 analog (Oldenlandia affinis) | NA | NA | ||
| 21576247 | 2011 | GLPVCGEKCVGGTCNTPGCTCSWPVCTRN{cyc:N-C} | T8K | Free | Free | Cyclic | L | None | 29 | Hemolytic and Anti-HIV | 3.4±0.7% hemolytic at 25μM | Human | kalata B1 analog (Oldenlandia affinis) | NA | NA | ||
| 21576247 | 2011 | GLPVCGETCKGGTCNTPGCTCSWPVCTRN{cyc:N-C} | V10K | Free | Free | Cyclic | L | None | 29 | Hemolytic and Anti-HIV | 0±1.7% hemolytic at 25μM | Human | kalata B1 analog (Oldenlandia affinis) | NA | Non-hemolytic | ||
| 21576247 | 2011 | GLPVCGETCVGGTCKTPGCTCSWPVCTRN{cyc:N-C} | N15K | Free | Free | Cyclic | L | None | 29 | Hemolytic and Anti-HIV | 2.1±0.4% hemolytic at 25μM | Human | kalata B1 analog (Oldenlandia affinis) | NA | NA | ||
| 21576247 | 2011 | GLPVCGETCVGGTCNKPGCTCSWPVCTRN{cyc:N-C} | T16K | Free | Free | Cyclic | L | None | 29 | Hemolytic and Anti-HIV | 4.3±0.1% hemolytic at 25μM | Human | kalata B1 analog (Oldenlandia affinis) | NA | NA | ||
| 21576247 | 2011 | GLPVCGETCVGGTCNTPGCKCSWPVCTRN{cyc:N-C} | T20K | Free | Free | Cyclic | L | None | 29 | Hemolytic and Anti-HIV | 51.3±1.6% hemolytic at 25μM | Human | kalata B1 analog (Oldenlandia affinis) | NA | NA | ||
| 21576247 | 2011 | GLPVCGETCVGGTCNTPGCTCSWPKCTRN{cyc:N-C} | V25K | Free | Free | Cyclic | L | None | 29 | Hemolytic and Anti-HIV | 1.1±1.0% hemolytic at 25μM | Human | kalata B1 analog (Oldenlandia affinis) | NA | NA | ||
| 21576247 | 2011 | GLPVCGETCVGGTCNTPGCTCSWPVCTRK{cyc:N-C} | N29K | Free | Free | Cyclic | L | None | 29 | Hemolytic and Anti-HIV | 54.5±0.9% hemolytic at 25μM | Human | kalata B1 analog (Oldenlandia affinis) | NA | NA | ||
| 21576247 | 2011 | GLPVCGETCVGGTCNTPGCTCSKPVCTRN{cyc:N-C} | W23K | Free | Free | Cyclic | L | None | 29 | Hemolytic and Anti-HIV | 2.4±0.7% hemolytic at 25μM | Human | kalata B1 analog (Oldenlandia affinis) | NA | NA | ||
| 21576247 | 2011 | GLPVCGETCVGGTCNTPGCNCSWPVCTRK{cyc:N-C} | T20N29K | Free | Free | Cyclic | L | None | 29 | Hemolytic and Anti-HIV | 64.4±2.2% hemolytic at 25μM | Human | kalata B1 analog (Oldenlandia affinis) | NA | NA | ||
| 21576247 | 2011 | GLPVCGETCVGGTCNTPGCTCSWPVCTKN{cyc:N-C} | R28K | Free | Free | Cyclic | L | None | 29 | Hemolytic and Anti-HIV | 12.0±1.8% hemolytic at 25μM | Human | kalata B1 analog (Oldenlandia affinis) | NA | NA | ||
| 19038369 | 2009 | ILPWKWPWWPWRR{cyc:N-C}{ct:Amid} | ID | Amidation | Free | Cyclic | L | None | 13 | Antimicrobial | 5-10% hemolysis at 25μg/mL | Human | Cytoplasmic granules of bovine neutrophils | NA | NA | ||
| 19038369 | 2009 | I{nnr:*}LPWKWPWWPWRR{cyc:N-C}{ct:Amid} | ID-I | Amidation | Free | Cyclic | L | * = Reduced amide bond ψCH2NH | 13 | Antimicrobial | 5-10% hemolysis at 25μg/mL | Human | Indolicidin analog | NA | NA | ||
| 19038369 | 2009 | ILPWKWPW{nnr:*}WPWRR{cyc:N-C}{ct:Amid} | ID-W | Amidation | Free | Cyclic | L | * = Reduced amide bond ψCH2NH | 13 | Antimicrobial | 5-10% hemolysis at 25μg/mL | Human | Indolicidin analog | NA | NA | ||
| 19038369 | 2009 | I{nnr:*}LPWKWPW{nnr:*}WPWRR{cyc:N-C}{ct:Amid} | ID-IW | Amidation | Free | Cyclic | L | * = Reduced amide bond ψCH2NH | 13 | Antimicrobial | 5% hemolysis at 25μg/mL | Human | Indolicidin analog | NA | NA | ||
| 19038369 | 2009 | ILPWKWPWWPWRR{cyc:N-C}{ct:Amid} | ID | Amidation | Free | Cyclic | L | None | 13 | Antimicrobial | 10% hemolysis at 50μg/mL | Human | Cytoplasmic granules of bovine neutrophils | NA | NA | ||
| 19038369 | 2009 | I{nnr:*}LPWKWPWWPWRR{cyc:N-C}{ct:Amid} | ID-I | Amidation | Free | Cyclic | L | * = Reduced amide bond ψCH2NH | 13 | Antimicrobial | 10% hemolysis at 50μg/mL | Human | Indolicidin analog | NA | NA | ||
| 19038369 | 2009 | ILPWKWPW{nnr:*}WPWRR{cyc:N-C}{ct:Amid} | ID-W | Amidation | Free | Cyclic | L | * = Reduced amide bond ψCH2NH | 13 | Antimicrobial | 10% hemolysis at 50μg/mL | Human | Indolicidin analog | NA | NA | ||
| 19038369 | 2009 | I{nnr:*}LPWKWPW{nnr:*}WPWRR{cyc:N-C}{ct:Amid} | ID-IW | Amidation | Free | Cyclic | L | * = Reduced amide bond ψCH2NH | 13 | Antimicrobial | 5% hemolysis at 50μg/mL | Human | Indolicidin analog | NA | NA | ||
| 19038369 | 2009 | ILPWKWPWWPWRR{cyc:N-C}{ct:Amid} | ID | Amidation | Free | Cyclic | L | None | 13 | Antimicrobial | 10% hemolysis at 100μg/mL | Human | Cytoplasmic granules of bovine neutrophils | NA | NA | ||
| 19038369 | 2009 | I{nnr:*}LPWKWPWWPWRR{cyc:N-C}{ct:Amid} | ID-I | Amidation | Free | Cyclic | L | * = Reduced amide bond ψCH2NH | 13 | Antimicrobial | 10-15% hemolysis at 100μg/mL | Human | Indolicidin analog | NA | NA | ||
| 19038369 | 2009 | ILPWKWPW{nnr:*}WPWRR{cyc:N-C}{ct:Amid} | ID-W | Amidation | Free | Cyclic | L | * = Reduced amide bond ψCH2NH | 13 | Antimicrobial | 10-15% hemolysis at 100μg/mL | Human | Indolicidin analog | NA | NA | ||
| 19038369 | 2009 | I{nnr:*}LPWKWPW{nnr:*}WPWRR{cyc:N-C}{ct:Amid} | ID-IW | Amidation | Free | Cyclic | L | * = Reduced amide bond ψCH2NH | 13 | Antimicrobial | 10% hemolysis at 100μg/mL | Human | Indolicidin analog | NA | NA | ||
| 19038369 | 2009 | ILPWKWPWWPWRR{cyc:N-C}{ct:Amid} | ID | Amidation | Free | Cyclic | L | None | 13 | Antimicrobial | 30% hemolysis at 200μg/mL | Human | Cytoplasmic granules of bovine neutrophils | NA | NA | ||
| 19038369 | 2009 | I{nnr:*}LPWKWPWWPWRR{cyc:N-C}{ct:Amid} | ID-I | Amidation | Free | Cyclic | L | * = Reduced amide bond ψCH2NH | 13 | Antimicrobial | 30% hemolysis at 200μg/mL | Human | Indolicidin analog | NA | NA | ||
| 19038369 | 2009 | ILPWKWPW{nnr:*}WPWRR{cyc:N-C}{ct:Amid} | ID-W | Amidation | Free | Cyclic | L | * = Reduced amide bond ψCH2NH | 13 | Antimicrobial | 30% hemolysis at 200μg/mL | Human | Indolicidin analog | NA | NA | ||
| 19038369 | 2009 | I{nnr:*}LPWKWPW{nnr:*}WPWRR{cyc:N-C}{ct:Amid} | ID-IW | Amidation | Free | Cyclic | L | * = Reduced amide bond ψCH2NH | 13 | Antimicrobial | ~10% hemolysis at 200μg/mL | Human | Indolicidin analog | NA | NA | ||
| 19961432 | 2010 | SVSNAATRVCRTGRSRWRDVCRNFMR{cyc:N-C} | Gr-1C(25-50) | Free | Free | Cyclic | L | None | 26 | Antimicrobial | 20-30% hemolysis at 50μM | Human | Derivative of granulysin (Synthetic peptide) | NA | NA | ||
| 19961432 | 2010 | SVSNAATRVCRTGRSRWRDVCRNFMR{cyc:N-C} | Gr-1C(25-50) | Free | Free | Cyclic | L | None | 26 | Antimicrobial | 40-50% hemolysis at 100μM | Human | Derivative of granulysin (Synthetic peptide) | NA | NA | ||
| 19961432 | 2010 | SVSNAATRVCRTGRSRWRDVCRNFMR{cyc:N-C} | Gr-1C(25-50) | Free | Free | Cyclic | L | None | 26 | Antimicrobial | 70% hemolysis at 200μM | Human | Derivative of granulysin (Synthetic peptide) | NA | NA | ||
| 21664395 | 2011 | WCPPMIPLCSRF{cyc:N-C}{ct:Amid} | Tigerinin-M1 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial | LC50 >500μM | Human | Derived from skin secretions of Xenopus muelleri | NA | NA | ||
| 21682682 | 2011 | CVDIHVWDGVC{cyc:N-C} | Cyclic C-PIP[59-67]C | Free | Free | Cyclic | L | None | 11 | Cytotoxic | 7.2% hemolysis at 100μM | Human | synthetic peptide | NA | NA | ||
| 22943778 | 2012 | FLPFLLSALPKVFCFFSKKC{cyc:N-C} | Brevinin-1ZHa | Free | Free | Cyclic | L | None | 20 | Antimicrobial | HC50 =3μM | Human | Derived from skin of Rana zhenhaiensis | NA | NA | ||
| 22943778 | 2012 | FLPLLLASLPSFLCLVFKKC{cyc:N-C} | Brevinin-1ZHb | Free | Free | Cyclic | L | None | 20 | Antimicrobial | HC50 =5μM | Human | Derived from skin of Rana zhenhaiensis | NA | NA | ||
| 22943778 | 2012 | GIMRVFKGVLKTAGKSVAKNVAGSFLDRLKCKISGGC{cyc:N-C} | Brevinin-2ZHa | Free | Free | Cyclic | L | None | 37 | Antimicrobial | HC50 =52μM | Human | Derived from skin of Rana zhenhaiensis | NA | NA | ||
| 10430870 | 1999 | CTCSWPVCTRNGLPVCGETCVGGTCNTPG{cyc:N-C} | Kalata B1 | Free | Free | Cyclic | L | None | 29 | Antimicrobial | 50% hemolysis at >400μM | Human | Kalata (Oldenlandia affinis) | NA | NA | ||
| 10430870 | 1999 | CSCKNKVCYRNGIPCGESCVWIPCISAALG{cyc:N-C} | Cir A | Free | Free | Cyclic | L | None | 30 | Antimicrobial | 50% hemolysis at >400μM | Human | Circulin A (Chassalia parvifolia) | NA | NA | ||
| 10430870 | 1999 | CSCKNKVCYRNGVIPCGESCVFIPCISTLLG{cyc:N-C} | Cir B | Free | Free | Cyclic | L | None | 30 | Antimicrobial | 50% hemolysis at >400μM | Human | Circulin B (Chassalia parvifolia) | NA | NA | ||
| 10430870 | 1999 | CSCKSKVCYKNSIPCGESCVFIPCTVTALLG{cyc:N-C} | CPT | Free | Free | Cyclic | L | None | 30 | Antimicrobial | 50% hemolysis at >400μM | Human | Cyclopsychotride (Psychotria longipes) | NA | NA | ||
| 10604598 | 1999 | CKLLKTFLSKWIC{cyc:N-C} | SC | Free | Free | Cyclic | L | None | 13 | Antibacterial | 100% hemolysis at 40μg/ml | Rat | Synthetic peptide | NA | NA | ||
| 10604598 | 1999 | CKLLKTFLSKWIC{cyc:N-C}{ct:Amid} | SAC | Amidation | Free | Cyclic | L | None | 13 | Antibacterial | 100% hemolysis at 5μg/ml | Rat | Synthetic peptide | NA | NA | ||
| 22074926 | 2012 | CGESCVFIPCITSLAGCSCKNKVCYYDGGSVP{cyc:N-C} | Parigidin_br1 | Free | Free | Cyclic | L | None | 32 | Antimicrobial | 41% hemolysis at 40µM | Human | Parigidinbr1 (Palicourea rigida) | NA | NA | ||
| 22074926 | 2012 | CGESCVFIPCITSLAGCSCKNKVCYYDGGSVP{cyc:N-C} | Parigidin_br1 | Free | Free | Cyclic | L | None | 32 | Antimicrobial | 28% hemolysis at 20µM | Human | Parigidinbr1 (Palicourea rigida) | NA | NA | ||
| 17764786 | 2007 | SIITMTKEAKLPQLWKQIACRLYNTC{cyc:N-C} | Pleurain-A1 | Free | Free | Cyclic | L | None | 26 | Antimicrobial | Little hemolysis at 200mg/ml | Human | Derived from skin secretion of Rana pleuraden | NA | NA | ||
| 17764786 | 2007 | SIITMTKEAKLPQSWKQIACRLYNTC{cyc:N-C} | Pleurain-A2 | Free | Free | Cyclic | L | None | 26 | Antimicrobial | Little hemolysis at 200mg/ml | Human | Derived from skin secretion of Rana pleuraden | NA | NA | ||
| 17764786 | 2007 | SIITMTREAKLPQLWKQIACRLYNTC{cyc:N-C} | Pleurain-A3 | Free | Free | Cyclic | L | None | 26 | Antimicrobial | Little hemolysis at 200mg/ml | Human | Derived from skin secretion of Rana pleuraden | NA | NA | ||
| 17764786 | 2007 | SIITTTKEAKLPQLWKQIACRLYNTC{cyc:N-C} | Pleurain-A4 | Free | Free | Cyclic | L | None | 26 | Antimicrobial | Little hemolysis at 200mg/ml | Human | Derived from skin secretion of Rana pleuraden | NA | NA | ||
| 8810288 | 1996 | F{d}PV{nnr:O}LF{d}PV{nnr:O}L{cyc:N-C} | GS | Free | Free | Cyclic | Mix | O = L-Ornithine | 10 | Antibacterial | 100% hemolysis at 39µg/ml | Human | Gramicidin S (Bacillus brevis) | NA | NA | ||
| 8810288 | 1996 | Y{d}PY{d}P{cyc:N-C} | GS4 | Free | Free | Cyclic | Mix | None | 4 | Antibacterial | 100% hemolysis at >800µg/ml | Human | Gramicidin S analog (Bacillus brevis) | NA | NA | ||
| 8810288 | 1996 | Y{d}PKY{d}PK{cyc:N-C} | GS6 | Free | Free | Cyclic | Mix | None | 6 | Antibacterial | 100% hemolysis at >1600µg/ml | Human | Gramicidin S analog (Bacillus brevis) | NA | NA | ||
| 8810288 | 1996 | Y{d}PVKY{d}PKL{cyc:N-C} | GS8 | Free | Free | Cyclic | Mix | None | 8 | Antibacterial | 100% hemolysis at >1600µg/ml | Human | Gramicidin S analog (Bacillus brevis) | NA | NA | ||
| 8810288 | 1996 | Y{d}PVKLY{d}PVKL{cyc:N-C} | GS10 | Free | Free | Cyclic | Mix | None | 10 | Antibacterial | 100% hemolysis at 67µg/ml | Human | Gramicidin S analog (Bacillus brevis) | NA | NA | ||
| 8810288 | 1996 | Y{d}PVKLKY{d}PKVKL{cyc:N-C} | GS12 | Free | Free | Cyclic | Mix | None | 12 | Antibacterial | 100% hemolysis at 250µg/ml | Human | Gramicidin S analog (Bacillus brevis) | NA | NA | ||
| 8810288 | 1996 | Y{d}PVKLKVY{d}PLKVKL{cyc:N-C} | GS14 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial | 100% hemolysis at 6µg/ml | Human | Gramicidin S analog (Bacillus brevis) | NA | NA | ||
| 8810288 | 1996 | Y{d}PLKVKY{d}PKLKV{cyc:N-C} | GS12LV | Free | Free | Cyclic | Mix | None | 12 | Antibacterial | 100% hemolysis at 92µg/ml | Human | Gramicidin S analog (Bacillus brevis) | NA | NA | ||
| 8810288 | 1996 | F{d}PVKLKF{d}PKVKL{cyc:N-C} | GS12F | Free | Free | Cyclic | Mix | None | 12 | Antibacterial | 100% hemolysis at 400µg/ml | Human | Gramicidin S analog (Bacillus brevis) | NA | NA | ||
| 8810288 | 1996 | F{d}PV{nnr:O}L{nnr:O}F{d}P{nnr:O}V{nnr:O}L{cyc:N-C} | GS12FO | Free | Free | Cyclic | Mix | O = L-Ornithine | 12 | Antibacterial | 100% hemolysis at 160µg/ml | Human | Gramicidin S analog (Bacillus brevis) | NA | NA | ||
| 8810288 | 1996 | F{d}PL{nnr:O}L{nnr:O}F{d}P{nnr:O}L{nnr:O}L{cyc:N-C} | GS12FO/LL | Free | Free | Cyclic | Mix | O = L-Ornithine | 12 | Antibacterial | 100% hemolysis at 170µg/ml | Human | Gramicidin S analog (Bacillus brevis) | NA | NA | ||
| 19540868 | 2009 | KDGYIIEHRGCKYSCFFGTNSWCNTECTLKKGSSGYCAWPACWCYGLPDNVKIFDSNNLKC{cyc:N-C} | Bactridine 1 | Free | Free | Cyclic | L | None | 61 | Antibacterial | 0.2% hemolysis at 90µM | Human | Derived from venom of Tityus discrepans | NA | NA | ||
| 19540868 | 2009 | KDGYIIEHRGCKYSCFFGTNSWCNTECTLKKGSSGYCAWPACWCYGLPDNVKIFDSNNLKC{cyc:N-C} | Bactridine 1 | Free | Free | Cyclic | L | None | 61 | Antibacterial | 1.0% hemolysis at 180µM | Human | Derived from venom of Tityus discrepans | NA | NA | ||
| 19540868 | 2009 | KDGYLVGNDGCKYSCFTRPGTYCANECSRVKGKDGYCYAWMACYCYSMPNWVKTWNRATNRCGR{cyc:N-C} | Bactridine 2 | Free | Free | Cyclic | L | None | 64 | Antibacterial | 7.6% hemolysis at 90µM | Human | Derived from venom of Tityus discrepans | NA | NA | ||
| 19540868 | 2009 | KDGYLVGNDGCKYSCFTRPGTYCANECSRVKGKDGYCYAWMACYCYSMPNWVKTWNRATNRCGR{cyc:N-C} | Bactridine 2 | Free | Free | Cyclic | L | None | 64 | Antibacterial | 21.0% hemolysis at 180µM | Human | Derived from venom of Tityus discrepans | NA | NA | ||
| 14636071 | 2003 | GALRGCWTKSYPPKPCK{cyc:N-C}{ct:Amid} | Ranacyclin T | Amidation | Free | Cyclic | L | None | 17 | Antimicrobial | 20% hemolysis at 100μM | Human | Derived from skin secretion of Rana temporaria | NA | NA | ||
| 14636071 | 2003 | SAPRGCWTKSYPPKPCK{cyc:N-C}{ct:Amid} | Ranacyclin E | Amidation | Free | Cyclic | L | None | 17 | Antimicrobial | 55% hemolysis at 100μM | Human | Derived from skin secretion of Rana esculenta | NA | NA | ||
| 14636071 | 2003 | LVRGCWTKSYPPKPCFVR{cyc:N-C} | pLR | Free | Free | Cyclic | L | None | 18 | Antimicrobial | 85% hemolysis at 100μM | Human | Derived from skin of Rana pipiens | NA | NA | ||
| 10224074 | 1999 | VOLF{d}PVOLF{d}P{cyc:N-C} | GS | Free | Free | Cyclic | Mix | None | 10 | Antimicrobial | 100% hemolysis at 12.5μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 10224074 | 1999 | VKLKVY{d}PLKVKLY{d}P{cyc:N-C} | GS14 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 100% hemolysis at 1.5μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 10224074 | 1999 | VKLKVY{d}PLKVKLY{d}P{cyc:N-C} | GS14V10 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 100% hemolysis at 6.2μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 10224074 | 1999 | VKL{d}KVY{d}PLKVKLY{d}P{cyc:N-C} | GS14L3 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 100% hemolysis at 12.5μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 10224074 | 1999 | VKLKVY{d}PLKVKLY{d}P{d}{cyc:N-C} | GS14P14 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 100% hemolysis at 6.2μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 10224074 | 1999 | VKLKVY{d}P{d}LKVKLY{d}P{cyc:N-C} | GS14P7 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 100% hemolysis at 12.5μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 10224074 | 1999 | V{d}KLKVYPLKVKLY{d}P{cyc:N-C} | GS14V1 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 100% hemolysis at 40μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 10224074 | 1999 | VKLKVY{d}PLKVKL{d}Y{d}P{cyc:N-C} | GS14L12 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 100% hemolysis at 25μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 10224074 | 1999 | VKLKV{d}Y{d}PLKVKLY{d}P{cyc:N-C} | GS14V5 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 100% hemolysis at 150μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 10224074 | 1999 | VKLKVY{d}PLKVKLYP{cyc:N-C} | GS14Y13 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 100% hemolysis at 12.5μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 10224074 | 1999 | VKLKVY{d}PL{d}KVKLY{d}P{cyc:N-C} | GS14L8 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 100% hemolysis at 50μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 10224074 | 1999 | VKLKVYPLKVKLY{d}P{cyc:N-C} | GS14Y6 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 100% hemolysis at 25μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 10224074 | 1999 | VK{d}LKVY{d}PLKVKLY{d}P{cyc:N-C} | GS14K2 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 100% hemolysis at 50μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 10224074 | 1999 | VKLKVY{d}PLK{d}VKLY{d}P{cyc:N-C} | GS14K9 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 100% hemolysis at 100μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 10224074 | 1999 | VKLK{d}VY{d}PLKVKLY{d}P{cyc:N-C} | GS14K4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 100% hemolysis at 200μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 10224074 | 1999 | VKLKVY{d}PLKVK{d}LY{d}P{cyc:N-C} | GS14K11 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 100% hemolysis at 150μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 10224074 | 1999 | VK{d}LK{d}VY{d}PLKVKLY{d}P{cyc:N-C} | GS14K2K4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 100% hemolysis at >200μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 10224074 | 1999 | VK{d}LK{d}VY{d}PLK{d}VK{d}LY{d}P{cyc:N-C} | GS14K2K4K9K11 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 100% hemolysis at >200μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 11318033 | 2001 | QL{d}LVDL{d}I{cyc:N-C} | Lichenysin | Free | Free | Cyclic | Mix | None | 7 | Chelating agent | 100% hemolysis at 15μM | Human | Bacillus licheniformis | NA | NA | ||
| 16441062 | 2005 | CAESCVWIPCTVTALLGCSCSNNVCYNGIP{cyc:N-C} | Cycloviolacin H4 | Free | Free | Cyclic | L | None | 30 | HIV inhibitory, Antimicrobial, Cytotoxic, Neurotensin antagonistic, Trypsin inhibitory, Insecticide | HD50 =5.5μM | Human | Viola hederaceae | NA | NA | ||
| 16488428 | 2006 | SAISCGETCFKFKCYTPRCSCSYPVCK{cyc:N-C} | Violacin A | Free | Free | Cyclic | L | None | 27 | Uterotonic, Insecticidal, Anti-HIV, Antimicrobial, Anti-neurotensive, Cytotoxic and Hemolytic | 30% hemolysis at 1.5μM | Human | Synthetic Peptide | NA | NA | ||
| 10600388 | 1999 | CAESCVYIPCTVTALLGCSCSNRVCYNGIP{cyc:N-C} | Cycloviolacin O1 | Free | Free | Cyclic | L | None | 30 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | CGESCVWIPCISSAIGCSCKSKVCYRNGIP{cyc:N-C} | Cycloviolacin O2 | Free | Free | Cyclic | L | None | 30 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | CGESCVWIPCLTSAIGCSCKSKVCYRNGIP{cyc:N-C} | Cycloviolacin O3 | Free | Free | Cyclic | L | None | 30 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | CGESCVWIPCISSAIGCSCKNKVCYRNGIP{cyc:N-C} | Cycloviolacin O4 | Free | Free | Cyclic | L | None | 30 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | CGESCVWIPCISSAVGCSCKNKVCYKNGTP{cyc:N-C} | Cycloviolacin O5 | Free | Free | Cyclic | L | None | 30 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | CGESCVWIPCISAAVGCSCKSKVCYKNGTLP{cyc:N-C} | Cycloviolacin O6 | Free | Free | Cyclic | L | None | 31 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | CGESCVWIPCTITALAGCKCKSKVCYNSIP{cyc:N-C} | Cycloviolacin O7 | Free | Free | Cyclic | L | None | 30 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | CESCVWIPCISSVVGCSCKSKVCYKNGTLP{cyc:N-C} | Cycloviolacin O8 | Free | Free | Cyclic | L | None | 30 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | CGESCVWIPCLTSAVGCSCKSKVCYRNGIP{cyc:N-C} | Cycloviolacin O9 | Free | Free | Cyclic | L | None | 30 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | CGESCVYIPCLTSAVGCSCKSKVCYRNGIP{cyc:N-C} | Cycloviolacin O10 | Free | Free | Cyclic | L | None | 30 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | CGESCVWIPCISAVVGCSCKSKVCYKNGTLP{cyc:N-C} | Cycloviolacin O11 | Free | Free | Cyclic | L | None | 31 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | CGESCVYIPCLTSAIGCSCKSKVCYRNGIP{cyc:N-C} | Cycloviolacin H1 | Free | Free | Cyclic | L | None | 30 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | CGESCVYIPCISGVIGCSCTDKVCYLNGTP{cyc:N-C} | Kalata B5 | Free | Free | Cyclic | L | None | 30 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | CGESCVWIPCISAALGCSCKNKVCYRNGIP{cyc:N-C} | Circulin A | Free | Free | Cyclic | L | None | 30 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | CGESCVFIPCISTLLGCSCKNKVCYRNGVIP{cyc:N-C} | Circulin B | Free | Free | Cyclic | L | None | 31 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | CGESCVFIPCVTALLGCSCKSKVCYKNSIP{cyc:N-C} | Cyclopsychotride A | Free | Free | Cyclic | L | None | 30 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | VCGETCVGGTCNTPGCSCSRPVCTRNGLP{cyc:N-C} | Violapeptide I | Free | Free | Cyclic | L | None | 29 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | ICGETCVGGTCNTPGCSCSWPVCTRNGLP{cyc:N-C} | Cycloviolacin O12 | Free | Free | Cyclic | L | None | 29 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | VCGETCFGGTCNTPGCSCTWPICTRDGLP{cyc:N-C} | Kalata B2 | Free | Free | Cyclic | L | None | 29 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | TCGETCFGGTCNTPGCTCDPWPICTDRGLP{cyc:N-C} | Kalata B3 | Free | Free | Cyclic | L | None | 30 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | VCGETCVGGTCNTPGCTCSWPVCTRDGLP{cyc:N-C} | Kalata B4 | Free | Free | Cyclic | L | None | 29 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | VCGETCEGGTCNTPGCSCSWPVCTRNGLP{cyc:N-C} | Kalata S | Free | Free | Cyclic | L | None | 29 | Anti-HIV | 51% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10441158 | 1999 | CGETCVGGTCNTPGCTCSWPVCTRNGLPV{cyc:N-C} | Kalata B1 | Free | Free | Cyclic | L | None | 29 | Uterotonic | HD50 =50μM | Human | O. affinis | NA | NA | ||
| 10441158 | 1999 | CGESCVFIPCISTLLGCSCKNKVCYRNGVIP{cyc:N-C} | Circulin B | Free | Free | Cyclic | L | None | 30 | Uterotonic | HD50 =30μM | Human | O. affinis | NA | NA | ||
| 20564013 | 2010 | GLPVCGETCVGGTCNTPGCTCSWPVCTRN{cyc:N-C} | Kalata B1 | Free | Free | Cyclic | L | None | 30 | Pesticidal | HD50 = 20.0±1.1μM | Human | Cyclotides (Oldenlandia affinis) | NA | NA | ||
| 20564013 | 2010 | GLPVCGETCTLGTVYTQGCTCSWPICKRN{cyc:N-C} | Kalata B7 | Free | Free | Cyclic | L | None | 30 | Pesticidal | HD50 = 55.2±1.3μM | Human | Cyclotides (Oldenlandia affinis) | NA | NA | ||
| 15009528 | 2004 | VKLKVY{d}PLKVKLY{d}P{cyc:N-C} | GS14KL4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | MHC =2 µg/ml | Human | Gramicidin S analog | NA | NA | ||
| 15009528 | 2004 | VKLLVY{d}PLKVKLY{d}P{cyc:N-C} | GS14LL4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | MHC =3 µg/ml | Human | Gramicidin S analog | NA | NA | ||
| 15009528 | 2004 | VKLVY{d}PLKVKLY{d}P{cyc:N-C} | GS14FL4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | MHC =3 µg/ml | Human | Gramicidin S analog | NA | NA | ||
| 15009528 | 2004 | VKLYY{d}YPLKVKLY{d}P{cyc:N-C} | GS14YL4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | MHC =8 µg/ml | Human | Gramicidin S analog | NA | NA | ||
| 15009528 | 2004 | VKLNVY{d}PLKVKLY{d}P{cyc:N-C} | GS14NL4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | MHC =2 µg/ml | Human | Gramicidin S analog | NA | NA | ||
| 15009528 | 2004 | VKLNVY{d}PLKVKLY{d}P{cyc:N-C} | GS14GL4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | MHC =3 µg/ml | Human | Gramicidin S analog | NA | NA | ||
| 16235231 | 2006 | {nnr:Z}CRRLCYKQRCVTYCRGR{cyc:N-C}{ct:Amid} | Gomesin | Amidation | Free | Cyclic | L | Z = pyroglutamic acid | 18 | Antimicrobial | ~ 40% hemolysis at 100µM | Human | Gomesin (Acanthoscurria gomesiana) | NA | NA | ||
| 16235231 | 2006 | {nnr:Z}SRRLCYKQRCVTYSRGR{cyc:N-C}{ct:Amid} | [Ser2,15]-Gm | Amidation | Free | Cyclic | L | Z = pyroglutamic acid | 18 | Antimicrobial | <10% hemolysis at 100µM | Human | Gomesin analogs | NA | NA | ||
| 16235231 | 2006 | {nnr:Z}CRRLSYKQRSVTYCRGR{cyc:N-C}{ct:Amid} | [Ser6,11]-Gm | Amidation | Free | Cyclic | L | Z = pyroglutamic acid | 18 | Antimicrobial | <10% hemolysis at 100µM | Human | Gomesin analogs | NA | NA | ||
| 16235231 | 2006 | {nnr:Z}DRRLSYKQRSVTYORGR{cyc:N-C}{ct:Amid} | Cyclo(2–15)[Asp2, Ser6, 11, Orn15]-Gm | Amidation | Free | Cyclic | L | Z = pyroglutamic acid | 18 | Antimicrobial | <10% hemolysis at 100µM | Human | Gomesin analogs | NA | NA | ||
| 16235231 | 2006 | {nnr:Z}SRRLOYKQRDVTYSRGR{cyc:N-C}{ct:Amid} | Cyclo(6-11)[Ser2,15, Orn6, Asp11]-Gm | Amidation | Free | Cyclic | L | Z = pyroglutamic acid | 18 | Antimicrobial | <10% hemolysis at 100µM | Human | Gomesin analogs | NA | NA | ||
| 16235231 | 2006 | {nnr:Z}CRRLEYKQRKVTYCRGR{cyc:N-C}{ct:Amid} | Bicyclo(2–15, 6–11)[Cys2, 15, Glu6, Lys11]-Gm | Amidation | Free | Cyclic | L | Z = pyroglutamic acid | 18 | Antimicrobial | <10% hemolysis at 100µM | Human | Gomesin analogs | NA | NA | ||
| 16235231 | 2006 | {nnr:Z}ERRLCYKQRCVTYKRGR{cyc:N-C}{ct:Amid} | Bicyclo(2–15, 6–11)[Glu2, Cys6, 11, Lys15]-Gm | Amidation | Free | Cyclic | L | Z = pyroglutamic acid | 18 | Antimicrobial | ~ 32% hemolysis at 100µM | Human | Gomesin analogs | NA | NA | ||
| 25997127 | 2015 | LIAGLAANFLPQILCKIARKC{cyc:N-C}{ct:Amid} | Cyclic B1CTcu5 | Amidation | Free | Cyclic | L | None | 21 | Antibacterial | 40 % Hemolysis at 25 μg/ml | Human | Smmd-B1Ctcu5 Analogs, Skin Secretion Of Frog Clinotarsus Curtipes | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 1 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at 215 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LRWLRWG{cyc:N-C} | 2 | Free | Free | Cyclic | L | None | 7 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LK{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 3 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LK{nnr:2-Nal}G{cyc:N-C} | 4 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LK{nnr:2-Nal}LK{nnr:2-Nal}G{cyc:N-C} | 5 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LKWLKWG{cyc:N-C} | 6 | Free | Free | Cyclic | L | None | 7 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LKFLKFG{cyc:N-C} | 7 | Free | Free | Cyclic | L | None | 7 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}({nnr:Abu}){cyc:N-C} | 8 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Abu = 4-aminobutyric acid | 4 | Antimicrobial | 50 % Hemolysis at 230 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}{nnr:6-Ahx}{cyc:N-C} | 9 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 6-Ahx = 6-aminohexanoic acid | 4 | Antimicrobial | 50 % Hemolysis at 115 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}{nnr:8-Aoc}{cyc:N-C} | 10 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 8-Aoc = 8-aminooctanoic acid | 4 | Antimicrobial | 50 % Hemolysis at 22 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}{nnr:10-Adc}{cyc:N-C} | 11 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 10-Adc = 10-aminodecanoic acid | 4 | Antimicrobial | 50 % Hemolysis at 15 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}({nnr:Dab}){cyc:N-C} | 12 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Dab = 2,4-diaminobutyric acid | 4 | Antimicrobial | 50 % Hemolysis at 265 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}({nnr:εK}){cyc:N-C} | 13 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, εK = coupling of 2-Nal6 has occurred on lysine’s ε-amino functionality | 4 | Antimicrobial | 50 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}({nnr:Dab}{nnr:Dab}){cyc:N-C} | 14 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Dab = 2,4-diaminobutyric acid | 4 | Antimicrobial | 50 % Hemolysis at >450 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}({nnr:Abu})({nnr:Dab}){cyc:N-C} | 15 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Dab = 2,4-diaminobutyric acid, Abu = 4-aminobutyric acid | 4 | Antimicrobial | 50 % Hemolysis at 420 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}({nnr:Dab})({nnr:Abu}){cyc:N-C} | 16 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Dab = 2,4-diaminobutyric acid, Abu = 4-aminobutyric acid | 4 | Antimicrobial | 50 % Hemolysis at 255 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR({nnr:Bip})LR({nnr:Bip})G{cyc:N-C} | 17 | Free | Free | Cyclic | Mix | Bip = 4,4’-biphenyl-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at 16 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR({nnr:Dip})LR({nnr:Dip})G{cyc:N-C} | 18 | Free | Free | Cyclic | Mix | Dip = 3,3-diphenyl-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at 145 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | {nnr:2-Aoc}R{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 19 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 2-Aoc = 2-aminooctanoic acid | 4 | Antimicrobial | 50 % Hemolysis at 55 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}{nnr:2-Aoc}R{nnr:2-Nal}G{cyc:N-C} | 20 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 2-Aoc = 2-aminooctanoic acid | 4 | Antimicrobial | 50 % Hemolysis at 33 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | ({nnr:Cha})R{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 21 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Cha = 3-cyclohexyl-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at 28 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}({nnr:Cha})R{nnr:2-Nal}G{cyc:N-C} | 22 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Cha = 3-cyclohexyl-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at 60 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}({nnr:Nle})R{nnr:2-Nal}G{cyc:N-C} | 23 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Nle = norleucine | 4 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | PR{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 24 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}PR{nnr:2-Nal}G{cyc:N-C} | 25 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LRYG{cyc:N-C} | 26 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 6 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | TR{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 27 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}TR{nnr:2-Nal}G{cyc:N-C} | 28 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | QR{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 29 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:D-2-Nal}{nnr:2-Aoc}R{nnr:2-Nal}G{cyc:N-C} | 30 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 2-Aoc = 2-aminooctanoic acid | 4 | Antimicrobial | 50 % Hemolysis at 55 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}(D-2-Aoc)R{nnr:2-Nal}G{cyc:N-C} | 31 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 2-Aoc = 2-aminooctanoic acid | 4 | Antimicrobial | 50 % Hemolysis at 55 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR(2NalNal)LR{nnr:D-2-Nal}G{cyc:N-C} | 32 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 8-Aoc = 8-aminooctanoic acid | 5 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | TR{nnr:2-Nal}IR{nnr:2-Nal}{nnr:8-Aoc}{cyc:N-C} | 33 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 8-Aoc = 8-aminooctanoic acid | 4 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}{nnr:2-Aoc}R{nnr:2-Nal}{nnr:Dab}{nnr:Dab}{cyc:N-C} | 34 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 3 | Antimicrobial | 50 % Hemolysis at 55 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 1 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 27 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LRWLRWG{cyc:N-C} | 2 | Free | Free | Cyclic | L | None | 7 | Antimicrobial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LK{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 3 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 14 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR(NalNaI)LK{nnr:2-Nal}G{cyc:N-C} | 4 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 19 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LK{nnr:2-Nal}LK{nnr:2-Nal}G{cyc:N-C} | 5 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 13 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LKWLKWG{cyc:N-C} | 6 | Free | Free | Cyclic | L | None | 7 | Antimicrobial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LKFLKFG{cyc:N-C} | 7 | Free | Free | Cyclic | L | None | 7 | Antimicrobial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}({nnr:Abu}){cyc:N-C} | 8 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Abu = 4-aminobutyric acid | 4 | Antimicrobial | 22 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}{nnr:6-Ahx}{cyc:N-C} | 9 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 6-Ahx = 6-aminohexanoic acid | 4 | Antimicrobial | 75 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}{nnr:8-Aoc}{cyc:N-C} | 10 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 8-Aoc = 8-aminooctanoic acid | 4 | Antimicrobial | 100 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}{nnr:10-Adc}{cyc:N-C} | 11 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 10-Adc = 10-aminodecanoic acid | 4 | Antimicrobial | 100 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}({nnr:Dab}){cyc:N-C} | 12 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Dab = 2,4-diaminobutyric acid | 4 | Antimicrobial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}({nnr:εK}){cyc:N-C} | 13 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, εK = coupling of 2-Nal6 has occurred on lysine’s ε-amino functionality | 4 | Antimicrobial | 51 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}{nnr:Dab}{nnr:Dab}{cyc:N-C} | 14 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Dab = 2,4-diaminobutyric acid | 4 | Antimicrobial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}({nnr:Abu})({nnr:Dab}){cyc:N-C} | 15 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Dab = 2,4-diaminobutyric acid, Abu = 4-aminobutyric acid | 4 | Antimicrobial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}({nnr:Dab})({nnr:Abu}){cyc:N-C} | 16 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Dab = 2,4-diaminobutyric acid, Abu = 4-aminobutyric acid | 4 | Antimicrobial | 12 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR({nnr:Bip})LR({nnr:Bip})G{cyc:N-C} | 17 | Free | Free | Cyclic | Mix | Bip = 4,4’-biphenyl-L-alanine | 5 | Antimicrobial | 96 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR({nnr:Dip})LR({nnr:Dip})G{cyc:N-C} | 18 | Free | Free | Cyclic | Mix | Dip = 3,3-diphenyl-L-alanine | 5 | Antimicrobial | 54 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | {nnr:2-Aoc}R{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 19 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 2-Aoc = 2-aminooctanoic acid | 4 | Antimicrobial | 100 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}{nnr:2-Aoc}R{nnr:2-Nal}G{cyc:N-C} | 20 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 2-Aoc = 2-aminooctanoic acid | 4 | Antimicrobial | 100 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | ({nnr:Cha})R{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 21 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Cha = 3-cyclohexyl-L-alanine | 4 | Antimicrobial | 99 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}({nnr:Cha})R{nnr:2-Nal}G{cyc:N-C} | 22 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Cha = 3-cyclohexyl-L-alanine | 4 | Antimicrobial | 96 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}({nnr:Nle})R{nnr:2-Nal}G{cyc:N-C} | 23 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Nle = norleucine | 4 | Antimicrobial | 35 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | PR{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 24 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}PR{nnr:2-Nal}G{cyc:N-C} | 25 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LRYG{cyc:N-C} | 26 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 6 | Antimicrobial | 19 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | TR{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 27 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}TR{nnr:2-Nal}G{cyc:N-C} | 28 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | QR{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 29 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:D-2-Nal}{nnr:2-Aoc}R{nnr:2-Nal}G{cyc:N-C} | 30 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 2-Aoc = 2-aminooctanoic acid | 4 | Antimicrobial | 92 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}(D-2-Aoc)R{nnr:2-Nal}G{cyc:N-C} | 31 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 2-Aoc = 2-aminooctanoic acid | 4 | Antimicrobial | 100 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:D-2-Nal}G{cyc:N-C} | 32 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 8-Aoc = 8-aminooctanoic acid | 4 | Antimicrobial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | TR{nnr:2-Nal}IR{nnr:2-Nal}{nnr:8-Aoc}{cyc:N-C} | 33 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 8-Aoc = 8-aminooctanoic acid | 4 | Antimicrobial | 10 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}{nnr:2-Aoc}R{nnr:2-Nal}{nnr:Dab}{nnr:Dab}{cyc:N-C} | 34 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 3 | Antimicrobial | 100 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26159095 | 2015 | GIVFLDHVESFQVKPKLRKFQLYF{cyc:N-C} | cMnALF24 | Free | Free | Cyclic | L | None | 24 | Antibacterial | ~10 % Hemolysis at 0.67 µM | Rabbit | Macrobrachium Nipponense | β-Sheets | Low hemolytic | ||
| 26159095 | 2015 | GIVFLDHVESFQVKPKLRKFQLYF{cyc:N-C} | cMnALF24 | Free | Free | Cyclic | L | None | 24 | Antibacterial | ~10 % Hemolysis at 3.35 µM | Rabbit | Macrobrachium Nipponense | β-Sheets | Low hemolytic | ||
| 26159095 | 2015 | GIVFLDHVESFQVKPKLRKFQLYF{cyc:N-C} | cMnALF24 | Free | Free | Cyclic | L | None | 24 | Antibacterial | ~10 % Hemolysis at 6.7 µM | Rabbit | Macrobrachium Nipponense | β-Sheets | Low hemolytic | ||
| 26159095 | 2015 | GIVFLDHVESFQVKPKLRKFQLYF{cyc:N-C} | cMnALF24 | Free | Free | Cyclic | L | None | 24 | Antibacterial | ~10 % Hemolysis at 33.5 µM | Rabbit | Macrobrachium Nipponense | β-Sheets | Low hemolytic | ||
| 26159095 | 2015 | GIVFLDHVESFQVKPKLRKFQLYF{cyc:N-C} | cMnALF24 | Free | Free | Cyclic | L | None | 24 | Antibacterial | 22 % Hemolysis at 67 µM | Rabbit | Macrobrachium Nipponense | β-Sheets | Low hemolytic | ||
| 26295533 | 2015 | RLARIVVIRVAR{cyc:N-C}{ct:Amid} | Bac2A | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | <5 % Hemolysis at 0.25 mg/ml | Human | Bovine Host Defense Peptide Variant | α-Helical | NA | ||
| 26295533 | 2015 | RLARIVVIRVAR{cyc:N-C}{ct:Amid} | Bac2A | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | <5 % Hemolysis at 0.1 mg/ml | Human | Bovine Host Defense Peptide Variant | α-Helical | NA | ||
| 26295533 | 2015 | RLARIVVIRVAR{cyc:N-C}{ct:Amid} | Bac2A | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | <5 % Hemolysis at 0.05 mg/ml | Human | Bovine Host Defense Peptide Variant | α-Helical | NA | ||
| 26295533 | 2015 | RLARIVVIRVAR{cyc:N-C}{ct:Amid} | Bac2A | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | <5 % Hemolysis at 0.025 mg/ml | Human | Bovine Host Defense Peptide Variant | α-Helical | NA | ||
| 26295533 | 2015 | RLRRIVVIRVAR{cyc:N-C}{ct:Amid} | R3 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | <5 % Hemolysis at 0.25 mg/ml | Human | Bac2A Derivative | α-Helical | NA | ||
| 26295533 | 2015 | RLRRIVVIRVAR{cyc:N-C}{ct:Amid} | R3 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | <5 % Hemolysis at 0.1 mg/ml | Human | Bac2A Derivative | α-Helical | NA | ||
| 26295533 | 2015 | RLRRIVVIRVAR{cyc:N-C}{ct:Amid} | R3 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | <5 % Hemolysis at 0.05 mg/ml | Human | Bac2A Derivative | α-Helical | NA | ||
| 26295533 | 2015 | RLRRIVVIRVAR{cyc:N-C}{ct:Amid} | R3 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | <5 % Hemolysis at 0.025 mg/ml | Human | Bac2A Derivative | α-Helical | NA | ||
| 26295533 | 2015 | RLARIVPIRVAR{cyc:N-C}{ct:Amid} | P7 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | <5 % Hemolysis at 0.25 mg/ml | Human | Bac2A Derivative | α-Helical | NA | ||
| 26295533 | 2015 | RLARIVPIRVAR{cyc:N-C}{ct:Amid} | P7 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | <5 % Hemolysis at 0.1 mg/ml | Human | Bac2A Derivative | α-Helical | NA | ||
| 26295533 | 2015 | RLARIVPIRVAR{cyc:N-C}{ct:Amid} | P7 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | <5 % Hemolysis at 0.05 mg/ml | Human | Bac2A Derivative | α-Helical | NA | ||
| 26295533 | 2015 | RLARIVPIRVAR{cyc:N-C}{ct:Amid} | P7 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | <5 % Hemolysis at 0.025 mg/ml | Human | Bac2A Derivative | α-Helical | NA | ||
| 26295533 | 2015 | VRWRIRVAVIRA{cyc:N-C}{ct:Amid} | W3 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | 10 % Hemolysis at 0.25 mg/ml | Human | Bac2A Derivative | α-Helical | NA | ||
| 26295533 | 2015 | VRWRIRVAVIRA{cyc:N-C}{ct:Amid} | W3 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | 5 % Hemolysis at 0.1 mg/ml | Human | Bac2A Derivative | α-Helical | NA | ||
| 26295533 | 2015 | VRWRIRVAVIRA{cyc:N-C}{ct:Amid} | W3 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | >5 % Hemolysis at 0.05 mg/ml | Human | Bac2A Derivative | α-Helical | NA | ||
| 26295533 | 2015 | VRWRIRVAVIRA{cyc:N-C}{ct:Amid} | W3 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | <5 % Hemolysis at 0.025 mg/ml | Human | Bac2A Derivative | α-Helical | NA | ||
| 26295533 | 2015 | RRWRIVVIRVRR{cyc:N-C}{ct:Amid} | Sub3 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | <10 % Hemolysis at 0.25 mg/ml | Human | Bac2A Derivative | α-Helical | NA | ||
| 26295533 | 2015 | RRWRIVVIRVRR{cyc:N-C}{ct:Amid} | Sub3 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | 10 % Hemolysis at 0.1 mg/ml | Human | Bac2A Derivative | α-Helical | NA | ||
| 26295533 | 2015 | RRWRIVVIRVRR{cyc:N-C}{ct:Amid} | Sub3 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | 5 % Hemolysis at 0.05 mg/ml | Human | Bac2A Derivative | α-Helical | NA | ||
| 26295533 | 2015 | RRWRIVVIRVRR{cyc:N-C}{ct:Amid} | Sub3 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | <5 % Hemolysis at 0.025 mg/ml | Human | Bac2A Derivative | α-Helical | NA | ||
| 25728268 | 2015 | FFWLSRRTK{cyc:N-C} | Pep6 | Free | Free | Cyclic | L | None | 9 | Antibacterial | 50 % Hemolysis at 5 µM | Human | Derived From Pepa8 | NA | NA | ||
| 25728268 | 2015 | FFWSRRTK{cyc:N-C} | Pep7 | Free | Free | Cyclic | L | None | 8 | Antibacterial | 50 % Hemolysis at 14 µM | Human | Derived From Pepa9 | NA | NA | ||
| 25728268 | 2015 | FFWRRTK{cyc:N-C} | Pep8 | Free | Free | Cyclic | L | None | 7 | Antibacterial | 50 % Hemolysis at 160 µM | Human | Derived From Pepa10 | NA | NA | ||
| 25728268 | 2015 | FFWLRR{nnr:aza-β3Hyt}K{cyc:N-C} | Pep10 | Free | Free | Cyclic | L | aza-b3 = homohydroxythreonine | 8 | Antibacterial | 50 % Hemolysis at 150 µM | Human | Derived From Pepa12 | NA | NA | ||
| 25728268 | 2015 | FFWRR{nnr:aza-β3Hyt}K{cyc:N-C} | Pep11 | Free | Free | Cyclic | L | aza-b3 = homohydroxythreonine | 7 | Antibacterial | 50 % Hemolysis at 840 µM | Human | Derived From Pepa13 | NA | NA | ||
| 25495219 | 2015 | {nnr:R1}-{nnr:dab}-[{nnr:Dab}-{nnr:Dab}-L-F{d}-{nnr:Dab}-{nnr:Dab}-L] | 13 | Free | Free | Cyclic | Mix | R1 = 4-methylhexanoyl, Dab = diaminobutyric acid | 3 | Antimicrobial | 2.02 % Hemolysis at 100 µM | Mouse | Synthetic Analogues Of Battacin | NA | NA | ||
| 25495219 | 2015 | {nnr:F{d}moc}-{nnr:dab}-[{nnr:Dab}-{nnr:Dab}-L-F{d}-{nnr:Dab}-{nnr:Dab}-L] | 12 | Free | Free | Cyclic | Mix | Dab = diaminobutyric acid, Fmoc = fluorenylmethyloxycarbonyl | 3 | Antimicrobial | 41 % Hemolysis at 100 µM | Mouse | Synthetic Analogues Of Battacin | NA | NA | ||
| 25583073 | 2015 | CVDIHVWDGVC{cyc:N-C} | Cyclic C-PIP[57-67]C | Free | Free | Cyclic | L | None | 11 | Antibacterial | 30 % Hemolysis at 100 μg/mL | Human | Python Reticulatus Serum Protein | β or Helical | NA | ||
| 27560386 | 2016 | RICTPIPFPMCY{cyc:N-C}{ct:Amid} | tigerinin-1O | Amidation | Free | Cyclic | L | None | 12 | Cytotoxic | 0 % Hemolysis at 500 µM | Mouse | African Crowned Bullfrog Hoplobatrachus Occipitalis | NA | Non-hemolytic | ||
| 27560386 | 2016 | RTCIPIPLVMC{cyc:N-C}{ct:Amid} | tigerinin-2O | Amidation | Free | Cyclic | L | None | 11 | Cytotoxic | 0 % Hemolysis at 500 µM | Mouse | African Crowned Bullfrog Hoplobatrachus Occipitalis | NA | Non-hemolytic | ||
| 27560386 | 2016 | RICTAIPLPMCL{cyc:N-C}{ct:Amid} | tigerinin-3O | Amidation | Free | Cyclic | L | None | 12 | Cytotoxic | 0 % Hemolysis at 500 µM | Mouse | African Crowned Bullfrog Hoplobatrachus Occipitalis | NA | Non-hemolytic | ||
| 27560386 | 2016 | RTCIPIPPVCF{cyc:N-C}{ct:Amid} | tigerinin-4O | Amidation | Free | Cyclic | L | None | 11 | Cytotoxic | 0 % Hemolysis at 500 µM | Mouse | African Crowned Bullfrog Hoplobatrachus Occipitalis | NA | Non-hemolytic | ||
| 27008420 | 2016 | KKLKKFKKLQ{cyc:N-C} | BPC194 | Free | Free | Cyclic | L | None | 10 | Anti-plant-pathogenic bacteria and fungi | 4 ± 1 % Hemolysis at 150 µM | Horse | Synthetic Peptide | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK({nnr:CO-C7H15})FKKLQ{cyc:N-C} | BPC498 | Free | Free | Cyclic | L | CO-C7H15 = octanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 78 ± 4 % Hemolysis at 150 µM | Horse | Synthetic Peptide | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK({nnr:CO-C3H7})FKKLQ{cyc:N-C} | BPC500 | Free | Free | Cyclic | L | CO-C3H7 = butanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 28 ± 5 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK({nnr:CO-C4H9})FKKLQ{cyc:N-C} | BPC526 | Free | Free | Cyclic | L | CO-C4H9 = pentanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 62 ± 2 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK({nnr:CO-isoC5H11})FKKLQ{cyc:N-C} | BPC504 | Free | Free | Cyclic | L | CO-isoC5H11 = 4-methylpentanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 89 ± 2 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK({nnr:CO-nC5H11})FKKLQ{cyc:N-C} | BPC528 | Free | Free | Cyclic | L | CO-nC5H11 = hexanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 98 ± 7 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK(LK-{nnr:CO-nC5H11})FKKLQ{cyc:N-C} | BPC596 | Free | Free | Cyclic | L | CO-nC5H11 = hexanoyl | 12 | Anti-plant-pathogenic bacteria and fungi | 93 ± 5 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK({nnr:CO-C6H13})FKKLQ{cyc:N-C} | BPC592 | Free | Free | Cyclic | L | CO-C6H13 = 2-methylhexanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 100 ± 4 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK({nnr:CO-C8H17})FKKLQ{cyc:N-C} | BPC594 | Free | Free | Cyclic | L | CO-C8H17 = 4-methyloctanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 93 ± 11 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK({nnr:CO-C11H23})FKKLQ{cyc:N-C} | BPC530 | Free | Free | Cyclic | L | CO-C11H23 = lauroyl | 10 | Anti-plant-pathogenic bacteria and fungi | 89 ± 7 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK({nnr:CO-C11H22OH})FKKLQ{cyc:N-C} | BPC524 | Free | Free | Cyclic | L | CO-C11H22OH = 12-hydroxylauroyl | 10 | Anti-plant-pathogenic bacteria and fungi | 100 ± 8 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK({nnr:CO-C15H31})FKKLQ{cyc:N-C} | BPC502 | Free | Free | Cyclic | L | CO-C15H31 = palmitoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 78 ± 1 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK({nnr:CO-C17H33})FKKLQ{cyc:N-C} | BPC622 | Free | Free | Cyclic | L | CO-C17H33 = oleoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 91 ± 2 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKKFKK({nnr:CO-nC5H11})LQ{cyc:N-C} | BPC582 | Free | Free | Cyclic | L | CO-nC5H11 = hexanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 92 ± 3 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKKFK({nnr:CO-nC5H11})KLQ{cyc:N-C} | BPC584 | Free | Free | Cyclic | L | CO-nC5H11 = hexanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 72 ± 5 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLK({nnr:CO-nC5H11})KFKKLQ{cyc:N-C} | BPC586 | Free | Free | Cyclic | L | CO-nC5H11 = hexanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 92 ± 9 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KK({nnr:CO-nC5H11})LKKFKKLQ{cyc:N-C} | BPC588 | Free | Free | Cyclic | L | CO-nC5H11 = hexanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 95 ± 4 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KK({nnr:CO-C3H7})LKKFKKLQ{cyc:N-C} | BPC708 | Free | Free | Cyclic | L | CO-C3H7 = butanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 2 ± 0.5 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | K({nnr:CO-nC5H11})KLKKFKKLQ{cyc:N-C} | BPC590 | Free | Free | Cyclic | L | CO-nC5H11 = hexanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 100 ± 9 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | K({nnr:CO-C3H7})KLKKFKKLQ{cyc:N-C} | BPC710 | Free | Free | Cyclic | L | CO-C3H7 = butanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 7 ± 1 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK{nnr:CO-C3H7}F{d}KKLQ{cyc:N-C} | BPC712 | Free | Free | Cyclic | Mix | CO-C3H7 = butanoyl, f = D-phenylalanine | 10 | Anti-plant-pathogenic bacteria and fungi | 30 ± 4 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKKLK-{nnr:CO-C3H7}F{d}KKLQ{cyc:N-C} | BPC726 | Free | Free | Cyclic | Mix | CO-C3H7 = butanoyl, f = D-phenylalanine | 12 | Anti-plant-pathogenic bacteria and fungi | 0 ± 1 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK{nnr:CO-nC5H11}F{d}KKLQ{cyc:N-C} | BPC624 | Free | Free | Cyclic | Mix | CO-nC5H11 = hexanoyl, f = D-phenylalanine | 10 | Anti-plant-pathogenic bacteria and fungi | 53 ± 5 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK{nnr:CO-isoC5H11}F{d}KKLQ{cyc:N-C} | BPC626 | Free | Free | Cyclic | Mix | CO-isoC5H11 = 4-methylpentanoyl, f = D-phenylalanine | 10 | Anti-plant-pathogenic bacteria and fungi | 51 ± 7 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKKLK-{nnr:CO-nC5H11}F{d}KKLQ{cyc:N-C} | BPC674 | Free | Free | Cyclic | Mix | CO-nC5H11 = hexanoyl, f = D-phenylalanine | 12 | Anti-plant-pathogenic bacteria and fungi | 51 ± 2 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK{nnr:CO-C7H15}F{d}KKLQ{cyc:N-C} | BPC668 | Free | Free | Cyclic | Mix | CO-C7H15 = octanoyl, f = D-phenylalanine | 10 | Anti-plant-pathogenic bacteria and fungi | 79 ± 2 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KK{nnr:CO-C3H7}LKKF{d}KKLQ{cyc:N-C} | BPC714 | Free | Free | Cyclic | Mix | CO-C3H7 = butanoyl, f = D-phenylalanine | 10 | Anti-plant-pathogenic bacteria and fungi | 3 ± 1 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KK{nnr:CO-nC5H11}LKKF{d}KKLQ{cyc:N-C} | BPC680 | Free | Free | Cyclic | Mix | CO-nC5H11 = hexanoyl, f = D-phenylalanine | 10 | Anti-plant-pathogenic bacteria and fungi | 77 ± 2 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | K{nnr:CO-C3H7}KLKKF{d}KKLQ{cyc:N-C} | BPC716 | Free | Free | Cyclic | Mix | CO-C3H7 = butanoyl, f = D-phenylalanine | 10 | Anti-plant-pathogenic bacteria and fungi | 2 ± 1 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | K{nnr:CO-nC5H11}KLKKF{d}KKLQ{cyc:N-C} | BPC686 | Free | Free | Cyclic | Mix | CO-nC5H11 = hexanoyl, f = D-phenylalanine | 10 | Anti-plant-pathogenic bacteria and fungi | 10 ± 0.2 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK{d}{nnr:CO-C3H7}FKKLQ{cyc:N-C} | BPC702 | Free | Free | Cyclic | Mix | CO-C3H7 = butanoyl, k = D-Lys | 10 | Anti-plant-pathogenic bacteria and fungi | 1 ± 0.1 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK{d}LK-{nnr:CO-C3H7}FKKLQ{cyc:N-C} | BPC724 | Free | Free | Cyclic | Mix | CO-C3H7 = butanoyl, k = D-Lys | 12 | Anti-plant-pathogenic bacteria and fungi | 3 ± 2 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK{d}{nnr:CO-nC5H11}FKKLQ{cyc:N-C} | BPC628 | Free | Free | Cyclic | Mix | CO-nC5H11 = hexanoyl, k = D-Lys | 10 | Anti-plant-pathogenic bacteria and fungi | 19 ± 2 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK{d}{nnr:CO-isoC5H11}FKKLQ{cyc:N-C} | BPC630 | Free | Free | Cyclic | Mix | CO-isoC5H11 = 4-methylpentanoyl, k = D-Lys | 10 | Anti-plant-pathogenic bacteria and fungi | 22 ± 2 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK{d}LK-{nnr:CO-nC5H11}FKKLQ{cyc:N-C} | BPC672 | Free | Free | Cyclic | Mix | CO-nC5H11 = hexanoyl, k = D-Lys | 12 | Anti-plant-pathogenic bacteria and fungi | 33 ± 2 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK{d}{nnr:CO-C7H15}FKKLQ{cyc:N-C} | BPC666 | Free | Free | Cyclic | Mix | CO-C7H15 = octanoyl, k = D-Lys | 10 | Anti-plant-pathogenic bacteria and fungi | 61 ± 2 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KK{d}{nnr:CO-nC5H11}LKKFKKLQ{cyc:N-C} | BPC678 | Free | Free | Cyclic | Mix | CO-nC5H11 = hexanoyl, k = D-Lys | 10 | Anti-plant-pathogenic bacteria and fungi | 68 ± 3 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KK{d}{nnr:CO-C3H7}LKKFKKLQ{cyc:N-C} | BPC704 | Free | Free | Cyclic | Mix | CO-C3H7 = butanoyl, k = D-Lys | 10 | Anti-plant-pathogenic bacteria and fungi | 9 ± 1 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | K{d}{nnr:CO-nC5H11}KLKKFKKLQ{cyc:N-C} | BPC684 | Free | Free | Cyclic | Mix | CO-nC5H11 = hexanoyl, k = D-Lys | 10 | Anti-plant-pathogenic bacteria and fungi | 8 ± 1 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | K{d}{nnr:CO-C3H7}KLKKFKKLQ{cyc:N-C} | BPC706 | Free | Free | Cyclic | Mix | CO-C3H7 = butanoyl, k = D-Lys | 10 | Anti-plant-pathogenic bacteria and fungi | 35 ± 3 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK{d}{nnr:CO-nC5H11}F{d}KKLQ{cyc:N-C} | BPC632 | Free | Free | Cyclic | Mix | CO-nC5H11 = hexanoyl, f = D-phenylalanine, k = D-Lys | 10 | Anti-plant-pathogenic bacteria and fungi | 21 ± 13 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK{d}{nnr:CO-isoC5H11}F{d}KKLQ{cyc:N-C} | BPC634 | Free | Free | Cyclic | Mix | CO-isoC5H11 = 4-methylpentanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 7 ± 1 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK({nnr:CO-C3H7})HKKLQ{cyc:N-C} | BPC718 | Free | Free | Cyclic | L | CO-C3H7 = butanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 3 ± 1 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK(LK-{nnr:CO-C3H7})HKKLQ{cyc:N-C} | BPC728 | Free | Free | Cyclic | L | CO-C3H7 = butanoyl | 12 | Anti-plant-pathogenic bacteria and fungi | 0 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Non-hemolytic | ||
| 27008420 | 2016 | KKLKK({nnr:CO-nC5H11})HKKLQ{cyc:N-C} | BPC636 | Free | Free | Cyclic | L | CO-nC5H11 = hexanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 5 ± 2 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK({nnr:CO-isoC5H11})HKKLQ{cyc:N-C} | BPC638 | Free | Free | Cyclic | L | CO-isoC5H11 = 4-methylpentanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 6 ± 2 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK(LK-{nnr:CO-nC5H11})HKKLQ{cyc:N-C} | BPC676 | Free | Free | Cyclic | L | CO-nC5H11 = hexanoyl | 12 | Anti-plant-pathogenic bacteria and fungi | 3 ± 0.3 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK({nnr:CO-C7H15})HKKLQ{cyc:N-C} | BPC670 | Free | Free | Cyclic | L | CO-C7H15 = octanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 34 ± 1 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KK({nnr:CO-nC5H11})LKKHKKLQ{cyc:N-C} | BPC682 | Free | Free | Cyclic | L | CO-nC5H11 = hexanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 20 ± 3 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KK({nnr:CO-C3H7})LKKHKKLQ{cyc:N-C} | BPC720 | Free | Free | Cyclic | L | CO-C3H7 = butanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 3 ± 1 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | K({nnr:CO-nC5H11})KLKKHKKLQ{cyc:N-C} | BPC688 | Free | Free | Cyclic | L | CO-nC5H11 = hexanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 1 ± 2 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | K({nnr:CO-C3H7})KLKKHKKLQ{cyc:N-C} | BPC722 | Free | Free | Cyclic | L | CO-C3H7= butanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 3 ± 0.2 % Hemolysis at 150 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKKFKKLQ{cyc:N-C} | BPC194 | Free | Free | Cyclic | L | None | 10 | Anti-plant-pathogenic bacteria and fungi | 6 ± 1 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK({nnr:CO-C7H15})FKKLQ{cyc:N-C} | BPC498 | Free | Free | Cyclic | L | CO-C7H15 = octanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 100 ± 12 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK({nnr:CO-C3H7})FKKLQ{cyc:N-C} | BPC500 | Free | Free | Cyclic | L | CO-C3H7 = butanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 38 ± 4 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK({nnr:CO-C4H9})FKKLQ{cyc:N-C} | BPC526 | Free | Free | Cyclic | L | CO-C4H9 = pentanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 78 ± 3 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK({nnr:CO-isoC5H11})FKKLQ{cyc:N-C} | BPC504 | Free | Free | Cyclic | L | CO-isoC5H11 = 4-methylpentanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 93 ± 3 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK({nnr:CO-nC5H11})FKKLQ{cyc:N-C} | BPC528 | Free | Free | Cyclic | L | CO-nC5H11 = hexanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 100 ± 1 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK(LK-{nnr:CO-nC5H11})FKKLQ{cyc:N-C} | BPC596 | Free | Free | Cyclic | L | CO-nC5H11 = hexanoyl | 12 | Anti-plant-pathogenic bacteria and fungi | 100 ± 11 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK({nnr:CO-C6H13})FKKLQ{cyc:N-C} | BPC592 | Free | Free | Cyclic | L | CO-C6H13 = 2-methylhexanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 98 ± 6 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK({nnr:CO-C8H17})FKKLQ{cyc:N-C} | BPC594 | Free | Free | Cyclic | L | CO-C8H17 = 4-methyloctanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 96 ± 3 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK({nnr:CO-C11H23})FKKLQ{cyc:N-C} | BPC530 | Free | Free | Cyclic | L | CO-C11H23 = lauroyl | 10 | Anti-plant-pathogenic bacteria and fungi | 91 ± 9 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK({nnr:CO-C11H22OH})FKKLQ{cyc:N-C} | BPC524 | Free | Free | Cyclic | L | CO-C11H22OH = 12-hydroxylauroyl | 10 | Anti-plant-pathogenic bacteria and fungi | 100 ± 6 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK({nnr:CO-C15H31})FKKLQ{cyc:N-C} | BPC502 | Free | Free | Cyclic | L | CO-C15H31 = palmitoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 99 ± 2 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK({nnr:CO-C17H33})FKKLQ{cyc:N-C} | BPC622 | Free | Free | Cyclic | L | CO-C17H33 = oleoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 97 ± 3 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKKFKK({nnr:CO-nC5H11})LQ{cyc:N-C} | BPC582 | Free | Free | Cyclic | L | CO-nC5H11 = hexanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 96 ± 10 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKKFK({nnr:CO-nC5H11})KLQ{cyc:N-C} | BPC584 | Free | Free | Cyclic | L | CO-nC5H11 = hexanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 97 ± 12 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLK({nnr:CO-nC5H11})KFKKLQ{cyc:N-C} | BPC586 | Free | Free | Cyclic | L | CO-nC5H11 = hexanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 95 ± 20 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KK({nnr:CO-nC5H11})LKKFKKLQ{cyc:N-C} | BPC588 | Free | Free | Cyclic | L | CO-nC5H11 = hexanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 92 ± 12 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KK({nnr:CO-C3H7})LKKFKKLQ{cyc:N-C} | BPC708 | Free | Free | Cyclic | L | CO-C3H7 = butanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 3 ± 1 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | K({nnr:CO-nC5H11})KLKKFKKLQ{cyc:N-C} | BPC590 | Free | Free | Cyclic | L | CO-nC5H11 = hexanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 100 ± 9 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | K({nnr:CO-C3H7})KLKKFKKLQ{cyc:N-C} | BPC710 | Free | Free | Cyclic | L | CO-C3H7 = butanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 13 ± 2 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK{nnr:CO-C3H7}F{d}KKLQ{cyc:N-C} | BPC712 | Free | Free | Cyclic | Mix | CO-C3H7 = butanoyl, f = D-phenylalanine | 10 | Anti-plant-pathogenic bacteria and fungi | 38 ± 7 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKKLK-{nnr:CO-C3H7}F{d}KKLQ{cyc:N-C} | BPC726 | Free | Free | Cyclic | Mix | CO-C3H7 = butanoyl, f = D-phenylalanine | 12 | Anti-plant-pathogenic bacteria and fungi | 4 ± 2 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK{nnr:CO-nC5H11}F{d}KKLQ{cyc:N-C} | BPC624 | Free | Free | Cyclic | Mix | CO-nC5H11 = hexanoyl, f = D-phenylalanine | 10 | Anti-plant-pathogenic bacteria and fungi | 64 ± 9 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK{nnr:CO-isoC5H11}F{d}KKLQ{cyc:N-C} | BPC626 | Free | Free | Cyclic | Mix | CO-isoC5H11 = 4-methylpentanoyl, f = D-phenylalanine | 10 | Anti-plant-pathogenic bacteria and fungi | 54 ± 4 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKKLK-{nnr:CO-nC5H11}F{d}KKLQ{cyc:N-C} | BPC674 | Free | Free | Cyclic | Mix | CO-nC5H11 = hexanoyl, f = D-phenylalanine | 12 | Anti-plant-pathogenic bacteria and fungi | 56 ± 2 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK{nnr:CO-C7H15}F{d}KKLQ{cyc:N-C} | BPC668 | Free | Free | Cyclic | Mix | CO-C7H15 = octanoyl, f = D-phenylalanine | 10 | Anti-plant-pathogenic bacteria and fungi | 79 ± 1 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KK{nnr:CO-C3H7}LKKF{d}KKLQ{cyc:N-C} | BPC714 | Free | Free | Cyclic | Mix | CO-C3H7 = butanoyl, f = D-phenylalanine | 10 | Anti-plant-pathogenic bacteria and fungi | 3 ± 0.5 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KK{nnr:CO-nC5H11}LKKF{d}KKLQ{cyc:N-C} | BPC680 | Free | Free | Cyclic | Mix | CO-nC5H11 = hexanoyl, f = D-phenylalanine | 10 | Anti-plant-pathogenic bacteria and fungi | 81 ± 4 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | K{nnr:CO-C3H7}KLKKF{d}KKLQ{cyc:N-C} | BPC716 | Free | Free | Cyclic | Mix | CO-C3H7 = butanoyl, f = D-phenylalanine | 10 | Anti-plant-pathogenic bacteria and fungi | 4 ± 0.5 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | K{nnr:CO-nC5H11}KLKKF{d}KKLQ{cyc:N-C} | BPC686 | Free | Free | Cyclic | Mix | CO-nC5H11 = hexanoyl, f = D-phenylalanine | 10 | Anti-plant-pathogenic bacteria and fungi | 14 ± 0.4 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK{d}{nnr:CO-C3H7}FKKLQ{cyc:N-C} | BPC702 | Free | Free | Cyclic | Mix | CO-C3H7 = butanoyl, k = D-Lys | 10 | Anti-plant-pathogenic bacteria and fungi | 2 ± 0.3 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK{d}LK-{nnr:CO-C3H7}FKKLQ{cyc:N-C} | BPC724 | Free | Free | Cyclic | Mix | CO-C3H7 = butanoyl, k = D-Lys | 12 | Anti-plant-pathogenic bacteria and fungi | 3 ± 0.5 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK{d}{nnr:CO-nC5H11}FKKLQ{cyc:N-C} | BPC628 | Free | Free | Cyclic | Mix | CO-nC5H11 = hexanoyl, k = D-Lys | 10 | Anti-plant-pathogenic bacteria and fungi | 34 ± 3 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK{d}{nnr:CO-isoC5H11}FKKLQ{cyc:N-C} | BPC630 | Free | Free | Cyclic | Mix | CO-isoC5H11 = 4-methylpentanoyl, k = D-Lys | 10 | Anti-plant-pathogenic bacteria and fungi | 28 ± 3 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK{d}LK-{nnr:CO-nC5H11}FKKLQ{cyc:N-C} | BPC672 | Free | Free | Cyclic | Mix | CO-nC5H11 = hexanoyl, k = D-Lys | 12 | Anti-plant-pathogenic bacteria and fungi | 33 ± 2 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK{d}{nnr:CO-C7H15}FKKLQ{cyc:N-C} | BPC666 | Free | Free | Cyclic | Mix | CO-C7H15 = octanoyl, k = D-Lys | 10 | Anti-plant-pathogenic bacteria and fungi | 73 ± 3 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KK{d}{nnr:CO-nC5H11}LKKFKKLQ{cyc:N-C} | BPC678 | Free | Free | Cyclic | Mix | CO-nC5H11 = hexanoyl, k = D-Lys | 10 | Anti-plant-pathogenic bacteria and fungi | 73 ± 4 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KK{d}{nnr:CO-C3H7}LKKFKKLQ{cyc:N-C} | BPC704 | Free | Free | Cyclic | Mix | CO-C3H7 = butanoyl, k = D-Lys | 10 | Anti-plant-pathogenic bacteria and fungi | 16 ± 2 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | K{d}{nnr:CO-nC5H11}KLKKFKKLQ{cyc:N-C} | BPC684 | Free | Free | Cyclic | Mix | CO-nC5H11 = hexanoyl, k = D-Lys | 10 | Anti-plant-pathogenic bacteria and fungi | 13 ± 1 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | K{d}{nnr:CO-C3H7}KLKKFKKLQ{cyc:N-C} | BPC706 | Free | Free | Cyclic | Mix | CO-C3H7 = butanoyl, k = D-Lys | 10 | Anti-plant-pathogenic bacteria and fungi | 46 ± 3 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK{d}{nnr:CO-nC5H11}F{d}KKLQ{cyc:N-C} | BPC632 | Free | Free | Cyclic | Mix | CO-nC5H11 = hexanoyl, f = D-phenylalanine, k = D-Lys | 10 | Anti-plant-pathogenic bacteria and fungi | 22 ± 10 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK{d}({nnr:CO-isoC5H11})F{d}KKLQ{cyc:N-C} | BPC634 | Free | Free | Cyclic | L | CO-isoC5H11 = 4-methylpentanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 17 ± 8 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK({nnr:CO-C3H7})HKKLQ{cyc:N-C} | BPC718 | Free | Free | Cyclic | L | CO-C3H7 = butanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 4 ± 1 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK(LK-{nnr:CO-C3H7})HKKLQ{cyc:N-C} | BPC728 | Free | Free | Cyclic | L | CO-C3H7 = butanoyl | 12 | Anti-plant-pathogenic bacteria and fungi | 7 ± 1 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK({nnr:CO-nC5H11})HKKLQ{cyc:N-C} | BPC636 | Free | Free | Cyclic | L | CO-nC5H11 = hexanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 16 ± 5 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK({nnr:CO-isoC5H11})HKKLQ{cyc:N-C} | BPC638 | Free | Free | Cyclic | L | CO-isoC5H11 = 4-methylpentanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 8 ± 5 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK(LK-{nnr:CO-nC5H11})HKKLQ{cyc:N-C} | BPC676 | Free | Free | Cyclic | L | CO-nC5H11 = hexanoyl | 12 | Anti-plant-pathogenic bacteria and fungi | 3 ± 1 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KKLKK({nnr:CO-C7H15})HKKLQ{cyc:N-C} | BPC670 | Free | Free | Cyclic | L | CO-C7H15 = octanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 40 ± 1 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KK({nnr:CO-nC5H11})LKKHKKLQ{cyc:N-C} | BPC682 | Free | Free | Cyclic | L | CO-nC5H11 = hexanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 27 ± 1 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | KK({nnr:CO-C3H7})LKKHKKLQ{cyc:N-C} | BPC720 | Free | Free | Cyclic | L | CO-C3H7 = butanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 4 ± 1 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27008420 | 2016 | K({nnr:CO-nC5H11})KLKKHKKLQ{cyc:N-C} | BPC688 | Free | Free | Cyclic | L | CO-nC5H11 = hexanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 1 ± 0.2 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Non-hemolytic | ||
| 27008420 | 2016 | K({nnr:CO-C3H7})KLKKHKKLQ{cyc:N-C} | BPC722 | Free | Free | Cyclic | L | CO-C3H7= butanoyl | 10 | Anti-plant-pathogenic bacteria and fungi | 3 ± 0.1 % Hemolysis at 250 µM | Horse | Synthetic Cyclolipopeptides | NA | Low hemolytic | ||
| 27487329 | 2017 | GLPVCGETCVGGTCNTPGCTCSWPVCTRN{cyc:N-C} | kB1 | Free | Free | Cyclic | L | None | 29 | cytotoxic | <60 % Hemolysis at 50 µM | Human | Möbius Family | Loop | NA | ||
| 27487329 | 2017 | GLPVCGETCVGGTCPGACTCSWPVCTRN{cyc:N-C} | kL3 | Free | Free | Cyclic | L | None | 28 | cytotoxic | 0 % Hemolysis at 10-50 µM | Human | Chimeric Cyclotides | Loop | Non-hemolytic | ||
| 27487329 | 2017 | GLPVCGETCVGGTCNTPGCICSWPVCTRN{cyc:N-C} | kL4 | Free | Free | Cyclic | L | None | 29 | cytotoxic | <60 % Hemolysis at 50 µM | Human | Chimeric Cyclotides | Loop | NA | ||
| 27487329 | 2017 | GLPVCGETCVGGTCNTPGCTCRGNGYCTRN{cyc:N-C} | kL5 | Free | Free | Cyclic | L | None | 30 | cytotoxic | 0 % Hemolysis at 10-50 µM | Human | Chimeric Cyclotides | Loop | Non-hemolytic | ||
| 27487329 | 2017 | GGVCGETCRRDSDCPGACICRGNGYCGSGSD{cyc:N-C} | ML1 | Free | Free | Cyclic | L | None | 31 | cytotoxic | 0 % Hemolysis at 10-50 µM | Human | Chimeric Cyclotides | Loop | Non-hemolytic | ||
| 27487329 | 2017 | GGVCPKILKKCVGGTCPGACICRGNGYCGSGSD{cyc:N-C} | ML2 | Free | Free | Cyclic | L | None | 33 | cytotoxic | 0 % Hemolysis at 10-50 µM | Human | Chimeric Cyclotides | Loop | Non-hemolytic | ||
| 27487329 | 2017 | GGVCPKILKKCRRDSDCNTPGCICRGNGYCGSGSD{cyc:N-C} | ML3 | Free | Free | Cyclic | L | None | 35 | cytotoxic | 0 % Hemolysis at 10-50 µM | Human | Chimeric Cyclotides | Loop | Non-hemolytic | ||
| 27487329 | 2017 | GGVCPKILKKCRRDSDCPGACTCRGNGYCGSGSD{cyc:N-C} | ML4 | Free | Free | Cyclic | L | None | 34 | cytotoxic | 0 % Hemolysis at 10-50 µM | Human | Chimeric Cyclotides | Loop | Non-hemolytic | ||
| 27487329 | 2017 | GGVCPKILKKCRRDSDCPGACICRGNGYCGSGSD{cyc:N-C} | MCoTI-II | Free | Free | Cyclic | L | None | 34 | cytotoxic | 0 % Hemolysis at 10-50 µM | Human | Momordica Cochinchinensis | Loop | Non-hemolytic | ||
| 28165293 | 2017 | FKCRRWQWRMKKLGAPSITCVRRAF{cyc:N-C} | LFcinB | Free | Free | Cyclic | L | None | 25 | Anticancer | <2 % Hemolysis at 10 µM | Human | Bovine Lf (Blf) | β-Hairpin | NA | ||
| 28165293 | 2017 | GRRRRSVQWCA{cyc:N-C} | Cyclo-hLF11 | Free | Free | Cyclic | L | None | 11 | Anticancer | <2 % Hemolysis at 10 µM | Human | Human-Derived | β-Hairpin | NA | ||
| 28165293 | 2017 | GRRRRSVQWCA{cyc:N-C} | Cyclo-hLF11C10S | Free | Free | Cyclic | L | None | 11 | Anticancer | <2 % Hemolysis at 10 µM | Human | Human-Derived | β-Hairpin | NA | ||
| 28165293 | 2017 | APRKNVRWCT{cyc:N-C} | Cyclo-bLF10 | Free | Free | Cyclic | L | None | 10 | Anticancer | <2 % Hemolysis at 10 µM | Human | Bovine Derived | β-Hairpin | NA | ||
| 28533236 | 2017 | {nnr:Dap}L{d}WK{d}N{d}R{d}{cyc:N-C} | CLP-4 | Free | Free | Cyclic | Mix | Dap = 2,3-diaminopropionic acid, l = D-leucine, k = D-lysine, n = D-asparagine, r = D-arginine | 5 | Antibacterial, Antibiofilm | 0 % Hemolysis at 8 μg/ml | Human | Fusaricidin | NA | Non-hemolytic | ||
| 28533236 | 2017 | {nnr:Dap}L{d}WK{d}N{d}R{d}{cyc:N-C} | CLP-4 | Free | Free | Cyclic | Mix | Dap = 2,3-diaminopropionic acid, l = D-leucine, k = D-lysine, n = D-asparagine, r = D-arginine | 5 | Antibacterial, Antibiofilm | 0 % Hemolysis at 15.6 μg/ml | Human | Fusaricidin | NA | Non-hemolytic | ||
| 28533236 | 2017 | {nnr:Dap}L{d}WK{d}N{d}R{d}{cyc:N-C} | CLP-4 | Free | Free | Cyclic | Mix | Dap = 2,3-diaminopropionic acid, l = D-leucine, k = D-lysine, n = D-asparagine, r = D-arginine | 5 | Antibacterial, Antibiofilm | 0 % Hemolysis at 31.2 μg/ml | Human | Fusaricidin | NA | Non-hemolytic | ||
| 28533236 | 2017 | {nnr:Dap}L{d}WK{d}N{d}R{d}{cyc:N-C} | CLP-4 | Free | Free | Cyclic | Mix | Dap = 2,3-diaminopropionic acid, l = D-leucine, k = D-lysine, n = D-asparagine, r = D-arginine | 5 | Antibacterial, Antibiofilm | 0 % Hemolysis at 62.5 μg/ml | Human | Fusaricidin | NA | Non-hemolytic | ||
| 28533236 | 2017 | {nnr:Dap}L{d}WK{d}N{d}R{d}{cyc:N-C} | CLP-4 | Free | Free | Cyclic | Mix | Dap = 2,3-diaminopropionic acid, l = D-leucine, k = D-lysine, n = D-asparagine, r = D-arginine | 5 | Antibacterial, Antibiofilm | 0 % Hemolysis at 125 μg/ml | Human | Fusaricidin | NA | Non-hemolytic | ||
| 28533236 | 2017 | {nnr:Dap}L{d}WK{d}N{d}R{d}{cyc:N-C} | CLP-4 | Free | Free | Cyclic | Mix | Dap = 2,3-diaminopropionic acid, l = D-leucine, k = D-lysine, n = D-asparagine, r = D-arginine | 5 | Antibacterial, Antibiofilm | 0 % Hemolysis at 250 μg/ml | Human | Fusaricidin | NA | Non-hemolytic | ||
| 28533236 | 2017 | {nnr:Dap}L{d}WK{d}N{d}R{d}{cyc:N-C} | CLP-4 | Free | Free | Cyclic | Mix | Dap = 2,3-diaminopropionic acid, l = D-leucine, k = D-lysine, n = D-asparagine, r = D-arginine | 5 | Antibacterial, Antibiofilm | 0 % Hemolysis at 500 μg/ml | Human | Fusaricidin | NA | Non-hemolytic | ||
| 28533236 | 2017 | {nnr:Dap}L{d}WK{d}N{d}R{d}{cyc:N-C} | CLP-4 | Free | Free | Cyclic | Mix | Dap = 2,3-diaminopropionic acid, l = D-leucine, k = D-lysine, n = D-asparagine, r = D-arginine | 5 | Antibacterial, Antibiofilm | <10 % Hemolysis at 1000 μg/ml | Human | Fusaricidin | NA | Non-hemolytic | ||
| 29163899 | 2017 | C{d}WK{d}KK{d}C{cyc:N-C}{ct:Amid} | RH1 | Amidation | Free | Cyclic | Mix | None | 6 | Antimicrobial | MHC at 1000 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CW{d}WK{d}KK{d}C{cyc:N-C}{ct:Amid} | RH2 | Amidation | Free | Cyclic | Mix | None | 7 | Antimicrobial | MHC at 125 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | C{d}WW{d}KK{d}KK{d}C{cyc:N-C}{ct:Amid} | RH3 | Amidation | Free | Cyclic | Mix | None | 8 | Antimicrobial | MHC at 500 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CW{d}WW{d}KK{d}KK{d}C{cyc:N-C}{ct:Amid} | RH4 | Amidation | Free | Cyclic | Mix | None | 9 | Antimicrobial | MHC at 125 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CW{d}WW{d}KK{d}KK{d}KC{cyc:N-C}{ct:Amid} | RH5 | Amidation | Free | Cyclic | Mix | None | 10 | Antimicrobial | MHC at 1000 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CW{d}WW{d}WK{d}KK{d}KK{d}C{cyc:N-C}{ct:Amid} | RH6 | Amidation | Free | Cyclic | Mix | None | 11 | Antimicrobial | MHC at 31 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | C{d}WW{d}WW{d}KK{d}KK{d}KK{d}C{cyc:N-C}{ct:Amid} | RH7 | Amidation | Free | Cyclic | Mix | None | 12 | Antimicrobial | MHC at 31 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CwWwWkKkKkC{cyc:N-C}{ct:Amid} | RH6m | Amidation | Free | Cyclic | Mix | Cyclized with α,α′-dichloro-meta-xylene | 11 | Antimicrobial | MHC at 31 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CwWwWkKkKkC{cyc:N-C}{ct:Amid} | RH6o | Amidation | Free | Cyclic | Mix | Cyclized with α,α′-dichloro-ortho-xylene. | 11 | Antimicrobial | MHC at 31 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CwWwWkKkKkC{cyc:N-C}{ct:Amid} | RH6ss | Amidation | Free | Cyclic | Mix | Cyclized with disulfide bridge | 11 | Antimicrobial | Minimum Hemolytic Concentration | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CF{d}FF{d}FK{d}KK{d}KK{d}C{cyc:N-C}{ct:Amid} | RH8 | Amidation | Free | Cyclic | Mix | None | 11 | Antimicrobial | MHC at 500 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CL{d}LL{d}LK{d}KK{d}KK{d}C{cyc:N-C}{ct:Amid} | RH9 | Amidation | Free | Cyclic | Mix | None | 11 | Antimicrobial | MHC at >2000 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CK{d}KK{d}WW{d}WW{d}KK{d}C{cyc:N-C}{ct:Amid} | RH10 | Amidation | Free | Cyclic | Mix | None | 11 | Antimicrobial | MHC at 250 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CW{d}WK{d}KK{d}KK{d}WW{d}C{cyc:N-C}{ct:Amid} | RH11 | Amidation | Free | Cyclic | Mix | None | 11 | Antimicrobial | MHC at 125 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | C{d}WW{d}KK{d}KK{d}KW{d}WC{d}{cyc:N-C}{ct:Amid} | dRH11 | Amidation | Free | Cyclic | Mix | None | 11 | Antimicrobial | Minimum Hemolytic Concentration | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CwWkKkKkWwC{cyc:N-C}{ct:Amid} | RH11m | Amidation | Free | Cyclic | Mix | Cyclized with α,α′-dichloro-meta-xylene | 11 | Antimicrobial | Minimum Hemolytic Concentration | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CwWkKkKkWwC{cyc:N-C}{ct:Amid} | RH11o | Amidation | Free | Cyclic | Mix | Cyclized with α,α′-dichloro-ortho-xylene. | 11 | Antimicrobial | Minimum Hemolytic Concentration | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CK{d}WK{d}WK{d}WK{d}WK{d}C{cyc:N-C}{ct:Amid} | RH12 | Amidation | Free | Cyclic | Mix | None | 10 | Antimicrobial | MHC at 1000 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CWW{d}KK{d}KK{d}KW{d}WW{d}C{cyc:N-C}{ct:Amid} | RH13 | Amidation | Free | Cyclic | Mix | None | 12 | Antimicrobial | MHC at 125 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | C{d}W{d}WK{d}KK{d}KK{d}WW{d}WC{d}{cyc:N-C}{ct:Amid} | dRH13 | Amidation | Free | Cyclic | Mix | None | 12 | Antimicrobial | Minimum Hemolytic Concentration | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CW{d}WK{d}KK{d}KW{d}WW{d}C{cyc:N-C}{ct:Amid} | RH14 | Amidation | Free | Cyclic | Mix | None | 11 | Antimicrobial | MHC at 8 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CW{d}KK{d}KK{d}KK{d}WW{d}C{cyc:N-C}{ct:Amid} | RH15 | Amidation | Free | Cyclic | Mix | None | 11 | Antimicrobial | MHC at 250 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CL{d}LK{d}KK{d}KK{d}LL{d}C{cyc:N-C}{ct:Amid} | RH16 | Amidation | Free | Cyclic | Mix | None | 11 | Antimicrobial | MHC at >2000 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CWWKKKKKWWC{cyc:N-C}{ct:Amid} | RH17 | Amidation | Free | Cyclic | Mix | None | 11 | Antimicrobial | MHC at 250 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | C({nnr:Me})wWkKkKkW({nnr:Me})wC{cyc:N-C}{ct:Amid} | RH18 | Amidation | Free | Cyclic | Mix | Me = N-methylation of the peptide bond. | 11 | Antimicrobial | MHC at 8 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | Cw({nnr:Me})WkKkKkW({nnr:Me})wC{cyc:N-C}{ct:Amid} | RH19 | Amidation | Free | Cyclic | Mix | Me = N-methylation of the peptide bond. | 11 | Antimicrobial | MHC at 1000 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CwW({nnr:Me})kKkK({nnr:Me})kWwC{cyc:N-C}{ct:Amid} | RH20 | Amidation | Free | Cyclic | Mix | Me = N-methylation of the peptide bond. | 11 | Antimicrobial | MHC at 1000 µg/mL | Human | Camp | β-Sheet | NA | ||
| 28026016 | 2017 | KKLKKFKKLQ{cyc:N-C} | BPC194 | Free | Free | Cyclic | L | None | 10 | Antimicrobial | 3 ± 0.6 % Hemolysis at 150 µM | Horse | Synthetic Peptidotriazoles | NA | NA | ||
| 28026016 | 2017 | KKLKKFKKLQ{cyc:N-C} | BPC194 | Free | Free | Cyclic | L | None | 10 | Antimicrobial | 3 ± 0.6 % Hemolysis at 250 µM | Horse | Synthetic Peptidotriazoles | NA | NA | ||
| 28026016 | 2017 | KKLKKFKKLQ{cyc:N-C} | BPC194 | Free | Free | Cyclic | L | None | 10 | Antimicrobial | 4 ± 0.7 % Hemolysis at 375 µM | Horse | Synthetic Peptidotriazoles | NA | NA | ||
| 28026016 | 2017 | AAA{nnr:Tr-Bn}{cyc:N-C} | BPC458 | Free | Free | Cyclic | L | Tr-Bn = triazole bearing a benzyl group | 3 | Antimicrobial | 2 ± 0.3 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAA{nnr:Tr-Bn}{cyc:N-C} | BPC458 | Free | Free | Cyclic | L | Tr-Bn = triazole bearing a benzyl group | 3 | Antimicrobial | 3 ± 0.5 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAA{nnr:Tr-Bn}{cyc:N-C} | BPC458 | Free | Free | Cyclic | L | Tr-Bn = triazole bearing a benzyl group | 3 | Antimicrobial | 5 ± 0.2 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAA{nnr:Tr-Nle}{cyc:N-C} | BPC460 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Nle = triazole bearing a 2-aminohexanoic acid | 3 | Antimicrobial | 0 ± 0.3 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAA{nnr:Tr-Nle}{cyc:N-C} | BPC460 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Nle = triazole bearing a 2-aminohexanoic acid | 3 | Antimicrobial | 0 ± 0.3 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAA{nnr:Tr-Nle}{cyc:N-C} | BPC460 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Nle = triazole bearing a 2-aminohexanoic acid | 3 | Antimicrobial | 0 ± 0.1 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAA{nnr:TrPhNH2}{cyc:N-C} | BPC518 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph-NH2 = triazole bearing an aniline moiety | 3 | Antimicrobial | 1 ± 0.1 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAA{nnr:TrPhNH2}{cyc:N-C} | BPC518 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph-NH2 = triazole bearing an aniline moiety | 3 | Antimicrobial | 1 ± 0.1 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAA{nnr:TrPhNH2}{cyc:N-C} | BPC518 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph-NH2 = triazole bearing an aniline moiety | 3 | Antimicrobial | 1 ± 0.1 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAA{nnr:TrPhMe}{cyc:N-C} | BPC540 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph-Me = triazole bearing a tolyl group | 3 | Antimicrobial | 2 ± 0.5 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAA{nnr:TrPhMe}{cyc:N-C} | BPC540 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph-Me = triazole bearing a tolyl group | 3 | Antimicrobial | 4 ± 0.4 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAA{nnr:TrPhMe}{cyc:N-C} | BPC540 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph-Me = triazole bearing a tolyl group | 3 | Antimicrobial | 6 ± 1 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAA{nnr:TrPhOMe}{cyc:N-C} | BPC542 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-PhOMe = triazole bearing an anisole moiety | 3 | Antimicrobial | 1 ± 0.6 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAA{nnr:TrPhOMe}{cyc:N-C} | BPC542 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-PhOMe = triazole bearing an anisole moiety | 3 | Antimicrobial | 2 ± 0.2 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAA{nnr:TrPhOMe}{cyc:N-C} | BPC542 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-PhOMe = triazole bearing an anisole moiety | 3 | Antimicrobial | 4 ± 0.4 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAA{nnr:TrPh}{cyc:N-C} | BPC544 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph = triazole bearing a phenyl group | 3 | Antimicrobial | 1 ± 0.4 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAA{nnr:TrPh}{cyc:N-C} | BPC544 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph = triazole bearing a phenyl group | 3 | Antimicrobial | 1 ± 0.3 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAA{nnr:TrPh}{cyc:N-C} | BPC544 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph = triazole bearing a phenyl group | 3 | Antimicrobial | 2 ± 0.4 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPh}{cyc:N-C} | BPC516 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph = triazole bearing a phenyl group | 3 | Antimicrobial | 5 ± 0.2 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPh}{cyc:N-C} | BPC516 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph = triazole bearing a phenyl group | 3 | Antimicrobial | 6 ± 0.4 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPh}{cyc:N-C} | BPC516 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph = triazole bearing a phenyl group | 3 | Antimicrobial | 8 ± 0.1 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPhNH2}{cyc:N-C} | BPC538 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph-NH2 = triazole bearing an aniline moiety | 3 | Antimicrobial | 1 ± 0.8 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPhNH2}{cyc:N-C} | BPC538 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph-NH2 = triazole bearing an aniline moiety | 3 | Antimicrobial | 1 ± 0.4 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPhNH2}{cyc:N-C} | BPC538 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph-NH2 = triazole bearing an aniline moiety | 3 | Antimicrobial | 2 ± 0.4 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPhMe}{cyc:N-C} | BPC548 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph-Me = triazole bearing a tolyl group | 3 | Antimicrobial | 12 ± 0.3 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPhMe}{cyc:N-C} | BPC548 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph-Me = triazole bearing a tolyl group | 3 | Antimicrobial | 24 ± 1 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPhMe}{cyc:N-C} | BPC548 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph-Me = triazole bearing a tolyl group | 3 | Antimicrobial | 26 ± 4 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPhOMe}{cyc:N-C} | BPC550 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-PhOMe = triazole bearing an anisole moiety | 3 | Antimicrobial | 7 ± 0.8 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPhOMe}{cyc:N-C} | BPC550 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-PhOMe = triazole bearing an anisole moiety | 3 | Antimicrobial | 10 ± 0.8 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPhOMe}{cyc:N-C} | BPC550 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-PhOMe = triazole bearing an anisole moiety | 3 | Antimicrobial | 19 ± 5 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | KKK{nnr:COTr}{cyc:N-C} | BPC692 | Free | Free | Cyclic | L | Tr = unsubsituted triazole | 3 | Antimicrobial | 5 ± 0.7 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | KKK{nnr:COTr}{cyc:N-C} | BPC692 | Free | Free | Cyclic | L | Tr = unsubsituted triazole | 3 | Antimicrobial | 5 ± 0.8 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | KKK{nnr:COTr}{cyc:N-C} | BPC692 | Free | Free | Cyclic | L | Tr = unsubsituted triazole | 3 | Antimicrobial | 7 ± 0.2 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | KKK{nnr:COTrBn}{cyc:N-C} | BPC696 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Bn = triazole bearing a benzyl group | 3 | Antimicrobial | 19 ± 4 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | KKK{nnr:COTrBn}{cyc:N-C} | BPC696 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Bn = triazole bearing a benzyl group | 3 | Antimicrobial | 20 ± 5 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | KKK{nnr:COTrBn}{cyc:N-C} | BPC696 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Bn = triazole bearing a benzyl group | 3 | Antimicrobial | 30 ± 4 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | KKK{nnr:COTrNle}{cyc:N-C} | BPC700 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Nle = triazole bearing a 2-aminohexanoic acid | 3 | Antimicrobial | 0 ± 2 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | KKK{nnr:COTrNle}{cyc:N-C} | BPC700 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Nle = triazole bearing a 2-aminohexanoic acid | 3 | Antimicrobial | 0 ± 0.4 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | KKK{nnr:COTrNle}{cyc:N-C} | BPC700 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Nle = triazole bearing a 2-aminohexanoic acid | 3 | Antimicrobial | 0 ± 0.1 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAAAA({nnr:TrBn}{cyc:N-C} | BPC510 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Bn = triazole bearing a benzyl group | 5 | Antimicrobial | 32 ± 2 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAAAA({nnr:TrBn}{cyc:N-C} | BPC510 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Bn = triazole bearing a benzyl group | 5 | Antimicrobial | 35 ± 3 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAAAA({nnr:TrBn}{cyc:N-C} | BPC510 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Bn = triazole bearing a benzyl group | 5 | Antimicrobial | 40 ± 4 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAAAA{nnr:Tr-Nle}{cyc:N-C} | BPC512 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Nle = triazole bearing a 2-aminohexanoic acid | 5 | Antimicrobial | 2 ± 0.1 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAAAA{nnr:Tr-Nle}{cyc:N-C} | BPC512 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Nle = triazole bearing a 2-aminohexanoic acid | 5 | Antimicrobial | 2 ± 0.2 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAAAA{nnr:Tr-Nle}{cyc:N-C} | BPC512 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Nle = triazole bearing a 2-aminohexanoic acid | 5 | Antimicrobial | 3 ± 0.4 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAAAA{nnr:TrPhNH2}{cyc:N-C} | BPC514 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph-NH2 = triazole bearing an aniline moiety | 5 | Antimicrobial | 16 ± 0.9 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAAAA{nnr:TrPhNH2}{cyc:N-C} | BPC514 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph-NH2 = triazole bearing an aniline moiety | 5 | Antimicrobial | 19 ± 0.8 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | AAAAA{nnr:TrPhNH2}{cyc:N-C} | BPC514 | Free | Free | Cyclic | L | Tr = unsubsituted triazole, Tr-Ph-NH2 = triazole bearing an aniline moiety | 5 | Antimicrobial | 23 ± 2 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPh}{cyc:N-C} | BPC562 | Free | Free | Cyclic | L | Tr-Ph = triazole bearing a phenyl group | 5 | Antimicrobial | 42 ± 5 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPh}{cyc:N-C} | BPC562 | Free | Free | Cyclic | L | Tr-Ph = triazole bearing a phenyl group | 5 | Antimicrobial | 51 ± 3 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPh}{cyc:N-C} | BPC562 | Free | Free | Cyclic | L | Tr-Ph = triazole bearing a phenyl group | 5 | Antimicrobial | 58 ± 1 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPhNH2}{cyc:N-C} | BPC572 | Free | Free | Cyclic | L | Tr-Ph-NH2 = triazole bearing an aniline moiety | 5 | Antimicrobial | 8 ± 0.2 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPhNH2}{cyc:N-C} | BPC572 | Free | Free | Cyclic | L | Tr-Ph-NH2 = triazole bearing an aniline moiety | 5 | Antimicrobial | 13 ± 0.2 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPhNH2}{cyc:N-C} | BPC572 | Free | Free | Cyclic | L | Tr-Ph-NH2 = triazole bearing an aniline moiety | 5 | Antimicrobial | 25 ± 5 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPhOMe}{cyc:N-C} | BPC558 | Free | Free | Cyclic | L | Tr-PhOMe = triazole bearing an anisole moiety | 5 | Antimicrobial | 54 ± 4 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPhOMe}{cyc:N-C} | BPC558 | Free | Free | Cyclic | L | Tr-PhOMe = triazole bearing an anisole moiety | 5 | Antimicrobial | 76 ± 8 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | {nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:Nle}{nnr:TrPhOMe}{cyc:N-C} | BPC558 | Free | Free | Cyclic | L | Tr-PhOMe = triazole bearing an anisole moiety | 5 | Antimicrobial | 90 ± 8 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | KKKKK{nnr:COTr}){cyc:N-C} | BPC690 | Free | Free | Cyclic | L | Tr = unsubsituted triazole | 5 | Antimicrobial | 47 ± 7 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | KKKKK{nnr:COTr}){cyc:N-C} | BPC690 | Free | Free | Cyclic | L | Tr = unsubsituted triazole | 5 | Antimicrobial | 67 ± 8 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | KKKKK{nnr:COTr}){cyc:N-C} | BPC690 | Free | Free | Cyclic | L | Tr = unsubsituted triazole | 5 | Antimicrobial | 75 ± 7 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | KKKKK{nnr:COTrBn}{cyc:N-C} | BPC694 | Free | Free | Cyclic | L | Tr-Bn = triazole bearing a benzyl group | 5 | Antimicrobial | 57 ± 5 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | KKKKK{nnr:COTrBn}{cyc:N-C} | BPC694 | Free | Free | Cyclic | L | Tr-Bn = triazole bearing a benzyl group | 5 | Antimicrobial | 74 ± 15 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | KKKKK{nnr:COTrBn}{cyc:N-C} | BPC694 | Free | Free | Cyclic | L | Tr-Bn = triazole bearing a benzyl group | 5 | Antimicrobial | 93 ± 15 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | KKKKK{nnr:COTrNle}{cyc:N-C} | BPC698 | Free | Free | Cyclic | L | Tr-Bn = triazole bearing a benzyl group | 5 | Antimicrobial | 3 ± 0.5 % Hemolysis at 150 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | KKKKK{nnr:COTrNle}{cyc:N-C} | BPC698 | Free | Free | Cyclic | L | Tr-Bn = triazole bearing a benzyl group | 5 | Antimicrobial | 4 ± 1 % Hemolysis at 250 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28026016 | 2017 | KKKKK{nnr:COTrNle}{cyc:N-C} | BPC698 | Free | Free | Cyclic | L | Tr-Bn = triazole bearing a benzyl group | 5 | Antimicrobial | 5 ± 0.7 % Hemolysis at 375 µM | Horse | Bpc194 Analog | NA | NA | ||
| 28833783 | 2017 | IDWKKLLKAAK{nnr:Pra}IL{cyc:N-C}{nt:Acet}{ct:Amid} | C-MPI-1 | Amidation | Acetylation | Cyclic | Mix | Pra = L-propargylglycine | 16 | Antimicrobial | 30 % Hemolysis at 50 µM | Human | Mpi Analogs | α-Helical | NA | ||
| 28833783 | 2017 | IDWKKLLKAAK{nnr:Pra}IL{cyc:N-C}{nt:Acet}{ct:Amid} | C-MPI-1 | Amidation | Acetylation | Cyclic | Mix | Pra = L-propargylglycine | 16 | Antimicrobial | 35 % Hemolysis at 150 µM | Human | Mpi Analogs | α-Helical | NA | ||
| 38663759 | 2024 | RRRW-{nnr:Dip}-{nnr:Dip}{cyc:N-C} | 1a | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at 50 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRR-{nnr:Dip}-W-{nnr:Dip}{cyc:N-C} | 1b | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at 75 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRR-{nnr:Dip}-{nnr:Dip}-W{cyc:N-C} | 1c | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at 65 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRW-{nnr:Nal}-{nnr:Nal}{cyc:N-C} | 2a | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at 60 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRR-{nnr:Nal}-W-{nnr:Nal}{cyc:N-C} | 2b | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at 55 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRR-{nnr:Nal}-{nnr:Nal}-W{cyc:N-C} | 2c | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at 45 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRRW-{nnr:Dip}-{nnr:Dip}{cyc:N-C} | 3a | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at 85 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRR-{nnr:Dip}-W-{nnr:Dip}{cyc:N-C} | 3b | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at 230 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRR-{nnr:Dip}-{nnr:Dip}-W{cyc:N-C} | 3c | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at 100 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRRW-{nnr:Nal}-{nnr:Nal}{cyc:N-C} | 4a | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at 150 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRR-{nnr:Nal}-W-{nnr:Nal}{cyc:N-C} | 4b | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at 175 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRR-{nnr:Nal}-{nnr:Nal}-W{cyc:N-C} | 4c | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at 105 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRRW-{nnr:Dip}-W{cyc:N-C} | 5a | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 6 | Antimicrobial | 50 % Hemolysis at 220 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRRW-{nnr:Nal}-W{cyc:N-C} | 5b | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 6 | Antimicrobial | 50 % Hemolysis at 200 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRR-{nnr:Dip}-L-{nnr:Dip}{cyc:N-C} | 6a | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at 155 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRR-{nnr:Nal}-L-{nnr:Nal}{cyc:N-C} | 6b | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at 170 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | {nnr:Agp}-{nnr:Agp}-{nnr:Agp}-{nnr:Agp}-{nnr:Dip}-W-{nnr:Dip}{cyc:N-C} | 7a | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine, Agp = (S)−2-amino-3-guanidinopropionic acid | 1 | Antimicrobial | 50 % Hemolysis at 240 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | {nnr:Agb}-{nnr:Agb}-{nnr:Agb}-{nnr:Agb}-{nnr:Dip}-W-{nnr:Dip}{cyc:N-C} | 7b | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine, Agb = (S)−2-amino-4-guanidinobutyric acid | 1 | Antimicrobial | 50 % Hemolysis at 190 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | {nnr:hArg}R{nnr:hArg}R{nnr:Dip}W{nnr:Dip}{cyc:N-C} | 7c | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine, hArg = homo-arginine (S)−2-amino-6-guanidino-hexanoic acid | 7 | Antimicrobial | 50 % Hemolysis at 160 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRR-{nnr:Dip}-{nnr:Dip}-{nnr:Dip}{cyc:N-C} | 8a | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at 70 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRR-{nnr:Nal}-{nnr:Nal}-{nnr:Nal}{cyc:N-C} | 8b | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at 80 μg/mL | Human | Synthetic | NA | NA | ||
| 29077406 | 2017 | F{d}PV{nnr:O}L-F{d}PV{nnr:O}L{cyc:N-C} | GS | Free | Free | Cyclic | Mix | O = Ornithine, f = D-Phenylalanine | 10 | Antimicrobial | 90 % Hemolysis at 12 μg/mL | Human | Aneurinibacillus Migulanus | C2-symmetric antiparallel β-Sheet | NA | ||
| 29077406 | 2017 | F{d}({nnr:Dyp})V{nnr:O}LF{d}PV{nnr:O}L{cyc:N-C} | GS mimetic 15 | Free | Free | Cyclic | Mix | O = Ornithine, Dyp = cis-dihydroxyproline, f = D-Phenylalanine | 10 | Antimicrobial | 90 % Hemolysis at 85 μg/mL | Human | Gs Derivative Synthesized | β-Turn | NA | ||
| 29077406 | 2017 | {nnr:D-Hot═Tap}-V-{nnr:O}-L-F{d}-P-V-{nnr:O}-L{cyc:N-C} | dimethylketal modified GS analogue | Free | Free | Cyclic | Mix | O = Ornithine, Dyp = cis-dihydroxyproline, D-Hot═Tap = D-Hot═Tap, f = D-Phenylalanine | 9 | Antimicrobial | 90 % Hemolysis at >200 μg/mL | Human | Dihydroxylated Dipeptide D-Hot═Tap (D-Hydroxythreonine═Thiaproline With The “═” Representing The Two Covalent Ring Connections) | twisted β-Sheet structure | NA | ||
| 29077406 | 2017 | {nnr:D-Hot[(7S,8S)-{nnr:O}-(2(S)-decyliden)]═Tap}-V-{nnr:O}-L-F{d}-P-V-{nnr:O}-L{cyc:N-C} | GS mimetic 17 | Free | Free | Cyclic | Mix | O = Ornithine, Dyp = cis-dihydroxyproline, D-Hot═Tap = D-Hot═Tap, f = D-Phenylalanine | 10 | Antimicrobial | 90 % Hemolysis at 38 μg/mL | Human | Gs Analogue Modified With A C8- Alkyl Chain | twisted β-Sheet structure | NA | ||
| 29077406 | 2017 | {nnr:D-Hot[(7S,8S)-{nnr:O}-(2(S)-pentadecyliden)]═Tap}-V-{nnr:O}-L- F{d}-P-V-{nnr:O}-L{cyc:N-C} | GS mimetic 18 | Free | Free | Cyclic | Mix | O = Ornithine, Dyp = cis-dihydroxyproline, D-Hot═Tap = D-Hot═Tap, f = D-Phenylalanine | 10 | Antimicrobial | 90 % Hemolysis at 6 μg/mL | Human | Gs Analogue 18 Modified With A C13-Alkyl Chain | twisted β-Sheet structure | NA | ||
| 29077406 | 2017 | {nnr:D-Hot[(7S,8S)-{nnr:O}-(2(S)-8-pentadecyliden)]═Tap}-V-{nnr:O}L-F{d}-P-V-{nnr:O}-L{cyc:N-C} | GS mimetic 19 | Free | Free | Cyclic | Mix | O = Ornithine, Dyp = cis-dihydroxyproline, D-Hot═Tap = D-Hot═Tap, f = D-Phenylalanine | 10 | Antimicrobial | 90 % Hemolysis at 5 μg/mL | Human | Gs Analogue Modified With Two C7-Alkyl Chains | twisted β-Sheet structure | NA | ||
| 29568446 | 2017 | ACLLQSLLCPYSTHRCG{cyc:N-C} | P8-d-C10 | Free | Free | Bicyclic | L | None | 17 | Antibacterial | 6 % Hemolysis at 32 μg/mL | Sheep | Peptide Phage | NA | Low hemolytic | ||
| 29568446 | 2017 | ACLLQSLLCPYSTHACG{cyc:N-C} | P8-d-(R15A)-C10 | Free | Free | Bicyclic | L | None | 17 | Antibacterial | 0 % Hemolysis at 32 μg/mL | Sheep | Peptide Phage | NA | Non-hemolytic | ||
| 29568446 | 2017 | ACLLQSLLCPYSTARCG{cyc:N-C} | P8-d-(H14R, R15A)-C10 | Free | Free | Bicyclic | L | None | 17 | Antibacterial | 2 % Hemolysis at 32 μg/mL | Sheep | Peptide Phage | NA | Low hemolytic | ||
| 29568446 | 2017 | ACLLQSLLCAYSTHRCG{cyc:N-C} | P8-d-(P10R, R15A)-C10 | Free | Free | Bicyclic | L | None | 17 | Antibacterial | 0 % Hemolysis at 32 μg/mL | Sheep | Peptide Phage | NA | Non-hemolytic | ||
| 29568446 | 2017 | ACLLQALLCPYSTHRCG{cyc:N-C} | P8-d-(S6R, R15A)-C10 | Free | Free | Bicyclic | L | None | 17 | Antibacterial | 0 % Hemolysis at 32 μg/mL | Sheep | Peptide Phage | NA | Non-hemolytic | ||
| 29568446 | 2017 | ACLLQALLCPYSTHRCG{cyc:N-C} | P8-L-(S6R, R15A)-C10 | Free | Free | Bicyclic | L | None | 17 | Antibacterial | 0 % Hemolysis at 32 μg/mL | Sheep | Peptide Phage | NA | Non-hemolytic | ||
| 29140694 | 2017 | F{d}PFF{d}NQYV{nnr:O}L{cyc:N-C} | Tyrocidine A | Free | Free | Cyclic | Mix | BE2 = 2-AMINOBENZOIC ACID, f = D-Phenylalanine, O = L-Ornithine | 10 | Antimicrobial | 100 % Hemolysis at 5 μg/ml | Mouse | Bacillus Brevis | β-Hairpin | NA | ||
| 29140694 | 2017 | F{d}{nnr:BE2}FF{d}NQYV{nnr:O}L{cyc:N-C} | Tyrocidine A analogue AC3.27 | Free | Free | Cyclic | Mix | BE2 = 2-AMINOBENZOIC ACID, f = D-Phenylalanine, O = L-Ornithine | 10 | Antifungal | ~60 % Hemolysis at 38 μg/ml | Mouse | Synthetic Analogue Of Tyrocidine A | β-Hairpin | NA | ||
| 29140694 | 2017 | F{d}{nnr:BE2}FF{d}NKYV{nnr:O}L{cyc:N-C} | Tyrocidine A analogue AC3.28 | Free | Free | Cyclic | Mix | BE2 = 2-AMINOBENZOIC ACID, f = D-Phenylalanine, O = L-Ornithine | 10 | Antifungal | ~60 % Hemolysis at 38 μg/ml | Mouse | Synthetic Analogue Of Tyrocidine A | β-Hairpin | NA | ||
| 29188836 | 2017 | F{d}PVRLF{d}PVRL{cyc:N-C} | GS-2 | Free | Free | Cyclic | Mix | None | 10 | Antibiotic | 50 % Hemolysis at 10.03±0.49 (mean±SD, μM) | Human | Bacillus Brevis (Gramicidin S (Gs)) | NA | Low hemolytic | ||
| 29188836 | 2017 | A{d}PVRLF{d}PVRL{cyc:N-C} | MGR-1 | Free | Free | Cyclic | Mix | None | 10 | Antibiotic | 50 % Hemolysis at 67.18±2.94 (mean±SD, μM) | Human | Bacillus Brevis (Gramicidin S (Gs)) | NA | Low hemolytic | ||
| 29188836 | 2017 | F{d}AVRLF{d}PVRL{cyc:N-C} | MGR-2 | Free | Free | Cyclic | Mix | None | 10 | Antibiotic | 50 % Hemolysis at 55.03±1.77 (mean±SD, μM) | Human | Bacillus Brevis (Gramicidin S (Gs)) | NA | Low hemolytic | ||
| 29188836 | 2017 | F{d}PARLF{d}PVRL{cyc:N-C} | MGR-3 | Free | Free | Cyclic | Mix | None | 10 | Antibiotic | 50 % Hemolysis at 30.56±1.80 (mean±SD, μM) | Human | Bacillus Brevis (Gramicidin S (Gs)) | NA | Low hemolytic | ||
| 29188836 | 2017 | F{d}PVALF{d}PVRL{cyc:N-C} | MGR-4 | Free | Free | Cyclic | Mix | None | 10 | Antibiotic | 50 % Hemolysis at 14.41±0.51 (mean±SD, μM) | Human | Bacillus Brevis (Gramicidin S (Gs)) | NA | Low hemolytic | ||
| 29188836 | 2017 | F{d}PVRAF{d}PVRL{cyc:N-C} | MGR-5 | Free | Free | Cyclic | Mix | None | 10 | Antibiotic | 50 % Hemolysis at 36.33±1.98 (mean±SD, μM) | Human | Bacillus Brevis (Gramicidin S (Gs)) | NA | Low hemolytic | ||
| 29188836 | 2017 | A{d}PVRLA{d}PVRL{cyc:N-C} | DGR-1 | Free | Free | Cyclic | Mix | None | 10 | Antibiotic | 50 % Hemolysis at 137.40±6.20 (mean±SD, μM) | Human | Bacillus Brevis (Gramicidin S (Gs)) | NA | Low hemolytic | ||
| 29188836 | 2017 | F{d}AVRLF{d}AVRL{cyc:N-C} | DGR-2 | Free | Free | Cyclic | Mix | None | 10 | Antibiotic | 50 % Hemolysis at 199.90±9.80 (mean±SD, μM) | Human | Bacillus Brevis (Gramicidin S (Gs)) | NA | Low hemolytic | ||
| 29188836 | 2017 | F{d}PARLF{d}PARL{cyc:N-C} | DGR-3 | Free | Free | Cyclic | Mix | None | 10 | Antibiotic | 50 % Hemolysis at 88.95±7.51 (mean±SD, μM) | Human | Bacillus Brevis (Gramicidin S (Gs)) | NA | Low hemolytic | ||
| 29188836 | 2017 | F{d}PVALF{d}PVAL{cyc:N-C} | DGR-4 | Free | Free | Cyclic | Mix | None | 10 | Antibiotic | 50 % Hemolysis at >200 (mean±SD, μM) | Human | Bacillus Brevis (Gramicidin S (Gs)) | NA | Low hemolytic | ||
| 29188836 | 2017 | F{d}PVRAF{d}PVRA{cyc:N-C} | DGR-5 | Free | Free | Cyclic | Mix | None | 10 | Antibiotic | 50 % Hemolysis at >200 (mean±SD, μM) | Human | Bacillus Brevis (Gramicidin S (Gs)) | NA | Low hemolytic | ||
| 29038271 | 2018 | NPYNQTS{nnr:X}{cyc:N-C}{ct:Xaa - β-amino fatty acid variant} | AF3 | Xaa - β-amino fatty acid variant | Free | Cyclic | L | X = Xaa is a β-amino fatty acid variant for AF3-anteiso-C17 | 8 | Antifungal | 10 % Hemolysis at 8 μg/ml | Human | Bacillus Subtilis Rlid 12.1 | NA | NA | ||
| 29038271 | 2018 | NPYNQTS{nnr:X}{cyc:N-C}{ct:Xaa - β-amino fatty acid variant} | AF3 | Xaa - β-amino fatty acid variant | Free | Cyclic | L | X = Xaa is a β-amino fatty acid variant for AF3-anteiso-C17 | 8 | Antifungal | 50 % Hemolysis at 16.4 μg/ml | Human | Bacillus Subtilis Rlid 12.1 | NA | NA | ||
| 29038271 | 2018 | NPYNQTS{nnr:X}{cyc:N-C}{ct:Xaa - β-amino fatty acid variant} | AF4 | Xaa - β-amino fatty acid variant | Free | Cyclic | L | X = Xaa is a β-amino fatty acid variant for AF4-iso-C17 | 8 | Antifungal | ∼5.6 % Hemolysis at 8 μg/ml | Human | Bacillus Subtilis Rlid 12.1 | NA | NA | ||
| 29038271 | 2018 | NPYNQTS{nnr:X}{cyc:N-C}{ct:Xaa - β-amino fatty acid variant} | AF4 | Xaa - β-amino fatty acid variant | Free | Cyclic | L | X = Xaa is a β-amino fatty acid variant for AF4-iso-C17 | 8 | Antifungal | 50 % Hemolysis at 17.7 μg/ml | Human | Bacillus Subtilis Rlid 12.1 | NA | NA | ||
| 29038271 | 2018 | NPYNQTS{nnr:X}{cyc:N-C}{ct:Xaa - β-amino fatty acid variant} | AF5 | Xaa - β-amino fatty acid variant | Free | Cyclic | L | X = Xaa is a β-amino fatty acid variant for AF5-iso-C18 | 8 | Antifungal | 50 % Hemolysis at 8 μg/ml | Human | Bacillus Subtilis Rlid 12.1 | NA | NA | ||
| 29038271 | 2018 | NPYNQTS{nnr:X}NPYNQTS{nnr:X}{cyc:N-C}{ct:Xaa - β-amino fatty acid variant, Xaa - β-amino fatty acid variant} | AF3, AF4 | Xaa - β-amino fatty acid variant, Xaa - β-amino fatty acid variant | Free | Cyclic | L | X = Xaa is a β-amino fatty acid variant for AF3-anteiso-C17, X = Xaa is a β-amino fatty acid variant for AF4-iso-C17 | 16 | Antifungal, Antifungal | 3.87±3.7 % Hemolysis at 4,4 μg/ml | Human | Bacillus Subtilis Rlid 12.1 | NA | NA | ||
| 29038271 | 2018 | NPYNQTS{nnr:X}NPYNQTS{nnr:X}{cyc:N-C}{ct:Xaa - β-amino fatty acid variant, Xaa - β-amino fatty acid variant} | AF3, AF5 | Xaa - β-amino fatty acid variant, Xaa - β-amino fatty acid variant | Free | Cyclic | L | X = Xaa is a β-amino fatty acid variant for AF3-anteiso-C17, X = Xaa is a β-amino fatty acid variant for AF5-iso-C18 | 16 | Antifungal, Antifungal | 3.43±3.1 % Hemolysis at 4,4 μg/ml | Human | Bacillus Subtilis Rlid 12.1 | NA | NA | ||
| 29038271 | 2018 | NPYNQTS{nnr:X}NPYNQTS{nnr:X}{cyc:N-C}{ct:Xaa - β-amino fatty acid variant, Xaa - β-amino fatty acid variant} | AF3, AF5 | Xaa - β-amino fatty acid variant, Xaa - β-amino fatty acid variant | Free | Cyclic | L | X = Xaa is a β-amino fatty acid variant for AF3-anteiso-C17, X = Xaa is a β-amino fatty acid variant for AF5-iso-C18 | 16 | Antifungal, Antifungal | 4.11±5.9 % Hemolysis at 2,4 μg/ml | Human | Bacillus Subtilis Rlid 12.1 | NA | NA | ||
| 29038271 | 2018 | NPYNQTS{nnr:X}NPYNQTS{nnr:X}{cyc:N-C}{ct:Xaa - β-amino fatty acid variant, Xaa - β-amino fatty acid variant} | AF4, AF5 | Xaa - β-amino fatty acid variant, Xaa - β-amino fatty acid variant | Free | Cyclic | L | X = Xaa is a β-amino fatty acid variant for AF4-iso-C17, X = Xaa is a β-amino fatty acid variant for AF5-iso-C18 | 16 | Antifungal, Antifungal | 3.12±3.4 % Hemolysis at 4,4 μg/ml | Human | Bacillus Subtilis Rlid 12.1 | NA | NA | ||
| 29038271 | 2018 | NPYNQTS{nnr:X}NPYNQTS{nnr:X}{cyc:N-C}{ct:Xaa - β-amino fatty acid variant, Xaa - β-amino fatty acid variant} | AF4, AF5 | Xaa - β-amino fatty acid variant, Xaa - β-amino fatty acid variant | Free | Cyclic | L | X = Xaa is a β-amino fatty acid variant for AF4-iso-C17, X = Xaa is a β-amino fatty acid variant for AF5-iso-C18 | 16 | Antifungal, Antifungal | 2.96±4.1 % Hemolysis at 2,4 μg/ml | Human | Bacillus Subtilis Rlid 12.1 | NA | NA | ||
| 29360748 | 2018 | RVCSAIPLPICH{cyc:3-11}{ct:Amid} | tigerinin-1R | Amidation | Free | Cyclic | L | C–C in parentheses means that the two Cys residues in the sequences form intermolecular disulfide bond | 12 | Non-toxic insulin-releasing peptide | <2 % Hemolysis at 250 μM | Human | Frog (Hoplobatrachus Ugulosus) | Random coils (48), and type I reverse βTurns (12) in 50 aqueous TFE | Non-hemolytic | ||
| 29360748 | 2018 | RVCSLLPLPLCH{cyc:3-11}{ct:Amid} | tigerinin-1R-L4 | Amidation | Free | Cyclic | L | C–C in parentheses means that the two Cys residues in the sequences form intermolecular disulfide bond | 12 | Non-toxic insulin-releasing peptide | <3 % Hemolysis at 250 μM | Human | Tigerinin-1R Analogs | Random coil | Low hemolytic | ||
| 29360748 | 2018 | CSAIPLPIC{cyc:1-9}{ct:Amid} | tigerinin-cyclic | Amidation | Free | Cyclic | L | C–C in parentheses means that the two Cys residues in the sequences form intermolecular disulfide bond | 9 | Non-toxic insulin-releasing peptide | <2 % Hemolysis at 250 μM | Human | Tigerinin-1R Analogs | Random coil | Non-hemolytic | ||
| 29277569 | 2018 | VYPFCWGGAYAFCKAKLV{cyc:N-C}{ct:Amid} | cVT18-CAKKLV | Amidation | Free | Cyclic | L | None | 18 | Antibacterial | 1.8 % Hemolysis at 100 µg/ml | Human | Vt18-Cakklv Cyclized Between Cys88 And Cys96 | Double Strand β-Sheet | Low hemolytic | ||
| 29411917 | 2018 | aza-β3Lys-K-{nnr:aza-β3-1Nal}-K-{nnr:aza-β3-1Nal}-L{cyc:N-C} | ACPP20 | Free | Free | Cyclic | L | aza-β3-Lys = aza-β3-Lysine, aza-β3-1Nal = aza-β3-1-Naphthylalanine | 6 | Antimicrobial cyclic pseudopeptides (ACPPs) | 1.5 % Hemolysis at 100 µM | Sheep | Synthesis Of Mixed Aza-Β3-Pseudopeptides | NA | Low hemolytic | ||
| 29411917 | 2018 | aza-β3Lys-K-{nnr:aza-β3-2Nal}-L-{nnr:aza-β3-2Nal}-L{cyc:N-C} | ACPP21 | Free | Free | Cyclic | L | aza-β3-Lys = aza-β3-Lysine, aza-β3-2Nal = aza-β3-2-Naphthylalanine | 6 | Antimicrobial cyclic pseudopeptides (ACPPs) | 8 % Hemolysis at 100 µM | Sheep | Synthesis Of Mixed Aza-Β3-Pseudopeptides | NA | NA | ||
| 29411917 | 2018 | aza-β3Lys-K-{nnr:aza-β3-1Nal}-L-{nnr:aza-β3-4Fluo-1Nal}-L{cyc:N-C} | ACPP22 | Free | Free | Cyclic | L | aza-β3-Leu = aza-β3-Leucine, aza-β3-1Nal = aza-β3-1-Naphthylalanine, aza-β3-4Fluo-1Nal = aza-β3-4Fluoro-1-Nahphtylalanine | 6 | Antimicrobial cyclic pseudopeptides (ACPPs) | 5 % Hemolysis at 100 µM | Sheep | Synthesis Of Mixed Aza-Β3-Pseudopeptides | NA | Low hemolytic | ||
| 29411917 | 2018 | K-aza-β3Lys-L-{nnr:aza-β3-1Nal}-aza-β3Leu-{nnr:aza-β3-1Nal}{cyc:N-C} | ACPP23 | Free | Free | Cyclic | L | aza-β3-Lys = aza-β3-Lysine, aza-β3-1Nal = aza-β3-1-Naphthylalanine, aza-β3-Leu = aza-β3-Leucine, aza-β3-1Nal = aza-β3-1-Naphthylalanine | 6 | Antimicrobial cyclic pseudopeptides (ACPPs) | 6 % Hemolysis at 100 µM | Sheep | Synthesis Of Mixed Aza-Β3-Pseudopeptides | NA | NA | ||
| 29411917 | 2018 | aza-β3Arg-R-{nnr:aza-β3-1Nal}-L-{nnr:aza-β3-1Nal}-L{cyc:N-C} | ACPP24 | Free | Free | Cyclic | L | aza-β3-Arg = aza-β3-Arginine, aza-β3-1Nal = aza-β3-1-Naphthylalanine | 6 | Antimicrobial cyclic pseudopeptides (ACPPs) | 12 % Hemolysis at 100 µM | Sheep | Synthesis Of Mixed Aza-Β3-Pseudopeptides | NA | NA | ||
| 29411917 | 2018 | aza-β3Lys-R-{nnr:aza-β3-2Nal}-F-{nnr:aza-β3-2Nal}-F{cyc:N-C} | ACPP25 | Free | Free | Cyclic | L | aza-β3-Lys = aza-β3-Lysine, aza-β3-2Nal = aza-β3-2-Naphthylalanine | 6 | Antimicrobial cyclic pseudopeptides (ACPPs) | 50 % Hemolysis at 100 µM | Sheep | Synthesis Of Mixed Aza-Β3-Pseudopeptides | NA | NA | ||
| 29904274 | 2018 | CLNLKALLAVAKKILC{cyc:N-C}{ct:Amid} | cMP-C | Amidation | Free | Cyclic | L | None | 16 | Antimicrobial | 50 % Hemolysis at 9.19 µM | Horse | Modifcation In Mp-C A Skeleton-Based Cyclization By Two Cysteine Residues | α-Helical at aq, α-Helical at membrane mimic solution | NA | ||
| 29621496 | 2018 | {nnr:Nap}{nnr:Npm}{nnr:Nap}{nnr:Npm}{nnr:Nap}{nnr:Npm}{cyc:N-C} | C1 | Free | Free | Cyclic | Mix | Nap = N-(3-aminopropyl)glycine, Npm = N-(1-phenylmethyl)glycine | 6 | Antibacterial | 10 % Hemolysis at 250 μg/mL | Human | Synthetic Peptoids Mimic Antimicrobial Peptides | NA | NA | ||
| 29621496 | 2018 | {nnr:Nap}{nnr:Ndmb}{nnr:Nap}{nnr:Ndmb}{nnr:Nap}{nnr:Ndmb}{cyc:N-C} | C2 | Free | Free | Cyclic | Mix | Nap = N-(3-aminopropyl)glycine, Ndmb = N-(3,5-dimethylbenzyl)glycine | 6 | Antibacterial | 10 % Hemolysis at 125 μg/mL | Human | Synthetic Peptoids Mimic Antimicrobial Peptides | NA | NA | ||
| 29621496 | 2018 | {nnr:Nap}{nnr:Nsne}{nnr:Nap}{nnr:Nsne}{nnr:Nap}{nnr:Nsne}{cyc:N-C} | C3 | Free | Free | Cyclic | Mix | Nap = N-(3-aminopropyl)glycine, Nsne = (S)-N-(1-naphthylethyl)glycine | 6 | Antibacterial | 10 % Hemolysis | Human | Synthetic Peptoids Mimic Antimicrobial Peptides | NA | NA | ||
| 29621496 | 2018 | {nnr:Nap}{nnr:Ndp}{nnr:Nap}{nnr:Ndp}{nnr:Nap}{nnr:Ndp}{cyc:N-C} | C4 | Free | Free | Cyclic | Mix | Nap = N-(3-aminopropyl)glycine, Ndp = N-(2,2-diphenylethyl)glycine | 6 | Antibacterial | 10 % Hemolysis at 31.3 μg/mL | Human | Synthetic Peptoids Mimic Antimicrobial Peptides | NA | NA | ||
| 29621496 | 2018 | {nnr:Nap}{nnr:Nbtfmb}{nnr:Nap}{nnr:Nbtfmb}{nnr:Nap}{nnr:Nbtfmb}{cyc:N-C} | C5 | Free | Free | Cyclic | Mix | Nap = N-(3-aminopropyl)glycine, Nbtfmb = N-(3,5-bis-trifluoromethylbenzyl)glycine | 6 | Antibacterial | 10 % Hemolysis at 31.3 μg/mL | Human | Synthetic Peptoids Mimic Antimicrobial Peptides | NA | NA | ||
| 29621496 | 2018 | {nnr:Nap}{nnr:Npm}{nnr:Nap}{nnr:Npm}{nnr:Nap}{nnr:Npm}{nnr:Nap}{nnr:Npm}{nnr:Nap}{nnr:Npm}{cyc:N-C} | C1dec | Free | Free | Cyclic | Mix | Nap = N-(3-aminopropyl)glycine, Npm = N-(1-phenylmethyl)glycine | 10 | Antibacterial | 10 % Hemolysis at 250 μg/mL | Human | Synthetic Peptoids Mimic Antimicrobial Peptides | NA | NA | ||
| 29621496 | 2018 | V{nnr:O}LF{d}PV{nnr:O}LF{d}P{cyc:N-C} | CGS (gramicidin S) | Free | Free | Cyclic | Mix | O = L-Ornithine, f = D-phenylalanine | 10 | Antibacterial | 10 % Hemolysis at >15.6 μg/mL | Human | Gram-Positive Bacterium Brevibacillus Brevis | NA | NA | ||
| 29750913 | 2018 | C{d}ILC-KKLFKKILKYL{cyc:1‑4} | Cyclo (1‑4)‑cILC-BP100 | Free | Free | Cyclic | Mix | disulfide bond between D-Cys1 and Cys4 at N-Terminal | 11 | Antimicrobial | 50 % Hemolysis at 8.7 μM | Human | Synthesized Analog Of Bp100 | membrane =Partly α-Helical and partly β-Turn | NA | ||
| 29760411 | 2018 | L/I-A-L/I-L/I-L/I-R-L/I -L/I-V-K-L/I-(K-K-S-L/I-T-L/I-K-V-L/I-L/I-R-I/L){cyc:N-C} | Paenialvin-A | Free | Free | Bicyclic | Mix | None | 23 | Antibacterial,Antitumor | 3.61 % Hemolysis at 50 μg/ml | Rabbit | Bacteria Paenibacillus Alvei Dsm 29 | NA | Non-hemolytic | ||
| 29760411 | 2018 | L/I-A-L/I-L/I-I/L-R-L/I -L/I-V-K-L/I-(K-K-A-L/I-T-L/I-K-V-L/I-L/I-R-I/L){cyc:N-C} | Paenialvin-B | Free | Free | Bicyclic | Mix | None | 23 | Antibacterial | 1.93 % Hemolysis at 50 μg/ml | Rabbit | Bacteria Paenibacillus Alvei Dsm 29 | NA | Non-hemolytic | ||
| 29760411 | 2018 | L-A-L-L-V-R-L-L-V-K-L-(K-K-S-L/I-T-L/I-K-V-L/I-L/I-R-V){cyc:N-C} | Paenialvin-C | Free | Free | Bicyclic | D | None | 23 | Antibacterial | 0 % Hemolysis at 50 μg/ml | Rabbit | Bacteria Paenibacillus Alvei Dsm 29 | NA | Non-hemolytic | ||
| 30112781 | 2018 | K{nnr:β}{nnr:cf}KK{cyc:N-C} | 5a | Free | Free | Cyclic | Mix | β = lipophilic β2,2‐amino acid, cf = 4-CF3 (β-phenylalanine derivative has a trifluoromethyl CF3 ) | 4 | Antibacterial | 50 % Hemolysis at >500 μg/mL | Human | Synthetic Cyclic Amps | NA | NA | ||
| 30112781 | 2018 | K{nnr:β}{nnr:cf}GK{cyc:N-C} | 5b | Free | Free | Cyclic | Mix | β = lipophilic β2,2‐amino acid, cf = 4-CF3 (β-phenylalanine derivative has a trifluoromethyl CF3 ) | 4 | Antibacterial | 50 % Hemolysis at >500 μg/mL | Human | Synthetic Cyclic Amps | NA | NA | ||
| 30112781 | 2018 | K{nnr:β}{nnr:cf}AK{cyc:N-C} | 5c | Free | Free | Cyclic | Mix | β = lipophilic β2,2‐amino acid, cf = 4-CF3 (β-phenylalanine derivative has a trifluoromethyl CF3 ) | 4 | Antibacterial | 50 % Hemolysis at >500 μg/mL | Human | Synthetic Cyclic Amps | NA | NA | ||
| 30112781 | 2018 | K{nnr:β}{nnr:cf}FK{cyc:N-C} | 5d | Free | Free | Cyclic | Mix | β = lipophilic β2,2‐amino acid, cf = 4-CF3 (β-phenylalanine derivative has a trifluoromethyl CF3 ) | 4 | Antibacterial | 50 % Hemolysis at 88 μg/mL | Human | Synthetic Cyclic Amps | NA | NA | ||
| 30112781 | 2018 | K{nnr:β}{nnr:dicf}KK{cyc:N-C} | 6a | Free | Free | Cyclic | Mix | β = β^(2,2), dicf = 3,5diCF3(β-phenylalanine derivative has trifluoromethyl CF3 groups) | 4 | Antibacterial | 50 % Hemolysis at 216 μg/mL | Human | Synthetic Cyclic Amps | NA | NA | ||
| 30112781 | 2018 | K{nnr:β}{nnr:dicf}GK{cyc:N-C} | 6b | Free | Free | Cyclic | Mix | β = β^(2,2), dicf = 3,5diCF3(β-phenylalanine derivative has trifluoromethyl CF3 groups) | 4 | Antibacterial | 50 % Hemolysis at 100 μg/mL | Human | Synthetic Cyclic Amps | NA | NA | ||
| 30112781 | 2018 | K{nnr:β}{nnr:dicf}AK{cyc:N-C} | 6c | Free | Free | Cyclic | Mix | β = β^(2,2), dicf = 3,5diCF3(β-phenylalanine derivative has trifluoromethyl CF3 groups) | 4 | Antibacterial | 50 % Hemolysis at 67 μg/mL | Human | Synthetic Cyclic Amps | NA | NA | ||
| 30112781 | 2018 | K{nnr:β}{nnr:dicf}FK{cyc:N-C} | 6d | Free | Free | Cyclic | Mix | β = β^(2,2), dicf = 3,5diCF3(β-phenylalanine derivative has trifluoromethyl CF3 groups) | 4 | Antibacterial | 50 % Hemolysis at 84 μg/mL | Human | Synthetic Cyclic Amps | NA | NA | ||
| 30135470 | 2018 | {nnr:R}-{nnr:dab}V{nnr:dab}FL{nnr:dab}VLS{cyc:N-C} | PGP-E | Free | Free | Cyclic | Mix | Dab = Diaminobutyric acid, R = CH2CH2CH3(propyl group) | 9 | Antimicrobial | <50 % Hemolysis at 200 µM | Human | Bacteria Paenibacillus Elgii Bc34-6 | NA | NA | ||
| 30325566 | 2018 | ELL{d}VDL{d}L{cyc:N-C}{nt:Amid} | surfactin | Free | Amidation | Cyclic | Mix | l = D-Leucine | 7 | Antimicrobial | high % Hemolysis at 100 µM | Human | Bacteria Bacillus Subtilis | NA | NA | ||
| 30387611 | 2018 | GLPICGETCVFGKCNTPGCSCRRPICYKN{cyc:N-C} | Rivi1 | Free | Free | Cyclic | L | None | 29 | Anticancer | 50 % Hemolysis at ≫10 µM | Human | Plant Rinorea Virgata | Loop | NA | ||
| 30387611 | 2018 | GSYLCGETCVQGKCYTPGCTCSWPICKKN{cyc:N-C} | Rivi2 | Free | Free | Cyclic | L | None | 29 | Anticancer | 50 % Hemolysis at ≫10 µM | Human | Plant Rinorea Virgata | Loop | NA | ||
| 30387611 | 2018 | GLPICGETCLLGKCYTPGCSCRRPVCYKN{cyc:N-C} | Rivi3 | Free | Free | Cyclic | L | None | 29 | Anticancer | 50 % Hemolysis at ≫10 µM | Human | Plant Rinorea Virgata | Loop | NA | ||
| 30973929 | 2019 | EVL{d}ADL{d}V{cyc:N-C}{nt:Palmityl}{ct:Amid} | SLP1 | Amidation | Palmityl | Cyclic | Mix | None | 7 | Anti-viral, Anti-PEDV(Porcine epidemic diarrhea virus) | 40 % Hemolysis at 10 μg/mL | Porcine | Synthetic Surfactin Lipopeptide Analogues | NA | NA | ||
| 30973929 | 2019 | EVL{d}DL{d}V{cyc:N-C}{nt:Palmityl}{ct:Amid} | SLP2 | Amidation | Palmityl | Cyclic | Mix | None | 6 | Anti-viral, Anti-PEDV(Porcine epidemic diarrhea virus) | 100 % Hemolysis at 10 μg/mL | Porcine | Synthetic Surfactin Lipopeptide Analogues | NA | NA | ||
| 30973929 | 2019 | EVL{d}DL{d}{cyc:N-C}{nt:Palmityl}{ct:Amid} | SLP3 | Amidation | Palmityl | Cyclic | Mix | None | 5 | Anti-viral, Anti-PEDV(Porcine epidemic diarrhea virus) | 80 % Hemolysis at 10 μg/mL | Porcine | Synthetic Surfactin Lipopeptide Analogues | NA | NA | ||
| 30973929 | 2019 | EVL{d}L{d}{cyc:N-C}{nt:Palmityl}{ct:Amid} | SLP4 | Amidation | Palmityl | Cyclic | Mix | None | 4 | Anti-viral, Anti-PEDV(Porcine epidemic diarrhea virus) | 5 % Hemolysis at 10 μg/mL | Porcine | Synthetic Surfactin Lipopeptide Analogues | NA | Low hemolytic | ||
| 30973929 | 2019 | KVL{d}KL{d}{cyc:N-C}{nt:Palmityl}{ct:Amid} | SLP6 | Amidation | Palmityl | Cyclic | Mix | None | 5 | Anti-viral, Anti-PEDV(Porcine epidemic diarrhea virus) | 90 % Hemolysis at 10 μg/mL | Porcine | Synthetic Surfactin Lipopeptide Analogues | NA | NA | ||
| 30973929 | 2019 | EVLDL{cyc:N-C}{nt:Palmityl}{ct:Amid} | SLP7 | Amidation | Palmityl | Cyclic | L | None | 5 | Anti-viral, Anti-PEDV(Porcine epidemic diarrhea virus) | 30 % Hemolysis at 10 μg/mL | Porcine | Synthetic Surfactin Lipopeptide Analogues | NA | NA | ||
| 30973929 | 2019 | EVL{d}L{d}D{cyc:N-C}{nt:Palmityl}{ct:Amid} | SLP8 | Amidation | Palmityl | Cyclic | Mix | None | 5 | Anti-viral, Anti-PEDV(Porcine epidemic diarrhea virus) | 100 % Hemolysis at 10 μg/mL | Porcine | Synthetic Surfactin Lipopeptide Analogues | NA | NA | ||
| 30973929 | 2019 | EDVL{d}L{d}{cyc:N-C}{nt:Palmityl}{ct:Amid} | SLP9 | Amidation | Palmityl | Cyclic | Mix | None | 5 | Anti-viral, Anti-PEDV(Porcine epidemic diarrhea virus) | 50 % Hemolysis at 10 μg/mL | Porcine | Synthetic Surfactin Lipopeptide Analogues | NA | NA | ||
| 30973929 | 2019 | EVlDl{cyc:N-C}{nt:Heptaalkyl-biphenyl-acid}{ct:Amid} | SLP10 | Amidation | Heptaalkyl-biphenyl-acid | Cyclic | Mix | Heptaalkyl-biphenyl-acid | 5 | Anti-viral, Anti-PEDV(Porcine epidemic diarrhea virus) | 55 % Hemolysis at 10 μg/mL | Porcine | Synthetic Surfactin Lipopeptide Analogues | NA | NA | ||
| 32641937 | 2019 | CGAGHVPC-YY{d}({nnr:GABA})F{d}YG{cyc:1-8} | MccJ25-derived peptide | Free | Free | Cyclic | Mix | GABA = gamma amino butyric acid | 14 | Antibacterial | 0.26 ± 0.01 % Hemolysis at 200 μM | Human | Bacteria Enterobacteriacea Mccj25- Derived Peptide | β-Sheet | Non-hemolytic | ||
| 31775224 | 2019 | IRPIRP{cyc:N-C} | OIR1 | Free | Free | Cyclic | L | None | 6 | Antibacterial | ≥5 % Hemolysis at >128 µM | Human | Synthetic Cyclic Amps | aqueous = unordered, β-Hairpin | Low hemolytic | ||
| 31775224 | 2019 | IRIRPIRIRP{cyc:N-C} | OIR2 | Free | Free | Cyclic | L | None | 10 | Antibacterial | ≥5 % Hemolysis at >128 µM | Human | Synthetic Cyclic Amps | aqueous = unordered, β-Hairpin | Low hemolytic | ||
| 31775224 | 2019 | IRIRIRPIRIRIRP{cyc:N-C} | OIR3 | Free | Free | Cyclic | L | None | 14 | Antibacterial, Anti-Inflammatory | ≥5 % Hemolysis at >128 µM | Human | Synthetic Cyclic Amps | aqueous = unordered, β-Hairpin | Low hemolytic | ||
| 32153522 | 2020 | AGGKRIVQRIKDFLRGAGGKRIVQRIKDFLRG{cyc:N-C} | cd4 | Free | Free | Cyclic | L | None | 32 | Antimicrobial | 50 % Hemolysis at >40 μM | Human | Cyclized Kr-12 Dimer | SDS = α-Helical, Tris-buffer = Random coil | NA | ||
| 32153522 | 2020 | AGGKRIVKRIKKFLRGAGGKRIVKRIKKFLRG{cyc:N-C} | cd4(Q5K,D9K) | Free | Free | Cyclic | L | None | 32 | Antimicrobial | 50 % Hemolysis at 10 μM | Human | Cyclized Kr-12 Dimer | SDS = α-Helical, Tris-buffer = Random coil | NA | ||
| 32437150 | 2020 | GIP-CGESCVYIPCITAALGCSCKSKVCYRN{cyc:N-C} | viar 1 | Free | Free | Cyclic | L | None | 30 | Anticancer | 50 % Hemolysis at 11.1 ± 0.02 μM | Human | Plant Viola Arcuata | α-Helical | Low hemolytic | ||
| 32437150 | 2020 | GIP-CGESCVWIPCISAAIGCSCKSKVCYRN{cyc:N-C} | cO13 | Free | Free | Cyclic | L | None | 30 | Anticancer | 50 % Hemolysis at 14.9 ± 0.01 μM | Human | Plant Viola Arcuata | α-Helical | Low hemolytic | ||
| 32437150 | 2020 | GLPVCGETCVGGTCNTPG--CSCSWPVCTRN{cyc:N-C} | kalata S | Free | Free | Cyclic | L | None | 29 | Anticancer | 50 % Hemolysis at ≥50 μM | Human | Plant Viola Arcuata | NA | NA | ||
| 32629881 | 2020 | K{nnr:Nal}KK{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}KN{cyc:N-C} | BSI-9 | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid | 9 | Antibacterial | 33 % Hemolysis at 150 μM | Human | Synthetic Cyclic Amp | NA | NA | ||
| 32629881 | 2020 | K{nnr:Nal}KK{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}NK{cyc:N-C} | BSI-9 stage-1 (1) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid | 9 | Antibacterial | Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32629881 | 2020 | K{nnr:Nal}KN{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}KK{cyc:N-C} | BSI-9 stage-1 (2) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid | 9 | Antibacterial | Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32629881 | 2020 | K{nnr:Nal}NK{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}KK{cyc:N-C} | BSI-9 stage-1 (3) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid | 9 | Antibacterial | Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32629881 | 2020 | N{nnr:Nal}KK{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}KK{cyc:N-C} | BSI-9 stage-1 (4) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid | 9 | Antibacterial | Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32629881 | 2020 | KFKK{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}KN{cyc:N-C} | BSI-9 stage-2 (5) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid | 9 | Antibacterial | 4 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | Non-hemolytic | ||
| 32629881 | 2020 | K{nnr:Nal}KKF-{nnr:O2Oc}-{nnr:Nal}KN{cyc:N-C} | BSI-9 stage-2 (6) | Free | Free | Cyclic | L | Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid | 9 | Antibacterial | 6 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | Non-hemolytic | ||
| 32629881 | 2020 | K{nnr:Nal}KK{nnr:Bip}-{nnr:O2Oc}-FKN{cyc:N-C} | BSI-9 stage-2 (7) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid | 9 | Antibacterial | 7 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | Non-hemolytic | ||
| 32629881 | 2020 | KFKKF-{nnr:O2Oc}-FKN{cyc:N-C} | BSI-9 stage-2 (8) | Free | Free | Cyclic | L | O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid | 9 | Antibacterial | 3 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | Non-hemolytic | ||
| 32629881 | 2020 | {nnr:Dab}{nnr:Nal}{nnr:Dab}{nnr:Dab}{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}{nnr:Dab}N{cyc:N-C} | BSI-9 stage-2 (9) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid, Dab = L‐2,4‐diaminobutyric acid | 9 | Antibacterial | 76 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32629881 | 2020 | R{nnr:Nal}{nnr:Dab}{nnr:Dab}{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}{nnr:Dab}N{cyc:N-C} | BSI-9 stage-3 (10) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid, Dab = L‐2,4‐diaminobutyric acid | 9 | Antibacterial | 66 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32629881 | 2020 | {nnr:Dab}{nnr:Nal}R{nnr:Dab}{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}{nnr:Dab}N{cyc:N-C} | BSI-9 stage-3 (11) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid, Dab = L‐2,4‐diaminobutyric acid | 9 | Antibacterial | 36 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32629881 | 2020 | {nnr:Dab}{nnr:Nal}{nnr:Dab}R{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}{nnr:Dab}N{cyc:N-C} | BSI-9 stage-3 (12) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid, Dab = L‐2,4‐diaminobutyric acid | 9 | Antibacterial | 98 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32629881 | 2020 | {nnr:Dab}{nnr:Nal}{nnr:Dab}{nnr:Dab}{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}RN{cyc:N-C} | BSI-9 stage-3 (13) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid, Dab = L‐2,4‐diaminobutyric acid | 9 | Antibacterial | 80 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32629881 | 2020 | R{nnr:Nal}RR{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}RN{cyc:N-C} | BSI-9 stage-3 (14) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid | 9 | Antibacterial | 68 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32629881 | 2020 | R{nnr:Nal}RDap{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}{nnr:Dab}N{cyc:N-C} | BSI-9 stage-4 (15) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid, Dab = L‐2,4‐diaminobutyric acid | 9 | Antibacterial | 100 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32629881 | 2020 | R{nnr:Nal}R{nnr:Dab}F-{nnr:O2Oc}-{nnr:Nal}{nnr:Dab}N{cyc:N-C} | BSI-9 stage-4 (16) | Free | Free | Cyclic | L | Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid, Dab = L‐2,4‐diaminobutyric acid | 9 | Antibacterial | 16 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32629881 | 2020 | R{nnr:Nal}{nnr:Dab}{nnr:Dab}F-{nnr:O2Oc}-{nnr:Nal}{nnr:Dab}N{cyc:N-C} | BSI-9 stage-4 (17) | Free | Free | Cyclic | L | Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid, Dab = L‐2,4‐diaminobutyric acid | 9 | Antibacterial | 3 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | Non-hemolytic | ||
| 32629881 | 2020 | {nnr:Dab}{nnr:Nal}R{nnr:Dab}F-{nnr:O2Oc}-{nnr:Nal}{nnr:Dab}N{cyc:N-C} | BSI-9 stage-4 (18) | Free | Free | Cyclic | L | Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid, Dab = L‐2,4‐diaminobutyric acid | 9 | Antibacterial | 30 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32126228 | 2020 | CVRRFPWWYPFLRRC{cyc:N-C}{ct:Amid} | Tritrp-DiSu* | Amidation | Free | Cyclic | L | None | 15 | Anticancer | 50 % Hemolysis at 20.9 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32171739 | 2020 | GIINTLQKYYCRVRGGRSAVLSSLPKEEQIGKSSTRGRKCSRRKK{cyc:N-C} | hBD-3-c | Free | Free | Cyclic | L | None | 45 | Antibacterial | >15 % Hemolysis at 250 µg/mL | Human | Hbd-3 Cyclic Variant With One Disulfide Bond | LPS aggregates = α-Helical | Low hemolytic | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab}-N{cyc:N-C} | S3(B) | Free | Free | Cyclic | L | Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 77 % Hemolysis at 150 μM | Human | Cyclic Antimicrobial Peptide S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab(C10)}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab}-N{cyc:N-C} | (C10)1 | Free | Free | Cyclic | L | Dab(C10) = Dab(C10), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 100 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Dab(C10)}-R-{nnr:Dab}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab}-N{cyc:N-C} | (C10)2 | Free | Free | Cyclic | L | Dab(C10) = Dab(C10), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 100 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Dab(C12)}-R-{nnr:Dab}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab}-N{cyc:N-C} | (C12)2 | Free | Free | Cyclic | L | Dab(C12) = Dab(C12), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 100 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Dab(C14)}-R-{nnr:Dab}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab}-N{cyc:N-C} | (C14)2 | Free | Free | Cyclic | L | Dab(C14) = Dab(C14), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 100 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab(C10)}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab}-N{cyc:N-C} | (C10)4 | Free | Free | Cyclic | L | Dab(C10) = Dab(C10), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 100 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Dab(C4)}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab}-N{cyc:N-C} | (C4)5 | Free | Free | Cyclic | L | Dab(C4) = Dab(C4), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 5 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | Low hemolytic | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Dab(C6)}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab}-N{cyc:N-C} | (C6)5 | Free | Free | Cyclic | L | Dab(C6) = Dab(C6), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 13 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Dab(C8)}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab}-N{cyc:N-C} | (C8)5 | Free | Free | Cyclic | L | Dab(C8) = Dab(C8), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 42 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Dab(C10)}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab}-N{cyc:N-C} | (C10)5 | Free | Free | Cyclic | L | Dab(C10) = Dab(C10), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 100 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Dab(C12)}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab}-N{cyc:N-C} | (C12)5 | Free | Free | Cyclic | L | Dab(C12) = Dab(C12), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 100 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Dab(C14)}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab}-N{cyc:N-C} | (C14)5 | Free | Free | Cyclic | L | Dab(C14) = Dab(C14), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 100 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Dab(C4)}-{nnr:Dab}-N{cyc:N-C} | (C4)7 | Free | Free | Cyclic | L | Dab(C4) = Dab(C4), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 4 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | Low hemolytic | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Dab(C6)}-{nnr:Dab}-N{cyc:N-C} | (C6)7 | Free | Free | Cyclic | L | Dab(C6) = Dab(C6), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 8 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Dab(C8)}-{nnr:Dab}-N{cyc:N-C} | (C8)7 | Free | Free | Cyclic | L | Dab(C8) = Dab(C8), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 56 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Dab(C10)}-{nnr:Dab}-N{cyc:N-C} | (C10)7 | Free | Free | Cyclic | L | Dab(C10) = Dab(C10), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 100 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Dab(C12)}-{nnr:Dab}-N{cyc:N-C} | (C12)7 | Free | Free | Cyclic | L | Dab(C12) = Dab(C12), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 96 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Dab(C14)}-{nnr:Dab}-N{cyc:N-C} | (C14)7 | Free | Free | Cyclic | L | Dab(C14) = Dab(C14), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 98 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab(C10)}-N{cyc:N-C} | (C10)8 | Free | Free | Cyclic | L | Dab(C10) = Dab(C10), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 100 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 34159664 | 2021 | GGVCPKILQRCRRDSDCPGACICRGNGYCGSGSGGRLCYCRRRFCVCVGRR{cyc:N-C} | MCo-PG2 | Free | Free | Cyclic | L | None | 51 | Antibacterial | 50 % Hemolysis at 88± 5 µM | Human | Cyclotide Mcoti-I Modified From Pg-1 | NA | NA | ||
| 34635758 | 2021 | CTKTDVHFC{cyc:N-C} | CP2 | Free | Free | Cyclic | L | None | 9 | Antiviral against WNV (West Nile virus) | 0.2 % Hemolysis at 6 μM | Sheep | Synthetic Cyclic Peptide | NA | Low hemolytic | ||
| 34635758 | 2021 | CIHSSTRAC{cyc:N-C} | CP4 | Free | Free | Cyclic | L | None | 9 | Antiviral against WNV (West Nile virus) | 0.2 % Hemolysis at 6 μM | Sheep | Synthetic Cyclic Peptide | NA | Low hemolytic | ||
| 34635758 | 2021 | CTYENHRTC{cyc:N-C} | CP12 | Free | Free | Cyclic | L | None | 9 | Antiviral against WNV (West Nile virus) | 0.2 % Hemolysis at 6 μM | Sheep | Synthetic Cyclic Peptide | NA | Low hemolytic | ||
| 34635758 | 2021 | CLAQSHPLC{cyc:N-C} | CP16 | Free | Free | Cyclic | L | None | 9 | Antiviral against WNV (West Nile virus) | 0.2 % Hemolysis at 6 μM | Sheep | Synthetic Cyclic Peptide | NA | Low hemolytic | ||
| 34977576 | 2021 | {nnr:B}KKLLKCLKCL{cyc:7-10} | bp3 | Free | Free | Bicyclic | L | B = 3,5-bis(methylene)toluoyl | 11 | Antibacterial | MHC at 500 μg/ml | Human | Synthetic Peptide | 5 mM DPC = α-Helical | Low hemolytic | ||
| 34977576 | 2021 | {nnr:B}KKLLKCLKCLL{cyc:7-10} | bp65 | Free | Free | Bicyclic | L | B = 3,5-bis(methylene)toluoyl | 12 | Antibacterial | MHC at 16.6 μg/ml | Human | Synthetic Peptide | 5 mM DPC = α-Helical | NA | ||
| 34977576 | 2021 | {nnr:B}K{d}KL{d}LK{d}CL{d}KC{d}LL{d}{cyc:7-10} | bp67 | Free | Free | Bicyclic | Mix | B = 3,5-bis(methylene)toluoyl | 12 | Antibacterial | MHC at >2000 μg/ml | Human | Synthetic Peptide | 5 mM DPC = α-Helical | Low hemolytic | ||
| 34977576 | 2021 | {nnr:B}KKLLKC{d}LKC{d}LL{cyc:7-10} | bp68 | Free | Free | Bicyclic | Mix | B = 3,5-bis(methylene)toluoyl | 12 | Antibacterial | MHC at 16.6 μg/ml | Human | Synthetic Peptide | 5 mM DPC = α-Helical | NA | ||
| 34977576 | 2021 | {nnr:B}K{d}K{d}LLK{d}CLK{d}CLL{cyc:7-10} | bp69 | Free | Free | Bicyclic | Mix | B = 3,5-bis(methylene)toluoyl | 12 | Antibacterial | MHC at 16.6 μg/ml | Human | Synthetic Peptide | 5 mM DPC = α-Helical | NA | ||
| 35145500 | 2022 | RRLFRRILRWL{cyc:N-C}{ct:Amid} | RW-BP100-cycle | Amidation | Free | Cyclic | L | None | 11 | Antibacterial | 0.47 ± 0.61 % Hemolysis at 50 μg/mL | Sheep | Rw-Bp-100 Analogue | NA | Low hemolytic | ||
| 35145500 | 2022 | RRLFRRILRWL{cyc:N-C}{ct:Amid} | RW-BP100-cycle | Amidation | Free | Cyclic | L | None | 11 | Antibacterial | 1.19 ± 0.05 % Hemolysis at 100 μg/mL | Sheep | Rw-Bp-100 Analogue | NA | Low hemolytic | ||
| 35145500 | 2022 | RRLFRRILRWL{cyc:N-C}{ct:Amid} | RW-BP100-cycle | Amidation | Free | Cyclic | L | None | 11 | Antibacterial | 17.23 ± 3.08 % Hemolysis at 150 μg/mL | Sheep | Rw-Bp-100 Analogue | NA | NA | ||
| 35145500 | 2022 | RRLFRRILRWL{cyc:N-C}{ct:Amid} | RW-BP100-cycle | Amidation | Free | Cyclic | L | None | 11 | Antibacterial | 48.67 ± 2.17 % Hemolysis at 300 μg/mL | Sheep | Rw-Bp-100 Analogue | NA | NA | ||
| 34978443 | 2022 | R-R-R-{nnr:Bip}-{nnr:Bip}-{nnr:Bip}{cyc:N-C} | 1C | Free | Free | Cyclic | L | Bip = 4,4′-biphenyl-L-alanine | 6 | Antibacterial | 50 % Hemolysis | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-{nnr:Dip}-{nnr:Dip}-{nnr:Dip}{cyc:N-C} | 2C | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 6 | Antibacterial | 50 % Hemolysis at 45 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-{nnr:Nal}-{nnr:Nal}-{nnr:Nal}{cyc:N-C} | 3C | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 6 | Antibacterial | 50 % Hemolysis at 50 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Bip}-{nnr:Bip}-{nnr:Bip}-{nnr:Bip}{cyc:N-C} | 4C | Free | Free | Cyclic | L | Bip = 4,4′-biphenyl-L-alanine | 8 | Antibacterial | 50 % Hemolysis | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Dip}-{nnr:Dip}-{nnr:Dip}-{nnr:Dip}{cyc:N-C} | 5C | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 8 | Antibacterial | 50 % Hemolysis at 40 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Nal}-{nnr:Nal}-{nnr:Nal}-{nnr:Nal}{cyc:N-C} | 6C | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 8 | Antibacterial | 50 % Hemolysis at 30 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Bip}-{nnr:Bip}-{nnr:Bip}{cyc:N-C} | 7C | Free | Free | Cyclic | L | Bip = 4,4′-biphenyl-L-alanine | 7 | Antibacterial | 50 % Hemolysis | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Dip}-{nnr:Dip}-{nnr:Dip}{cyc:N-C} | 8C | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 7 | Antibacterial | 50 % Hemolysis at 70 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Nal}-{nnr:Nal}-{nnr:Nal}{cyc:N-C} | 9C | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 7 | Antibacterial | 50 % Hemolysis at 80 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Dip}-{nnr:Dip}{cyc:N-C} | 10C | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 6 | Antibacterial | 50 % Hemolysis at 110 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Nal}-{nnr:Nal}{cyc:N-C} | 11C | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 6 | Antibacterial | 50 % Hemolysis at 125 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-R-{nnr:Dip}-{nnr:Dip}-{nnr:Dip}{cyc:N-C} | 12C | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 8 | Antibacterial | 50 % Hemolysis at 100 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-R-{nnr:Nal}-{nnr:Nal}-{nnr:Nal}{cyc:N-C} | 13C | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 8 | Antibacterial | 50 % Hemolysis at 90 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | K-K-K-K-{nnr:Dip}-{nnr:Dip}-{nnr:Dip}{cyc:N-C} | 14C | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 7 | Antibacterial | 50 % Hemolysis at 165 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | K-K-K-K-K-{nnr:Dip}-{nnr:Dip}-{nnr:Dip}{cyc:N-C} | 15C | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 8 | Antibacterial | 50 % Hemolysis at 180 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-{nnr:Dip}-R-R-{nnr:Dip}-{nnr:Dip}-R{cyc:N-C} | 16C | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 7 | Antibacterial | 50 % Hemolysis at 130 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-{nnr:Dip}-{nnr:Dip}-R-R-{nnr:Dip}{cyc:N-C} | 17C | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 7 | Antibacterial | 50 % Hemolysis at 145 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-{nnr:Nal}-R-R-{nnr:Nal}-{nnr:Nal}-R{cyc:N-C} | 18C | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 7 | Antibacterial | 50 % Hemolysis at 105 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-{nnr:Nal}-{nnr:Nal}-R-R-{nnr:Nal}{cyc:N-C} | 19C | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 7 | Antibacterial | 50 % Hemolysis at 110 μM | Human | Synthetic Peptide | NA | NA | ||
| 36430320 | 2022 | (CGKKWWGWKC)KL{cyc:N-C}{ct:Amid} | cTurg-2 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at >1045 μg/mL | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 36430320 | 2022 | (CGKKWGWWKC)KL{cyc:N-C}{ct:Amid} | cTurg-3 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at 849 μg/mL | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 36430320 | 2022 | (CGKKPWWWKC)KL{cyc:N-C}{ct:Amid} | cTurg-4 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at >1065 μg/mL | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 36430320 | 2022 | (CGRRWWGWRC)RL{cyc:N-C}{ct:Amid} | cTurg-5 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at >1101 μg/mL | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 36430320 | 2022 | (CGRRWGWWRC)RL{cyc:N-C}{ct:Amid} | cTurg-6 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at 1101 μg/mL | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 36430320 | 2022 | (CGRRPWWWRC)RL{cyc:N-C}{ct:Amid} | cTurg-7 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at 197 μg/mL | Human | Synthetic Peptide | NA | NA | ||
| 36430320 | 2022 | (CGKKPGGWKC)KL{cyc:N-C}{nt:C8}{ct:Amid} | C8-cTurg-1 | Amidation | C8 | Cyclic | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at >942 μg/mL | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 36430320 | 2022 | (CGKKPGGWKC)KL{cyc:N-C}{nt:C10}{ct:Amid} | C10-cTurg-1 | Amidation | C10 | Cyclic | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at >956 μg/mL | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 36430320 | 2022 | (CGKKPGGWKC)KL{cyc:N-C}{nt:C12}{ct:Amid} | C12-cTurg-1 | Amidation | C12 | Cyclic | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at 219 μg/mL | Human | Synthetic Peptide | NA | NA | ||
| 36430320 | 2022 | (CGKKWWGWKC)KL{cyc:N-C}{nt:C8}{ct:Amid} | C8-cTurg-2 | Amidation | C8 | Cyclic | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at 439 μg/mL | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 36430320 | 2022 | (CGKKWWGWKC)KL{cyc:N-C}{nt:C10}{ct:Amid} | C10-cTurg-2 | Amidation | C10 | Cyclic | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at 106 μg/mL | Human | Synthetic Peptide | NA | NA | ||
| 36430320 | 2022 | (CGKKWWGWKC)KL{cyc:N-C}{nt:C12}{ct:Amid} | C12-cTurg-2 | Amidation | C12 | Cyclic | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at 32 μg/mL | Human | Synthetic Peptide | NA | NA | ||
| 36430320 | 2022 | (CGRRWGWWRC)RL{cyc:N-C}{nt:C8}{ct:Amid} | C8-cTurg-6 | Amidation | C8 | Cyclic | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at 30 μg/mL | Human | Synthetic Peptide | NA | NA | ||
| 36430320 | 2022 | (CGRRWGWWRC)RL{cyc:N-C}{nt:C10}{ct:Amid} | C10-cTurg-6 | Amidation | C10 | Cyclic | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at 16 μg/mL | Human | Synthetic Peptide | NA | NA | ||
| 36430320 | 2022 | (CGRRWGWWRC)RL{cyc:N-C}{nt:C12}{ct:Amid} | C12-cTurg-6 | Amidation | C12 | Cyclic | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at 9 μg/mL | Human | Synthetic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRRWWWW{cyc:N-C} | 1 | Free | Free | Cyclic | L | None | 8 | Antibacterial | 50 % Hemolysis at 175 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRWWW{cyc:N-C} | 2a | Free | Free | Cyclic | L | None | 5 | Antibacterial | 50 % Hemolysis at 120 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRWWWW{cyc:N-C} | 2b | Free | Free | Cyclic | L | None | 6 | Antibacterial | 50 % Hemolysis at 85 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRWWW{cyc:N-C} | 3a | Free | Free | Cyclic | L | None | 6 | Antibacterial | 50 % Hemolysis at 155 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRWWWW{cyc:N-C} | 3b | Free | Free | Cyclic | L | None | 7 | Antibacterial | 50 % Hemolysis at 105 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRWWWWW{cyc:N-C} | 3c | Free | Free | Cyclic | L | None | 8 | Antibacterial | 50 % Hemolysis at 80 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRWWWWWW{cyc:N-C} | 3d | Free | Free | Cyclic | L | None | 9 | Antibacterial | 50 % Hemolysis at 65 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRWWWWWWW{cyc:N-C} | 3e | Free | Free | Cyclic | L | None | 10 | Antibacterial | 50 % Hemolysis at 60 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | R{d}R{d}R{d}R{d}WWWW{cyc:N-C} | 4a | Free | Free | Cyclic | Mix | r = D-Arginine | 8 | Antibacterial | 50 % Hemolysis at 110 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRRWWWWW{cyc:N-C} | 4b | Free | Free | Cyclic | L | None | 9 | Antibacterial | 50 % Hemolysis at 100 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRRWWWWWW{cyc:N-C} | 4c | Free | Free | Cyclic | L | None | 10 | Antibacterial | 50 % Hemolysis at 75 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRRWWWWWWW{cyc:N-C} | 4d | Free | Free | Cyclic | L | None | 11 | Antibacterial | 50 % Hemolysis at 60 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRRRWWWW{cyc:N-C} | 5a | Free | Free | Cyclic | L | None | 9 | Antibacterial | 50 % Hemolysis at 340 μg/mL | Human | Synthetic Cyclic Peptide | NA | Low hemolytic | ||
| 36442155 | 2022 | RRRRRWWWWW{cyc:N-C} | 5b | Free | Free | Cyclic | L | None | 10 | Antibacterial | 50 % Hemolysis at 230 μg/mL | Human | Synthetic Cyclic Peptide | NA | Low hemolytic | ||
| 36442155 | 2022 | RRRRRWWWWWW{cyc:N-C} | 5c | Free | Free | Cyclic | L | None | 11 | Antibacterial | 50 % Hemolysis at 140 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRRRWWWWWWW{cyc:N-C} | 5d | Free | Free | Cyclic | L | None | 12 | Antibacterial | 50 % Hemolysis at 115 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRRRRWWWW{cyc:N-C} | 6a | Free | Free | Cyclic | L | None | 10 | Antibacterial | 50 % Hemolysis at 265 μg/mL | Human | Synthetic Cyclic Peptide | NA | Low hemolytic | ||
| 36442155 | 2022 | RRRRRRWWWWW{cyc:N-C} | 6b | Free | Free | Cyclic | L | None | 11 | Antibacterial | 50 % Hemolysis at 255 μg/mL | Human | Synthetic Cyclic Peptide | NA | Low hemolytic | ||
| 36442155 | 2022 | RRRRRRWWWWWW{cyc:N-C} | 6c | Free | Free | Cyclic | L | None | 12 | Antibacterial | 50 % Hemolysis at 170 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRRRRWWWWWWW{cyc:N-C} | 6d | Free | Free | Cyclic | L | None | 13 | Antibacterial | 50 % Hemolysis at 85 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRRRRRWWWW{cyc:N-C} | 7a | Free | Free | Cyclic | L | None | 11 | Antibacterial | 50 % Hemolysis at 190 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRRRRRWWWWW{cyc:N-C} | 7b | Free | Free | Cyclic | L | None | 12 | Antibacterial | 50 % Hemolysis at 175 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRRRRRWWWWWW{cyc:N-C} | 7c | Free | Free | Cyclic | L | None | 13 | Antibacterial | 50 % Hemolysis at 170 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRRRRRWWWWWWW{cyc:N-C} | 7d | Free | Free | Cyclic | L | None | 14 | Antibacterial | 50 % Hemolysis at 140 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36941353 | 2023 | {nnr:Dab}-T-{nnr:Dab}-[C-{nnr:Dab}-L{d}-L-{nnr:Dab}-{nnr:Dab}-C]{cyc:4-10}{nt:C2} | PE-2C-C2-DH | Free | C2 | Cyclic | Mix | Dab = L-2,4-diaminobutyric acid | 10 | Antibacterial | 0 % Hemolysis at >1500 μg/mL | Rabbit | Synthetic Cyclic Peptide | NA | Non-hemolytic | ||
| 36941353 | 2023 | {nnr:Dab}-T-{nnr:Dab}-[C-{nnr:Dab}-L{d}-L-{nnr:Dab}-{nnr:Dab}-C]{cyc:4-10}{nt:C3} | PE-2C-C3-DH | Free | C3 | Cyclic | Mix | Dab = L-2,4-diaminobutyric acid | 10 | Antibacterial | 0 % Hemolysis at >1500 μg/mL | Rabbit | Synthetic Cyclic Peptide | NA | Non-hemolytic | ||
| 36941353 | 2023 | {nnr:Dab}-T-{nnr:Dab}-[C-{nnr:Dab}-L{d}-L-{nnr:Dab}-{nnr:Dab}-C]{cyc:4-10}{nt:C4} | PE-2C-C4-DH | Free | C4 | Cyclic | Mix | Dab = L-2,4-diaminobutyric acid | 10 | Antibacterial | 0 % Hemolysis at >1500 μg/mL | Rabbit | Synthetic Cyclic Peptide | NA | Non-hemolytic | ||
| 36941353 | 2023 | {nnr:Dab}-T-{nnr:Dab}-[C-{nnr:Dab}-L{d}-L-{nnr:Dab}-{nnr:Dab}-C]{cyc:4-10}{nt:C5} | PE-2C-C5-DH | Free | C5 | Cyclic | Mix | Dab = L-2,4-diaminobutyric acid | 10 | Antibacterial | 0 % Hemolysis at >1500 μg/mL | Rabbit | Synthetic Cyclic Peptide | NA | Non-hemolytic | ||
| 36941353 | 2023 | {nnr:Dab}-T-{nnr:Dab}-[C-{nnr:Dab}-L{d}-L-{nnr:Dab}-{nnr:Dab}-C]{cyc:4-10}{nt:C6} | PE-2C-C6-DH | Free | C6 | Cyclic | Mix | Dab = L-2,4-diaminobutyric acid | 10 | Antibacterial | 0 % Hemolysis at >1500 μg/mL | Rabbit | Synthetic Cyclic Peptide | NA | Non-hemolytic | ||
| 36941353 | 2023 | {nnr:Dab}-T-{nnr:Dab}-[C-{nnr:Dab}-L{d}-L-{nnr:Dab}-{nnr:Dab}-C]{cyc:4-10}{nt:C7} | PE-2C-C7-DH | Free | C7 | Cyclic | Mix | Dab = L-2,4-diaminobutyric acid | 10 | Antibacterial | 0 % Hemolysis at >1500 μg/mL | Rabbit | Synthetic Cyclic Peptide | NA | Non-hemolytic | ||
| 36941353 | 2023 | {nnr:Dab}-T-{nnr:Dab}-[C-{nnr:Dab}-L{d}-L-{nnr:Dab}-{nnr:Dab}-C]{cyc:4-10}{nt:C8} | PE-2C-C8-DH | Free | C8 | Cyclic | Mix | Dab = L-2,4-diaminobutyric acid | 10 | Antibacterial | 0 % Hemolysis at >1500 μg/mL | Rabbit | Synthetic Cyclic Peptide | NA | Non-hemolytic | ||
| 36941353 | 2023 | {nnr:Dab}-T-{nnr:Dab}-[C-{nnr:Dab}-L{d}-L-{nnr:Dab}-{nnr:Dab}-C]{cyc:4-10}{nt:6-MC7} | PE-2C-6-MC7-DH | Free | 6-MC7 | Cyclic | Mix | Dab = L-2,4-diaminobutyric acid | 10 | Antibacterial | 0 % Hemolysis at >1500 μg/mL | Rabbit | Synthetic Cyclic Peptide | NA | Non-hemolytic | ||
| 36941353 | 2023 | {nnr:Dab}-T-{nnr:Dab}-[C-{nnr:Dab}-L{d}-L-{nnr:Dab}-{nnr:Dab}-C]{cyc:4-10}{nt:6-MC8} | PE-2C-6-MC8-DH | Free | 6-MC8 | Cyclic | Mix | Dab = L-2,4-diaminobutyric acid | 10 | Antibacterial | 0 % Hemolysis at >1500 μg/mL | Rabbit | Synthetic Cyclic Peptide | NA | Non-hemolytic | ||
| 36941353 | 2023 | {nnr:Dab}-T-{nnr:Dab}-[C-{nnr:Dab}-L{d}-L-{nnr:Dab}-{nnr:Dab}-C]{cyc:4-10}{nt:LB-8} | PE-2C-LB-8-DH) | Free | LB-8 | Cyclic | Mix | Dab = L-2,4-diaminobutyric acid | 10 | Antibacterial | 0 % Hemolysis at 1500 μg/mL | Rabbit | Synthetic Cyclic Peptide | NA | Non-hemolytic | ||
| 35326879 | 2022 | RRRRWWWW{cyc:N-C} | [R4W4] | Free | Free | Cyclic | L | None | 8 | Antibacterial, Cytotoxic | 80 % Hemolysis at 500 µg/mL | Human | Synthetic | NA | NA | ||
| 35326879 | 2022 | [{conj:Levo}-{conj:C10}-KRRRWWWW]{cyc:N-C} | [Levo-C10-KR3W4] | Free | Free | Cyclic | L | Levo = Levofloxacin covalent conjugates, C10 = 10-hydroxy decanoic acid(linker) | 8 | Antibacterial, Cytotoxic | ∼30 % Hemolysis at 500 µg/mL | Human | Synthetic | NA | NA | ||
| 35326879 | 2022 | {conj:Levo}+ [RRRRWWWW]{cyc:N-C} | Levo + [R4W4] | Free | Free | Cyclic | L | Levo = Levofloxacin, physical mixture of Levofloxacin and peptides (500 µg/mL (1:1; w/w)) | 8 | Antibacterial, Cytotoxic | ∼22 % Hemolysis at 500 µg/mL | Human | Synthetic | NA | NA | ||
| 35978681 | 2022 | CKWKLFKKIGAVLKVL{cyc:N-C}{ct:Amid} | Cyc-CAM | Amidation | Free | Cyclic | L | None | 16 | Antibacterial | 50 % Hemolysis at >1000 μg/mL | Sheep | Synthetic; Analog Of The Pentadecapeptide Ca(1-7)M(2-9) | NA | NA | ||
| 36044031 | 2022 | GSVPCGESCVWIPCIS-GILGCSCSNKVCYYN{cyc:N-C} | anpy A | Free | Free | Cyclic | L | None | 32 | Cytotoxic | 50 % Hemolysis at 22 μM | Human | Anchietea Pyrifolia | NA | NA | ||
| 36044031 | 2022 | SIPCGESCVWIPCTVTALAGCSCKNKVCYKN{cyc:N-C} | anpy B | Free | Free | Cyclic | L | None | 31 | Cytotoxic | 50 % Hemolysis at 78 μM | Human | Anchietea Pyrifolia | NA | Low hemolytic | ||
| 36044031 | 2022 | GIPCGESCVWIPCIS-SAIGCSCKNKVCYRN{cyc:N-C} | cy04 | Free | Free | Cyclic | L | None | 31 | Cytotoxic | 50 % Hemolysis at >156 μM | Human | Anchietea Pyrifolia | NA | Non-hemolytic | ||
| 36044031 | 2022 | GIPCGESCVWIPCIS-AAIGCSCKNKVCYRN{cyc:N-C} | cy017 | Free | Free | Cyclic | L | None | 31 | Cytotoxic | 50 % Hemolysis at >156 μM | Human | Anchietea Pyrifolia | NA | Non-hemolytic | ||
| 16207177 | 2006 | GSVLNCGETCLLGTCYTTGCTCNKYRVCTKD{cyc:N-C} | Kalata B8 | Free | Free | Cyclic | L | None | 31 | Antiviral, Anti-HIV, Hemolytic | 0 % Hemolysis at 370µM | Human | Plant African Herb, Oldenlandia Affinis | Beta | Non-hemolytic | ||
| 16872274 | 2006 | GLPTCGETCFGGTCNTPGCTCDPWPVCTHN{cyc:N-C} | Cycloviolacin O24 | Free | Free | Cyclic | L | None | 30 | Antiviral, Anti-HIV, Hemolytic | 75 % Hemolytic at 25µg/ml | Human | Plant Viola Odorata | Bridge | NA | ||
| 21596752 | 2011 | GIPCGESCVFIPCITGAIGCSCKSKVCYRN{cyc:N-C} | Cliotide T1 | Free | Free | Cyclic | L | None | 30 | Antibacterial, Hemolytic, Anticancer | 50 % Hemolytic at 7.1µM | Human | Plant Clitoria Ternatea | NA | NA | ||
| 21596752 | 2011 | GLPTCGETCTLGTCYVPDCSCSWPICMKN{cyc:N-C} | Cliotide T3 | Free | Free | Cyclic | L | None | 29 | Hemolytic, Anticancer | 50 % Hemolytic at 13.1µM | Human | Plant Clitoria Ternatea | NA | NA | ||
| 21596752 | 2011 | GIPCGESCVFIPCITAAIGCSCKSKVCYRN{cyc:N-C} | Cliotide T4 | Free | Free | Cyclic | L | None | 30 | Antibacterial, Hemolytic, Anticancer | 50 % Hemolytic at 8.4µM | Human | Plant Clitoria Ternatea | NA | NA | ||
| 22074926 | 2012 | GGSVPCGESCVFIPCITSLAGCSCKNKVCYYD{cyc:N-C} | Parigidin-br1 | Free | Free | Cyclic | L | None | 32 | Insecticidal, Hemolytic | 28 % Hemolytic at 20µM | Human | Plant Palicourea Rigida (Rubiaceae) | Bridge | NA | ||
| 22074926 | 2012 | GGSVPCGESCVFIPCITSLAGCSCKNKVCYYD{cyc:N-C} | Parigidin-br1 | Free | Free | Cyclic | L | None | 32 | Insecticidal, Hemolytic | 41 % Hemolytic at 40µM | Human | Plant Palicourea Rigida (Rubiaceae) | Bridge | NA | ||
| 22467870 | 2012 | GDACGETCFTGICFTAGCSCNPWPTCTRN{cyc:N-C} | ChaC1 (chassatide C1) | Free | Free | Cyclic | L | None | 29 | Hemolytic, Anticancer | Hemolytic | Human | Hybrid Peptide | Bridge | NA | ||
| 22467870 | 2012 | GASCGETCFTGICFTAGCSCNPWPTCTRN{cyc:N-C} | ChaC4 (chassatide C4) | Free | Free | Cyclic | L | None | 29 | Hemolytic, Anticancer | Hemolytic | Human | Plant Chassalia Chartacea (Or Chassalia Curviflora) | Bridge | NA | ||
| 16872274 | 2006 | GIPCGESCVWIPCISSAIGCSCKSKVCYRN{cyc:N-C} | Cycloviolacin-O2 | Free | Free | Cyclic | L | None | 30 | Antimicrobial | HD50 % Hemolytic at 36µM | Human | Viola Odorata (Sweet Violet) | NA | NA | ||
| 16872274 | 2006 | GIPCGESCVWIPCISAAIGCSCKSKVCYRN{cyc:N-C} | Cycloviolacin-O13 (Cyclotide c3) | Free | Free | Cyclic | L | None | 30 | Antimicrobial | HD50 % Hemolytic at 11µM | Human | Viola Odorata (Sweet Violet) | NA | NA | ||
| 26322745 | 2015 | GKYTCGETCFKGKCYTPGCTCSYPICKKD{cyc:N-C} | Cyclotide mela-1 | Free | Free | Cyclic | L | None | 29 | Antibacterial | 50 % Hemolytic at >64µM | Human | Melicytus Latifolius (Norfolk Island Mahoe) (Hymenanthera Latifolia) | NA | Non-hemolytic | ||
| 26322745 | 2015 | GKPTCGETCFKGKCYTPGCTCSYPLCKKD{cyc:N-C} | Cyclotide mela-2 | Free | Free | Cyclic | L | None | 29 | Antibacterial | 50 % Hemolytic at >64µM | Human | Melicytus Latifolius (Norfolk Island Mahoe) (Hymenanthera Latifolia) | NA | Non-hemolytic | ||
| 26322745 | 2015 | GLPTCGETCFKGKCYTPGCSCSYPICKKD{cyc:N-C} | Cyclotide mela-6 | Free | Free | Cyclic | L | None | 29 | Antibacterial | 50 % Hemolytic at >64µM | Human | Melicytus Latifolius (Norfolk Island Mahoe) (Hymenanthera Latifolia) | NA | Non-hemolytic | ||
| 26322745 | 2015 | GLPTCGETCFKGKCYTPGCSCSYPICKKN{cyc:N-C} | Cyclotide mela-7 | Free | Free | Cyclic | L | None | 29 | Antibacterial | 50 % Hemolytic at >64µM | Human | Melicytus Latifolius (Norfolk Island Mahoe) (Hymenanthera Latifolia) | NA | Non-hemolytic | ||
| 26322745 | 2015 | GLPTCGETCTLGKCNTPKCTCNWPICYKD{cyc:N-C} | Cyclotide mech-2 | Free | Free | Cyclic | L | None | 29 | cytotoxicity | 50 % Hemolytic at >64µM | Human | Melicytus Chathamicus (Chatham Island Mahoe) (Hymenanthera Latifolia Var. Chathamica) | NA | Non-hemolytic | ||
| 26322745 | 2015 | GLPTCGETCTLGKCNTPKCTCNWPICYKN{cyc:N-C} | Cyclotide mech-3 | Free | Free | Cyclic | L | None | 29 | cytotoxicity | 50 % Hemolytic at >64µM | Human | Melicytus Chathamicus (Chatham Island Mahoe) (Hymenanthera Latifolia Var. Chathamica) | NA | Non-hemolytic | ||
| 22467870 | 2012 | GEYCGESCYLIPCFTPGCYCVSRQCVNKN{cyc:N-C} | Chassatide C10 (Cyclotide chaC10) | Free | Free | Cyclic | L | None | 29 | NA | 50 % Hemolytic at >25µM | Human | Chassalia Chartacea | NA | Non-hemolytic | ||
| 32414842 | 2020 | GVPCGESCVYIPCFTGIINCSCRDKVCYNN{cyc:N-C} | Cyclotide hyen-E | Free | Free | Cyclic | L | None | 30 | cytotoxicity | 50 % Hemolytic at >50µM | Human | Pigea Enneasperma (Spade Flower) (Hybanthus Enneaspermus) | NA | NA | ||
| 32414842 | 2020 | GIPCAESCVYIPCTVTALLGCSCSDKVCYN{cyc:N-C} | Cyclotide hyen-L | Free | Free | Cyclic | L | None | 30 | cytotoxicity | 50 % Hemolytic at >50µM | Human | Pigea Enneasperma (Spade Flower) (Hybanthus Enneaspermus) | NA | NA | ||
| 15893660 | 2005 | SLETKDVITRAAYENLVNSGAIQGITMTKTIISNPILEEALVSHFNRKLG{cyc:N-C} | Tricyclon-A | Free | Free | Cyclic | L | None | 50 | Plant defense | 2 % Hemolytic at 500µM | Human | Viola Arvensis (European Field Pansy) (Field Violet) | Helix and Extended | NA |